University of South Carolina

Scholar Commons
Theses and Dissertations
Spring 2017

Economic Burden of Tuberculosis among Bangladeshi Population
and Economic Evaluation of the Current Approaches of
Tuberculosis Control in Bangladesh
Mohammad Rifat Haider
University of South Carolina - Columbia

Follow this and additional works at: https://scholarcommons.sc.edu/etd
Part of the Health Policy Commons

Recommended Citation
Haider, M.(2017). Economic Burden of Tuberculosis among Bangladeshi Population and Economic
Evaluation of the Current Approaches of Tuberculosis Control in Bangladesh. (Doctoral dissertation).
Retrieved from https://scholarcommons.sc.edu/etd/4409

This Open Access Dissertation is brought to you by Scholar Commons. It has been accepted for inclusion in
Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please
contact digres@mailbox.sc.edu.

Economic burden of Tuberculosis among Bangladeshi population and Economic
Evaluation of the Current Approaches of Tuberculosis Control in Bangladesh
by
Mohammad Rifat Haider
Bachelor of Medicine and Surgery
University of Dhaka, 2007
Master of Health Economics
University of Dhaka, 2010
Master of Population Sciences
University of Dhaka, 2013

Submitted in Partial Fulfillment of the Requirements
For the Degree of Doctor of Philosophy in
Health Services Policy and Management
The Norman J. Arnold School of Public Health
University of South Carolina
2017

Accepted by:
M. Mahmud Khan, Major Professor
James W. Hardin, Committee Member
Zaina P. Qureshi, Committee Member
Md. Abdul Hamid Salim, Committee Member
Cheryl L. Addy, Vice Provost and Dean of the Graduate School

© Copyright by Mohammad Rifat Haider, 2017
All Rights Reserved.

ii

DEDICATION
I dedicate this dissertation to the Tuberculosis patients who participated in the
interviews for this study- not for money, just for the betterment of future TB care in the
country.

iii

ACKNOWLEDGEMENTS
I am truly grateful for the continuous support and inspiration from my supervisor
Dr. M. Mahmud Khan. Without his guidance, supervision, and mentorship, it would not
be a reality. I am thankful to Dr. Zaina P. Qureshi for her tremendous support throughout
my graduate studies here at the University of South Carolina (USC). I would also like to
thank the two other members of my dissertation committee, Dr. James W. Hardin and Dr.
Abdul Hamid Salim.
My dissertation work was funded by the post-graduate training grant from TDR,
the Special Programme for Research and Training in Tropical Diseases at the World
Health Organization (WHO), I am thankful to them. Primary data was collected from all
over Bangladesh for this dissertation. I cannot express enough gratitude to the TB
patients and health professionals who were interviewed for this dissertation. I also offer
my sincere gratitude to the data collectors for their tremendous effort. I would like to
thank Dr. Mojibur Rahman (National Tuberculosis Control Program), Dr. Aung Kya Jai
Maug (Damien Foundation), Dr. Shayla Islam (BRAC) for helping me with data
collection process. Dr. Shahriar Ahmed (icddr,b) indebted me with his tremendous
support throughout my research activities. I would like to thank Development Research
Initiative (dRi) for helping me out with data collection process. I would also like to thank
my co-researchers, Dr. Shakil Ahmed, Dr. Ibrahim Demir, Farahnaz Islam, Dr.
Mohammad Masudur Rahman, and Khairul Alam Siddiqi for their continuous support.

iv

Last but not least I would like to remember my family, especially my father
whose relentless inspiration helped me to be what I am today, my mother for her
monumental support, my siblings and my friends who were always there for me.

v

ABSTRACT
Introduction: Tuberculosis (TB) is major scourge for human history and causes
profound economic burden. Bangladesh is a high burden TB country with 12% of its
annual death is caused and 362 thousand people are infected by TB. DS-TB is the most
prominent type of TB found in Bangladesh and a 6 month drug regimen (2 month
intensive and 4 month continuation phase) is followed. But the directly observed
treatment short-course (DOTS) differ in delivery through community health workers
(CHW) and community members (CM). Bangladesh has also experienced surge in the
number of MDR-TB cases with a 29% of MDR-TB cases were found among the retreatment of pulmonary TB cases in 2015. In Bangladesh, two MDR-TB treatment
regimens (9 month and 20-24 month) are practiced. This dissertation aims to estimates
the economic burden of TB on the afflicted Bangladeshi population and conducts
economic evaluation among different programs for DS-TB and MDR-TB in Bangladesh.
Methods: This study collects direct and indirect cost for TB care data from 1,000
drug sensitive TB (DS-TB) and 145 multi-drug resistant (MDR-TB) patients from all
over Bangladesh. Provider cost for TB care was also collected from the health facilities.
Costs for DS-TB and MDR-TB patients were estimated using Generalized Linear Model
and summed up with per patient provider level costs to get the total costs per TB patients.
The incremental cost-effectiveness ratio (ICER) of treating DS-TB and MDR-TB
patients, CM versus CHW model for DS-TB and 9-month vs. 20-24 month regimen for
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MDR-TB were compared using a Markov model with life-time horizon. The measure of
effectiveness, Quality adjusted life year (QALY) and cost of treatment was collected
from 1,000 DS-TB and 145 MDR-TB patients (598 for CM model and 402 from CHW
model; 58 undergone 9 month treatment and 87 from 20-24 month regimen) in
Bangladesh. Transition probabilities between Markov states were estimated from
quarterly outcomes report collected from health facilities and cost and QALY both were
discounted at a rate of 3%. Both deterministic and probabilistic sensitivity analyses were
conducted in a Monte Carlo Simulation using R.
Results: Mean age of DS-TB patients under the study was 45.2 years while mean
age of MDR-TB patients were 35.5 years. In aggregate, DS-TB patients incurred total
average costs of BDT 21,235 (USD 265) for TB illness; while MDR-TB patients’
average costs were BDT 34,975 (USD 437). Including provider costs for each patient
(USD 9 for DSTB and USD 2,006 for MDR-TB patients) total average costs for each DSTB patient was BDT 22,003 (USD 275) and for each MDR-TB patient was BDT
1,95,449 (USD 2443).
Assuming 57% case notification rate, the actual costs for treating TB patients in
2015 was USD 55.6 million. If all DS-TB patients were treated the cost would have been
1 billion USD. For MDR-TB treatment, total cost was USD 12.5 million; treating all
MDR-TB patients would have costed USD 23 million.
Results show that each DS-TB patient under CM treatment model gains 3.61
QALYs with a cost of BDT 131,555. For the DS-TB patients under the CHW model the
cost is 81,650 and the QALY gain is 3.12. The Incremental Cost-Effectiveness Ratio
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(ICER) is 103,454, i.e., the CM model is cost-effective if per QALY gain if willingnessto-pay is set to the per capita GDP of Bangladesh (BDT 107,360 in 2015).
Based on the study data, each patient under 9 month regimen gained 6.21 QALY
with a total cost of BDT 987,418. Whereas, each patient under CHW model gained 5.74
QALY by incurring costs of BDT 1,501,221. Therefore, 9 month regimen is clearly
dominating over the 20-24 month regimen because it costs less while it gains more
QALY.
Conclusions: Results show that DS-TB patients incurred about 50% of their
household annual income for treatment while that goes up to 66% for the MDR-TB
patients. Pre-diagnosis cost constitutes about 63% of total costs for DS-TB patients and
42% of MDR-TB patient costs. This figures show the significant economic burden posed
by TB and early diagnosis of the disease can reduce the burden in great extent.
Our study results demonstrate that community based model of DS-TB treatment is
cost-effective even with changed costs and utility values in probabilistic sensitivity
analysis. Community members as DOTS provider are more capable of reducing stigma
related to TB, enhancing patient adherence and thereby reduce costs and increase utility
from the treatment. Community members should also be involved in contact tracing and
prevention activities to increase the effect of the involvement in TB control.
Our study results also suggest that shorter regimen remains cost-effective in
Bangladesh setting with changing costs and utility parameters changed in the
probabilistic sensitivity analysis. MDR-TB treatment is itself cost-effective in developed
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countries and with cost-effective shorter regimen both treatment adherence and efficacy
of the treatment will be improved.
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PREFACE
American Psychological Association, 6th edition was used in the dissertation.
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CHAPTER 1
INTRODUCTION
1.1 STATEMENT OF THE PROBLEM AND RATIONALE
In 2015, Tuberculosis (TB) ranked 18th among the highest burden diseases
globally and it constituted 47% of the global burden attributable to communicable,
maternal, neonatal, and nutritional disorders (Kassebaum et al., 2016). In 2015, 10
million new cases of TB were reported and almost two million people died from TB
worldwide (World Health Organization (WHO), 2016a). In 2015, TB became the top
infectious disease killer by claiming With the me1.1 million lives by matching the death
tolls by HIV/AIDS (Kassebaum et al., 2016).
Almost 85% of all new cases of TB and multi-drug resistant TB (MDR-TB) occur
in 30 high burden TB countries and Bangladesh is one them (World Health Organization
(WHO), 2015b). In 2015, 362,000 Bangladeshis developed TB and 73,000 died from it.
TB accounted for 12% of all deaths (609,800) that occurred in 2015 in Bangladesh
(Institute for Health Metrics and Evaluation (IHME), 2016). Although case notification
rate is only 57%, success of the treatment is high (93%) among DS-TB patients.
However, the success rate is 75% among MDR-TB patients which signifies how difficult
to treat drug resistant strains (World Health Organization (WHO), 2016a).

1

Despite having effective treatment, patient adherence to TB treatment remains
poor because of long duration of the regimen (six months for newly diagnosed cases) and
the need for daily dosing. Failure to adhere to the regimen results in MDR-TB (Gandy &
Zumla, 2002). The emergence of drug resistant TB strains has slowed down the progress
in global TB epidemic control over the last two decades. Bangladesh has also
experienced surge in the number of MDR-TB cases with a 1.6% of new cases are drug
resistant and 29% of MDR-TB cases were found among the re-treatment of pulmonary
TB cases in 2015 (World Health Organization (WHO), 2016a).
World has experienced a slow progress in TB control. TB incidence has fallen by
an average of 1.5% per year since 2000. However, this needs to accelerate to 4-5%
annual reduction to reach 2035 milestones of “End TB Strategy” (World Health
Organization (WHO), 2016b). End TB Strategy has set ambitious targets of 95%
reduction in TB deaths and 90% reductions in TB incidence by 2035 (Uplekar et al.,
2015).Bangladesh is also experiencing a slow reduction in TB incidence (360,000 in
2015 from 362,000 in 2014) and incidence rate (225 per 100,000 population in 2015 from
227 per 100,000 population in 2014) (World Health Organization (WHO), 2015a, 2016a).
Economic burden of TB in Bangladesh is a great concern, since it affects a sizable
number of people each year and causes 12% of the total death. Both disability and death
have grave economic implications in the form of lost income to the persons and their
families and lost Gross Domestic Product (GDP) for the country. Expensive treatment of
the disease also put burden on the patients, families, and the health system of the country.
The most affected group is the working age group persons, that also increases the costs
associated with the disease (World Health Organization (WHO), 2016b). Moreover,
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almost half (43%) of the patients in Bangladesh is not reported under the national
registries and goes untreated (World Health Organization (WHO), 2016a); this makes the
control and elimination of the disease extremely hard and expensive. Emergence of drug
resistant strain also contributes in escalating costs because of high death rates, costly
treatments, and poor outcomes (Fitzpatrick & Floyd, 2012).
Directly Observed Treatment, Short Course (DOTS) strategy for treating drug
sensitive TB (DS-TB) has been implemented in Bangladesh since 1993 and all the
Upazila Health Complexes (UHCs) have been brought under the purview of the service
from where TB detection and treatment services are given free of cost. The essence of the
strategy is the diagnosed TB patient has to go to the facility every day for taking the
drugs, thus treatment discontinuity and subsequently MDR-TB cases can be averted
(World Health Organization (WHO), 2013b).
Menacing drug resistant strains is a growing concern as discontinuity in treatment
often results into MDR-TB or XDR-TB. Treatment for both the conditions are costly and
also more time consuming as the shortest effective MDR-TB treatment regimen spans
over nine months (Deun et al., 2010). Therefore, this prolonged treatment schedule may
result into more incidence of treatment discontinuation. WHO in partnership with STOP
TB Partnership came up with the response plan in 2007-2008 and Bangladesh is one of
the seven countries using the shorter treatment regimens for MDR-TB in June 2013
(World Health Organization (WHO), 2013b).
Given the extent of the incidence and death rate of TB patients worldwide and in
Bangladesh, its overwhelming economic impact is of great importance. Few studies have
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been conducted to elucidate the social and economic costs of TB (Murrat, Styblo, &
Roullion, 1993). Recently few studies have been carried out in this regard (Muniyandi,
Ramachandran, Balasubramanian, & Narayanan, 2006; Rajeswari et al., 1999; Russell,
2004) but very few in the context of Bangladesh (Croft & Croft, 1998; Gospodarevskaya
et al., 2014; Islam, Wakai, Ishikawa, Chowdhury, & Vaughan, 2002). There is also
paucity of evidence on cost-effectiveness of the TB programs. One study compared costeffectiveness between an NGO and government intervention and found that NGO-driven
program is more cost-effective (Islam et al., 2002), however, no study has been
conducted after the advent of PPP model or using the cost-utility method.
The costs can be incurred on the patient directly (direct costs) or indirectly
(indirect costs) and most of the studies do not capture the whole picture as they often
concentrate on pre-diagnosis, pre-treatment or treatment costs (KNCV Tuberculosis
Foundation, 2008) only. Besides this the study will also capture the provider’s cost of
delivery health care services to the TB patients which is often absent in other studies.
This research proposal intends to contribute to the body of TB literature by
illustrating the cost associated with different types of TB and to estimate the total
economic burden of tuberculosis in Bangladesh. This dissertation also covers the
economic evaluation of ongoing treatments approaches for both DS-TB and MDR-TB.

4

1.2 CURRENT TB CARE APPROACHES IN BANGLADESH
Bangladesh National TB control program (NTP) adopted the Directly Observed
Treatment, Short Course (DOTs) strategy in November 1993. By 2007 the DOTS
services were available throughout the country including metropolitan areas (National
Tuberculosis Control Program (NTP), 2015).
NTP follows a PPP model where NGOs are working in collaboration with the
MOHFW. There are about 12 NGOs working in different areas of Bangladesh. Among
these BRAC, the largest NGO in the world and Damien Foundation Bangladesh, an
affiliate of the Belgian NGO running TB control programs worldwide is the principal
NGOs who get fund from Global Fund for Tuberculosis and Malaria (GFTAM) directly.
BRAC gives away the funds to number of NGOs as the sub-recipient to work in different
areas in Bangladesh. MOHFW also gets funding from the same source and equip the
National Institute of Diseases of the Chest and Hospital (NIDCH) and number of Medical
College Hospitals with diagnostic and treatment facilities for TB patients infected with
both drug sensitive and drug resistant strains(National Tuberculosis Control Program
(NTP), 2015).
For the drug sensitive TB patients, standard 6 months’ regimen is followed by all
participating NGOs. However, the mode of delivery is different for different NGOs.
BRAC has employed Community Health Workers (CHWs) besides the DOTs centers to
ensure patient compliance, while Damien Foundation (DF) trained and employed
influential community members to help the patients to be adhered to the treatment
protocol. Another NGO, Salvation Army Bangladesh, is using drug sellers at the
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pharmacies as the counselor and drug distributors for the TB patients. Since involving
different people, e.g., family members, neighbors, pharmacists falls under common
strategy of involving community members. This study will conduct economic evaluation
between these two different modes of DS-TB treatment delivery.
National Tuberculosis Control Program (NTP) in Bangladesh follows the 20-24
months treatment regimen for MDR-TB patients. It follows the Programmatic
Management of Drug-resistant TB (PMDT) guideline (Falzon et al., 2011). The patients
are admitted in the hospitals for first 6-8 months, after the intensive phase they are
released to go to their respective home. From then on their treatment is supervised and
administered by assigned CHWs (MOHFW, 2012). Intensive phase treatment for MDRTB patients are provided in NIDCH, which is situated in Dhaka, and Chest Disease
Hospitals (CDH) in Chittagong, Sylhet and Khulna.
Damien Foundation (DF) runs shorter protocol of treatment for MDR-TB
patients, which span over 9 months. DF generally admits the MDR-TB patients in one of
their three hospitals situated at Jalchatra of Madhupur, Tangail, Shomvuganj,
Mymensingh and at Netrakona for the intensive phase of treatment which spans over four
months followed by five months of continuation phase for which drugs are administered
at patients’ home (Damien Foundation, 2008). Rajshahi Chest Disease Hospital also
provides 9 months treatment. DF also follows the strategy of involving the community
members (Sharma, 2002) while BRAC programs deploy community health workers
(CHWs) to reach the patients (Liu, Sullivan, Khan, Sachs, & Singh, 2011). This study
will assess the cost-effectiveness of the two MDR-TB programs run by NTP and DF in
Bangladesh.
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1.3 RESEARCH OBJECTIVES
The study will focus on the following general objective:
To assess economic burden of drug sensitive and drug resistant tuberculosis on
the afflicted population of Bangladesh and to investigate economic evaluation of the
current approaches of Tuberculosis control in Bangladesh.
The specific objectives of the study are as follows:
1. To analyze the direct and indirect cost of diagnosis and treatment of drugsensitive TB and MDR-TB in Bangladesh.
2. To estimate the health system cost of diagnosis and treatment of drug-sensitive
TB and MDR-TB in Bangladesh.
3. To measure effects as quality-adjusted life-years (QALYs) gained and
disability-adjusted life-years (DALYs) averted.
4. To conduct a cost effectiveness analysis with QALYs and DALYs as the health
outcomes.

1.4 STRUCTURE OF THE DISSERTATION
This dissertation proposal is divided into introduction, literature review, methods
which are followed by three sections depicting the three studies conducted under the
purview of the dissertation. Three studies are namely economic burden of TB in
Bangladesh, economic evaluation of DS-TB treatment approaches and economic
evaluation of MDR-TB treatment approaches in Bangladesh.
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CHAPTER 2
LITERATURE REVIEW
2.1 INTRODUCTION AND SCOPE OF REVIEW
This chapter reviews the theoretical concepts of illness with tuberculosis and its
impact on individuals, families/households, and society as a whole. Following that the
chapter includes literature review of existing studies on economic burden of tuberculosis
studies as well as the studies on cost-effectiveness of both drug sensitive and drug
resistant TB treatments all around the globe.

2.2 ECONOMIC BURDEN OF TUBERCULOSIS
2.2.1 THEORETICAL CONCEPTS OF ECONOMIC BURDEN OF TUBERCULOSIS
In cost analysis three types of costs are taken into account, direct costs, indirect
costs and intangible costs due to illness. Direct costs include healthcare costs (hospital,
medication, emergency transportation, outpatient visit charges) and family costs (out-ofpocket payment (OOP), medication, transportation of families etc.). Indirect costs include
the opportunity costs of work-loss days, lost productivity/income on the part of both the
patients and his/her relatives. Intangible costs can arise from the functional limitations,
pains acquired in the process and cannot be quantified and highly subjective in nature
(Centers for Disease Control and Prevention (CDC), 2013).
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Besides these costs, there is another important cost incurred by the households through
coping strategies, which includes sale of assets, taking up debt, saving on food or other
items, taking a child out of school to care for the patient or taking up another job
(Russell, 2004).
The costs of communicable diseases fall on the households in three distinct phases:
1.

Pre-diagnosis

2.

During Diagnosis/Pre-treatment

3.

During Treatment

The causal linkages of these factors are depicted by Russell (2004):

Figure 2.1 Conceptual Framework for analyzing the economic burden of illness for
households (Russell, 2004)

9

At the stage of boxes 1 and 2, decisions are made whether and how treatment is
sought as a response to the event of illness. The health system is captured in Box 6.
Direct costs capture expenditures related to seeking treatment while indirect costs are loss
of labor time for patients and their caregivers. The severity of illness and characteristics
of health services affect direct and indirect costs and influence access to and choice of
provider. The cost burden and coping strategies of struggling with this burden
(mobilizing resources outside the household such as credit) determine household assets
and impoverishing processes, hence the link between illness and poverty (Russell, 2014).
McIntyre et al. (McIntyre et al., 2006) provided a flow-chart on economic
consequences of TB illness and payment for healthcare (Figure 2.2). According to
McIntyre there are four stages of tuberculosis treatment, e.g., illness experience,
treatment seeking behavior, economic consequences, and coping strategies and social
resources. In preliminary stages, perception of illness and treatment seeking can be
affected by the economic status of the person. If the patient with TB does not seek
treatment then only indirect costs is incurred in form of lost productivity, while if the
patient goes for treatment then direct costs also incurred on top of indirect costs. Indirect
costs further subdivided into productivity loss of the patient and the caregiver, whereas
direct cost is categorized into financial costs of healthcare (services and medicines) and
other financial costs.
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Figure 2.2 Simplified flow-chart of key issues relating to the economic consequences
of illness (McIntyre, Thiede, Dahlgren, & Whitehead, 2006)
Based on conceptual model of McIntyre et al. (McIntyre et al., 2006) Laokri et al.
(Laokri et al., 2014) (2014) provided an extended conceptual framework incorporating
intangible costs, e.g., pain and suffering, and social stigma; elaborating coping costs and
social burdens due to illness; and includes societal economic loss along with illness
poverty trap ensued due to illness (Figure 2.3). This extended model also includes
forgone activities of the informal caregivers as well as those of guardians accompanying
the TB patients for treatment. These foregone activities can culminate into labor
substitution, withdrawal of children from school, and informal caregiving activities of the
family members. Guardians lose time and income. Direct costs have been subdivided into
subsidized healthcare costs, non-subsidized healthcare costs, and non-healthcare costs.
Non-subsidized healthcare costs and non-healthcare costs along with income loss of the
guardian can result in (1) Financial resource mobilization, e.g., borrowing, selling assets,
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pledging, extra-earnings etc.; (2) Resource reallocation, e.g., dissaving, budget cuts,
deprivation, delayed investment etc. Non-subsidized healthcare costs and non-healthcare
costs can also lead to erratic care pathways which include redundant care visits,
alternative care seeking, diagnosis and treatment delays, and care interruption.
Intangible costs like pain and sufferings and social stigma can impose social
consequences like (1) Low awareness: low awareness of disease, denial of illness status,
bad living conditions, fear of losing position, social isolation, lack of family support,
patient-related delays; (2) Social exclusion: exclusion from services including public
healthcare services, from income and from participation.
Between McIntyre’s and Laokri’s conceptual frameworks, both of which are built
upon the framework proposed by Russell (2004), simpler McIntyre’s framework will be
adopted for this study. Both frameworks are more or less similar, while Laokri’s one is
more detailed and includes pain and suffering, and social stigma. It is difficult to assign
monetary value to intangible costs like pain and stigma. On the other hand, these
intangible phenomena affect the quality of life of the patients. In our adopted quality of
life measurement tool pain and stigma have included to offset their absence in the costs
estimation. It also prevents double counting; once included in costs and again take into
account while measuring quality of life.
There are four approaches to measure the cost of illness, e.g., human capital
method, willingness to pay method, production cost and friction cost method (Jo, 2014;
Malaney, 2003). Out of these human capital and willingness to pay methods are best
suited for calculating the costs of illness from the patient perspective (KNCV
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Tuberculosis Foundation, 2008). This study intends to employ both the method to capture
different dimensions of costs. As Human Capital method (HCM) captures the valuation
of forgone income and productivity and willingness to pay (WTP) captures the subjective
reporting of actual costs accrued to the household and the perceived costs of the illness. It
is argued that the HCM underestimates the total cost of illness than the WTP method,
since it fails to capture the costs which are difficult to measure in numeric terms, e.g.,
costs associated with pains and sufferings.
The study will estimate the cost to society in the form of lost future productivity
discounted to the present. The calculations aim at a sum of future earnings of the
premature dead by looking at life expectancy, labor force participation and average salary
data. This is sometimes called the ‘top-down-approach’. It includes direct and indirect
costs. Indirect costs are productivity losses, measured by estimating income foregone due
to morbidity and mortality. The cost of morbidity is the value of lost workdays. Future
earnings are discounted to assess the present value of lost income.
The study will measure the total cost of illness including the costs of illness in the
past and present along with the future projection of the costs based on the collected data.
The future projection of the costs is important in the sense that the debilitating disease
may accrue a long-term costs burden on the family and the society as a whole and these
costs can be quite high, even though often not considered explicitly in cost of illness
analysis. As in the case of Measles vaccination, it is found that although measles
vaccination prevents deaths within a short time frame (preventing measles death) it also
has longer term impact on child survival. In other words, mortality rate among measles
vaccinated children were lower than comparable children without vaccination (Koenig et
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al., 1990). Productivity effect of malaria persists for many years after the control of
malaria outbreaks in an area and imposes huge economic burden in the long run (Breman,
Egan, & Keusch, 2001). It is also likely that TB has these indirect long-term effects and
this study will try to get a handle on these longer-term outcomes.
From the institutions like DOTS centers, hospitals treating TB patients etc. data
will be collected for the variable costs, which is the direct function of number of patients
treated and includes costs such as drugs, reagents, and food during hospitalization. Then
the fixed costs like personnel salaries, costs of vehicles and their maintenance and other
administrative costs will also be enumerated to estimate programmatic costs (Murrat et
al., 1993).

2.2.1 EXISTING EVIDENCE ON ECONOMIC BURDEN OF TUBERCULOSIS
Islam et al. (Islam et al., 2002) conducted a cost-effectiveness study comparing
between community health workers (CHW) model adopted by BRAC and government
run TB program which did not include CHWs. As part of the study the authors estimated
the cost of delivering TB treatment from both patient and provider perspectives. From
the study areas they collected the costs of all health workers and administrative staff,
BRAC capital costs (including building costs) derived from accounting books and
financial reports and in the absence of government report on capital costs those were
estimated based on the local market price and current replacement costs. Capital costs
were annuitized by using 10 years lifetime for furniture, 5 years for vehicles and
equipment and were discounted at 5% per annum rate. Training costs were excluded
assuming the costs equal across the two types of programs.
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Figure 2.3 Conceptual framework to assess multidimensional economic burden of illness in a user’s perspective
(adapted from McIntyre et al., 2006) (Laokri, Dramaix‐Wilmet, Kassa, Anagonou, & Dujardin, 2014)

Recurrent costs were collected from accounting books and financial reports from both
programs and overhead costs for TB programs were calculated to be 10% in BRAC
facilities and 5% in government run facilities. Patient’s costs were elicited by
interviewing 18 BRAC and 20 government patients. Time and travel costs associated
with patients visits to health facilities for diagnosis, drug collection, and follow-up tests
as well as costs of people accompanying the patients in each visit was included in
patient’s costs. It was calculated that the total cost was about $10 (422 BDT in 19961997) in BRAC areas while the cost was US$19 (802 BDT in 1996-1997) in government
facilities (Islam et al., 2002). Using the Consumer Price Index (CPI) reported in the
World Bank website we get that the costs was in 1,392 in 2015 BDT in BRAC areas,
while the costs in government areas were 2,646 in 2015 BDT (The World Bank, 2017a).
Another study estimated the patient costs during TB treatment in Bangladesh and
Tanzania (Gospodarevskaya et al., 2014). Total 96 patients were interviewed to find out
the patient costs for six months DSTB treatment. The study sample includes 67 patients
from BRAC, 22 from Damien Foundation, and 7 from Population Services and Training
Centers. Total costs incurred during the six-month treatment regimen was estimated by
combining the cost incurred during two months of intensive phase plus twice the costs
incurred during two months of continuation phase. Total cost includes travel costs,
guardian/accompanying person costs, caregiver cost, as well as treatment costs, e.g.,
laboratory tests, administration fees, hospital admission charges, medicines and
supplements costs. Income lost due to TB for the patients and the guardians who would
otherwise be paid through employment was calculated to determine the indirect costs.
Indirect costs for students, prisoners, and those who were unemployed before the TB
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illness were not estimated assuming that these groups of people had no foregone costs.
But for those who do housework, their foregone wage at the rate paid for maid service
was calculated and added to the patient costs. Total patient costs in Bangladesh was $224
in 2012, which is equivalent to 16,690 in 2012 BDT and 20,720 in 2015 BDT.
Interestingly both of these studies excluded the costs incurred by patients before
reaching the treatment facilities. This constitutes a major source of costs for the patients.
Since the TB treatment is almost free except for traveling, this cost constitutes a major
portion of the total costs. A study conducted by Croft et al. (Croft & Croft, 1998) among
TB patients in Nilphamari, Bangladesh showed that a mean financial cost to the patients
due to foregone income and payments for doctors’ consultation and medicines were $245
in 1996 which is equal to $808 in 2015 and BDT 64,663 in 2015 (1 Dollar=80 BDT).
There are several systematic reviews on TB patient and health system costs have
been done. Laurence et al. (Laurence, Griffiths, & Vassall, 2015) searched for cost and
economic evaluation studies on both DS-TB and MDR-TB between January 1990 and
February 2015. The authors found mean DS-TB treatment costs were $273 in lower
middle-income countries (LMICs) and $258 in low income countries (LICs), whereas the
MDR-TB treatment costs were $6,313 and $1,218 respectively. Tanimura et al.
(Tanimura, Jaramillo, Weil, Raviglione, & Lönnroth, 2014) focused only on LMICs and
searched the database from inception to March 31, 2013. Mean total costs ranged from
$55 to $8,198, with an unweighted average of $847. Half of the total costs were reported
before treatment started, while the composition of costs was 20% to direct non-medical
costs, 20% to direct medical care costs, 60% to income loss due to TB illness. In a study
conducted with published literature on African countries showed that mean pre17

diagnostic costs were between $36 and $196, while post-diagnostic costs were between
$17 and $448.

2.3 HEALTH RELATED QUALITY OF LIFE (HRQOL)
In this section studies on health related quality of life (HRQoL) of TB patients is
reviewed. Main focus is on different measurements of HRQoL, e.g., Quality Adjusted
Life Year (QALY) and Disability Adjusted Life Year (DALY). Then different
measurement scales used for eliciting HRQoL measures for TB patients is explored.
Quality of life measurement uses utility theory to identify the degree of health
concerns related to any disease or health conditions. Quality adjusted life year (QALY)
and Disability adjusted life year (DALY) are the two summary estimates widely used in
health economic evaluations. While QALY views health outcomes from the perspective
of “healthiness”, DALY views health outcomes in terms of loss of life years due to
disabilities.
𝑖

𝑄𝐴𝐿𝑌𝑠 𝑔𝑎𝑖𝑛𝑒𝑑 = 𝑄 𝑖

1−𝑒 −𝑟𝐿
𝑟

− 𝑄

1−𝑒 −𝑟𝐿
𝑟

(1)

where 𝐿𝑖 and 𝑄 𝑖 are, respectively, the period over which treatment affects the
individual’s quality of life, and the quality of life weight with treatment; while L and Q
are the corresponding parameters without treatment.
The formula for calculating the number of QALYs gained through an intervention
i is as follows:
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(2)

𝑟

here the life expectancy with the intervention (𝐿𝑖 ) at age a is divided into P time
periods 𝑛𝑝 , and 𝑄𝑝𝑖 is a vector of health-related quality of life weights predicted (or
𝑖
observed) for each time period 𝑛𝑝 following the intervention. While 𝑄𝑚
is weight

associated with the health state before intervention and individual’s residual life
expectancy is divided into N time periods 𝑛𝑚 . Here 𝑡𝑝 𝑎𝑛𝑑 𝑡𝑚 are the of individual years
within the life expectancy.
On the other hand, Disability Adjusted Life Year (DALY) is the sum of the Years
of Life Lost (YLL) due to premature mortality and the Years Lost due to Disability
(YLD) for people living with the health condition or its consequence (World Health
Organization (WHO), 2013a).
DALY = YLL + YLD

(3)

We can derive the formula for YLL and YLD as follows (Diel et al., 2014):
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(5)

Where, K = Age-weighting modulation constant (1.00), C= Age-weighting
scaling constant, L= country-specific standard life expectancy at age of death (years),
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DW = Disability Weight (0.333; 95% CI= 0.224-0.454) as per the Global Burden of
Disease 2013 study weights (Salomon et al., 2015), T= treatment duration, and α = age of
onset of disability.

2.3.1. HEALTH RELATED QUALITY OF LIFE OF TUBERCULOSIS PATIENTS
Although several studies have been conducted to assess the health-related qualityof-life (HRQoL) for tuberculosis patients (Brown et al., 2015), there is no well-accepted
tuberculosis-specific HRQoL measurement instrument available. Most studies use EQ5D, SF-36, SF-6D and other generic HRQoL instruments (Guo, Marra, & Marra, 2009).
Only one study conducted in India used a TB-specific tool named DR-12, which has 12
items each ranked on a scale of 1–3 (Dhingra & Rajpal, 2003). Recently a
multidimensional TB-specific HRQoL instrument named Functional Assessment of
Chronic Illness Therapy-Tuberculosis (FACIT-TB) was developed and psychometrically
validated in Iraq (Dujaili et al., 2015). This FACIT-TB instrument includes physical,
mental, social and economic, functional, as well as spiritual well-being of the TB
patients. This instrument is unique in incorporating questions on adverse drug reaction
(ADR), perception about social stigma, and spirituality related with TB.
The scale comprises 45 items: 17 items covering physical well-being (possible
score range 0–68), seven items covering social and economic well-being (possible score:
range 0–28), 11 items covering emotional well-being/living with TB (possible score
range 0–44), seven items covering functional well-being (possible score range 0–28), and
three items covering spiritual well-being (possible score range 0–12). A 5-point Likert
type scale ranging from 0 (not at all) to 4 (very much) is assigned to each item.
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2.4 COST-EFFECTIVENESS OF TUBERCULOSIS PROGRAMS
Till date, to our best knowledge, the only cost-effectiveness analysis between two
TB control programs run by BRAC and government was conducted by Islam et al.
(2002). It showed that the government program was 50% more expensive for similar
outcomes.
Many cost-effectiveness analyses have been done in order to determine the costeffective diagnostic techniques, e.g., sputum examination (Walker et al., 2000),
serological tests vs. other diagnostic tests (Dowdy, Steingart, & Pai, 2011), dual or single
test for detection of latent tuberculosis infection (LTBI) (Pooran et al., 2010), . However,
since the focus of this thesis is to compare between two TB control programs we restrict
our review among those studies which conducted cost-effectiveness analyses between
programs.
Using Denver General Hospital data Burman et al. showed that although DOT is
costly at the outset it turns to be cost-effective than Self-administered Therapy (SAT)
because of higher cure rates (Burman, Dalton, Cohn, Butler, & Reves, 1997). The
outcome variable for this study was cure rate per cost unit.
Using published literature, records, and expert opinions Baltussen et al. showed
that DOT as well as incremental programs like DOTS plus, Full combination of DS-TB
and MDR-TB strategies all are cost-effective in terms of DALYs averted per cost unit in
high burden TB countries in Africa and South-East Asia (Baltussen, Floyd, & Dye,
2005).
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Several other studies have been conducted in different countries, e.g., Thailand
(Hunchangsith, Barendregt, Vos, & Bertram, 2012), Egypt and Syria (Vassall, Bagdadi,
Bashour, Zaher, & Maaren, 2002), Botswana (Moalosi et al., 2003), Haiti (Jacquet et al.,
2006), Uganda (Okello, Floyd, Adatu, Odeke, & Gargioni, 2003), Brazil(Mohan, Bishai,
Cavalcante, & Chaisson, 2007). These studies invariably documented that the DOTs
strategy or involving the communities in the care process is cost-effective over SAT.
In two studies conducted in South Africa (Sinanovic et al., 2003), and in India
(Pantoja et al., 2009) the authored showed that PPP models were more cost-effective by
virtue of reducing costs to patients by 64-100%in South Africa; while the patient cost fell
from US$154 to US$132 over four-years period in India.
A recent study shows that shortening of the DS-TB treatment from six-months to
four-months remain cost-effective option for Brazil, South Africa, Bangladesh and
Tanzania (Gomez et al., 2016). Another study results also support this finding in South
Africa (Knight et al., 2015).
Several studies have also been conducted to assess the cost-effectiveness of
different MDR-TB treatment regimens. Fitzpatrick et al. (2012) conducted a systemic
review of studies which used primary data and outcome which eventually includes only
four studies conducted in Estonia, Peru, the Philippines, and Tomsk, Russia. Cost per
DALY averted were $598, $163, $143, $745 respectively. The cost per DALY averted
was lower than GDP per capita in all 14 WHO sub-regions considered.
However, there was no study comparing between the shorter and longer regimen
for MDR-TB treatment. Two separate studies conducted by DF scientists assessed the
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effect of two regimes. One study which was conducted for the standardized regimen of
21-24 months published in 2004 (Van Deun, Salim, Kumar Das, Bastian, & Portaels,
2004)and another study on shorter regimen was published in 2010 (Deun et al., 2010).
Both of the studies showed that both treatment strategies are successful in treating MDRTB patients; however, in absence of any comparative cost-effectiveness analysis between
them we cannot tell which one is better.

2.4.1 METHODS OF COST-EFFECTIVENESS OF TUBERCULOSIS PROGRAMS
Cost-effectiveness analyses with DALY or QALY as outcome variable usually
employs various models like population model PopMod (Baltussen et al., 2005), Monte
Carlo simulation technique (Tupasi et al., 2003), dynamic state-transition model of TB
(Resch, Salomon, Murray, & Weinstein, 2006) etc. In this study, to conduct the economic
evaluations of different tuberculosis control programs, we shall use the Monte Carlo
simulation technique. A probabilistic Markov Chain Monte Carlo (MCMC) simulation
model will be fitted. The patient level data on treatment outcomes will help to get the
transitional probabilities between states as well as we can use regression techniques to get
the probabilities along with the uncertainties. That will help us to conduct the sensitivity
analysis of the results. Finally, we will estimate the Incremental Cost-Effectiveness Ratio
(ICER) between the different comparators and use the acceptability curves approach to
find out the cost-effective TB control program in Bangladesh.
Markov model has some unique characteristics which fit the progression of TB
well. For example, in Markov model states are mutually exclusive, states are complete
(i.e. no people are lost) and people remain in that state for a fixed period of time. Also,
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Markov model is preferred over the decision trees when health event repeats over time, or
have longer term health effects, effect of treatment either stops quickly after initial
treatment or continue at an earlier level, and the risk of different health events does not
depend on patient’s prior history (Briggs, Claxton, & Sculpher, 2006).
Here we can represent the Markov model for TB as below:

Cure

Default

Death
Death

Fail

Figure 2.4 Simplified Markov Model for Outcomes of Illness with Tuberculosis
From the Markov model we can find that after starting of the treatment the MDRTB patient can move to any of the four states, e.g., cure/treatment complete,
failure/relapse, default, and death. Here default and death are the absorbing states. If any
patient is cured he/she can remain cured, relapse/reinfection may occur, or can be dead.
On the other hand, the failed/relapsed patients undergo another cycle of treatment and can
culminate into cure, remain failed, can default, or can be dead as well.
Infectious disease often requires dynamic models which reflect the rate of
transmission of disease among the population. The rate of infection is a function of the
number of infected individuals in the community (Briggs et al., 2006). Epidemiology of
an infectious disease is important to take into account because due to change in the
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natural history of disease can affect the outcome of the disease and thereby, the costeffectiveness analysis will be flawed (Jit & Brisson, 2011).
TB is an infectious disease and have latent period and many latent cases which
does not turn into a full blown disease. But these latent TB infection (LTBI) can be
activated upon proper stimuli or absence of immunity, as in the case of HIV/AIDS.
Therefore, many researchers included these aspects in the infectious disease modeling
(Jacquet et al., 2006; Menzies, Cohen, Lin, Murray, & Salomon, 2012; Oxlade, Piatek,
Vincent, & Menzies, 2015; White & Abubakar, 2016). Dowdy et al. (2013) synthesized
that a single model is unlikely meet all criteria for all studies and prepared a wish list for
the TB modelers would love to have (Dowdy, Dye, & Cohen, 2013)
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CHAPTER 3
METHODS
3.1 INTRODUCTION
Bangladesh National Tuberculosis control program (NTP) follows a PPP model
where NGOs are working in collaboration with the MOHFW. There are about 12 NGOs
working in different areas of Bangladesh. Among these the largest NGO in the worldBRAC and Damien Foundation Bangladesh, an affiliate of the Belgian NGO running TB
control programs worldwide are the principal NGOs. These NGOs are recipients of the
funds provided by Global Fund for Tuberculosis and Malaria (GFTAM) along with NTP
being the principal recipient. BRAC gives away the funds to number of NGOs as the subrecipient to work in different areas in Bangladesh. NTP uses the fund for equipping the
National Institute of Diseases of the Chest and Hospital (NIDCH) and number of Medical
College Hospitals with diagnostic and treatment facilities for tuberculosis (TB) patients
infected with both drug sensitive and drug resistant strains (MOHFW, 2014).
For the drug sensitive TB patients standard 6 months regimen is followed by all
participating NGOs. However, the mode of delivery is different for different NGOs.
BRAC has employed Community Health Workers (CHWs) besides the DOTs centers to
ensure patient compliance, while Damien Foundation (DF) trained and employed
influential community members to help the patients to be adhered to the treatment
protocol.
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Another NGO, Salvation Army Bangladesh, is using drug sellers at the pharmacies as the
counselor and drug distributors for the TB patients. This study will conduct economic
evaluation between these two different programs.
NTP in Bangladesh follows the 20-24 months treatment regimen for Multi-Drug
Resistant TB (MDR-TB) patients. It follows the Programmatic Management of Drugresistant TB (PMDT) guideline (Falzon et al., 2011). Initially MDR-TB patients are
admitted to designated hospitals for intensive phase of treatment which generally last for
6-8 months. Then the patients are released to community and their treatment is supervised
and administered by CHWs for another 14-16 months (MOHFW, 2012). Damien
Foundation (DF) runs their own protocol of treatment for MDR-TB patients, which span
over 9 months and differs in mode of treatment. DF generally admits the MDR-TB
patients in one of their three hospitals situated at Jalchatra of Madhupur, Tangail,
Shomvuganj, Mymensingh and at Netrakona for the continuation phase of the treatment
which spans over four months followed by five months of continuation phase for which
drugs are administered at patients’ home (Damien Foundation, 2008). DF also follows the
strategy of involving the community members (Sharma, 2002) while BRAC programs
deploy community health workers (CHWs) to reach the patients (Liu et al., 2011). This
study will assess the cost-effectiveness of the two MDR-TB programs run by NTP and
DF in Bangladesh.

3.2 STUDY DESIGN
The study follows a stratified random sampling method. From the 64 districts of
Bangladesh nine districts from the eight divisions (at least one from each division) were
selected based on the high and low burden of TB cases. Then from each district two
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upazilas (sub-districts) will be selected randomly. From the registry of the DOTS center
of the UHCs of these eighteen upazilas lists of TB patients currently undergoing
treatment or recently finished will be collected.

3.3 STUDY SITE
3.3.1 DRUG SENSITIVE TB (DS-TB)
For total representation at least one district from all eight divisions of Bangladesh
was selected for the study. Since Dhaka division is bigger in size, three districts was
selected from Dhaka division including an urban area of Dhaka city. Selection was made
based upon the high and low TB burden among all districts. Therefore, five high burden
and four low burden districts have been selected under the purview of the study. Two
upazilas (sub-districts) from each of the selected districts was selected randomly.
Following is the list of all districts and upazilas covered under the study. From each
upazila 50 DS-TB patients were selected randomly for interview.

3.3.2 MULTI-DRUG SENSITIVE TB (MDR-TB)
For assessing economic burden of MDR-TB patients and the economic
evaluation of comparator MDR-TB control programs about 175 MDR-TB patients will
be selected purposively. According to the recent estimates in 2014 number of laboratoryconfirmed MDR-TB patients was 994 in Bangladesh (World Health Organization
(WHO), 2015a) and the prevalence of MDR-TB is 5,100 in 2015 (World Health
Organization (WHO), 2016a). In our study areas the number will be clearly significantly
lower. Therefore, we collected the information of the MDR-TB patients from the TB
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control programs and reach those who (Brazier, Roberts, & Deverill, 2002) were
accessible.

3.4 STUDY PARTICIPANTS
The inclusion criteria for the study participants will be as follows:
a) Older than 18 years of age,
b) Suffering or recently suffered from pulmonary TB (DS-TB/MDR-TB),
c) Undergoing treatment or finished treatment within last 6 months.

3.5 SAMPLE SIZE
Glick (H. A. Glick, 2011) proposed a sample size formula for cost-effectiveness
evaluation of clinical trials. Although our study is not a typical clinical trial, given the
nature of the intervention and the study design we can apply the formula for calculating
the required sample size for our study. The formula calculates the sample size for each of
the two groups with similar standard deviation of costs and effect and same sample size:
2

2

2 (𝑍𝛼 + 𝑍𝛽 ) [𝑠𝑑𝑐2 + (𝑊 ∗ 𝑠𝑑𝑞2 ) − (2 𝑊𝜌 ∗ 𝑠𝑑𝑐 ∗ 𝑠𝑑𝑞 )
𝑛=
(𝑊𝑄 − 𝐶)2
Where:
Zα is the Z-statistic for the level of Type I error (set at 95%)
Zβ is the Z-statistic for the level of Type II error (set at 80%)
sdq, sdc are the std deviations for each group for treatment effect and cost respectively
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W is the Maximum Willingness to Pay
Q is the expected mean difference in treatment effectiveness
C is the expected mean difference in treatment cost
ρ is the expected correlation of the difference in cost (C) and effect (Q)
This is a measure of the covariance of changes in effectiveness and changes in
cost. Negative covariance, where cost decreases with increasing effectiveness result in a
larger sample size. Positive covariance where cost increases with increasing effectiveness
result in smaller sample sizes.
DSTB:
With 95% confidence interval and 80% power of the test, we assumed that the
standard deviation of costs (sdc) is 400 USD, standard deviation of effect (sdq) is 0.2
QALY, ρ, correlation of difference in cost (C) and effect (Q) is 0.4. The expected mean
difference in treatment effectiveness (Q) is 0.4 QALY and expected mean difference in
treatment cost (C) is 500 USD. We set the willingness-to-pay threshold (W) at the three
times of GDP of Bangladesh which is 3942 USD (Macroeconomics, 2001). We found the
sample size for both treatment groups is 405.
MDR-TB:
With 95% confidence interval and 80% power of the test, we assumed that the
standard deviation of costs (sdc) is 100 USD, standard deviation of effect (sdq) is 0.25
QALY, ρ, correlation of difference in cost (C) and effect (Q) is 0.5. The expected mean
difference in treatment effectiveness (Q) is 0.15 QALY and expected mean difference in
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treatment cost (C) is 1000 USD. We set the willingness-to-pay threshold (W) at the three
times of GDP of Bangladesh which is 3942 USD (Macroeconomics, 2001). We found the
sample size for one group is 70 and another is 104 with a 2:1 sample size ratio.
Table 3.1 List of Districts and Sub-districts where the survey among DS-TB patients was
conducted

Division

District

Barisal

Pirojpur

Sub-District
Pirojpur Sadar

Chittagong

Laxmipur Sadar
Laxmipur
Faridpur

Dhaka

Najirpur

Manikganj

Ramganj
Faridpur Sadar
Nagarkanda

Number Treatment
of
Delivery
Patients
Surveyed
50
Community
Health
50
Worker
50
Community
Health
50
Worker
50
Community
Member
50

Manikganj Sadar

50

Shingair

50
100

Dhaka

Khulna

Kushtia

Mymensingh Netrokona
Rajshahi

ChapaiNawabganj

Rangpur

Panchangarh

Sylhet

Habiganj

Mirpur (Urban Area)
Kushtia Sadar

50

Doulatpur

50

Netrokona Sadar

50

Kendua

50

ChapaiNawabganj Sadar

50

Shibganj

50

Panchagarh Sadar

50

Debiganj

49

Habiganj Sadar

50

Bahubal

51
1,000

Total
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Community
Health
Worker
DOTs
center,
Pharmacists
Community
Health
Worker
Community
Member
Community
Member
Community
Member
Community
Member

Figure 3.1 Study Sites (Sub-districts) where DS-TB patients were interviewed
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Table 3.2 List of Districts where the survey among MDR-TB patients was conducted
Division
Chittagong

District
Chittagong

Number of Patients
Surveyed
78

Treatment Regimen
20-24 Months Regimen

23
Dhaka

Dhaka

20-24 Months Regimen
17

Mymensingh
Mymensingh

9 Months Regimen
32

Netrokona

9 Months Regimen
18

Rajshahi

Rajshahi

9 Months Regimen
168

Total

3.6 ETHICAL CONSIDERATION
The study has already got ethics approval from University of South Carolina in
the USA where the PI is a PhD student. Institutional Board Review (IRB) approval will
also be taken from Jahangirnagar University in Bangladesh. A third and final approval
was obtained from WHO Research Ethics Review Committee (WHO ERC).
The participants were approached at their households by the trained enumerators.
At first the enumerators politely introduced themselves and asked pleasantries. After
establishing rapport, the enumerators conveyed their purpose of the visit.
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Figure 3.2 Study Sites (Districts) where MDR-TB patients were interviewed
An informed consent was obtained from each participants of the study. At the
beginning the enumerator read the introduction in comprehensible manner to the patient.
In the introduction the name and whereabouts of the investigators, name of the funding
agency, and the purpose of the study are furnished. It also attests the right of the
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respondent to withdraw any time during the interview. The benefit of participating in the
study is also described in that part.
The data is kept in one laptop and under lock and key in the office of the principal
investigator. No one except the investigator have access to the stored data. For data
analysis the patient’s information is de-identified. Thus the data analysis and presentation
in the report is completely anonymous and in any circumstances it will be kept
confidential.

3.7 DATA COLLECTION INSTRUMENTS
3.7.1 PATIENT QUESTIONNAIRE
Stop-TB questionnaire on patient’s cost has been adopted for the study. The
patient questionnaire includes questions on the previous TB treatment costs including
number of visits, tests, drugs, travel, food, accommodation, and out-of-pocket and
insurance costs etc. The questionnaire also includes questions on the current or recent
treatment for TB, which comprises of treatment costs, follow-up costs, costs borne by
family or friends, hospitalization costs, food costs, other comorbidities cost, insurance,
coping costs. Therefore, the cost instrument is a comprehensive tool to capture all costs
incurred by the patients and their families for TB. The questionnaire was field tested
among the TB patients and changes were made accordingly to make the question
understandable and answerable.
The patient questionnaire also includes the health-related quality of life questions.
In this study Functional Assessment of Chronic Illness Therapy-TB (FACIT-TB)
questionnaire (Dujaili et al., 2015), which includes 45 items under five sub-groups, will
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be incorporated along with smaller generic instruments like EuroQol-5 Dimensions-5
Levels (EQ-5D-5L) with visual analogue scale (VAS), and SF-6D, which is an abridged
well-validated version from SF-36 (Brazier et al., 2002). These generic instruments will
be used to assign utility scores for various components of the FACIT-TB instruments.
Mapping function will be used to predict the utility values. This approach involves
estimating the relation between a non-preference-based measure (like FACIT-TB) and
generic preference-based measure using statistical association and this approach requires
overlap between the two measures applied on the same population (Young, Mukuria,
Rowen, Brazier, & Longworth, 2015). Multinomial logistic regression models will be
estimated for each dimension, and the estimates from these regressions will be used to
categorize respondents into five levels of each of the EQ-5D dimensions and thus predict
the EQ- 5D health state for each respondent. A total of 1000 Monte Carlo simulations
will be run to estimate EQ-5D health states. The standard set of UK general population
values will be then applied to each predicted health state to obtain EQ-5D values.
Mapping is usually performed using regression analysis and often preferred regressions
are OLS or tobit.

3.7.2 PROVIDER QUESTIONNAIRE
Institutional level data was also collected for assessing the direct health system
costs associated with TB treatment. From this secondary source the data on the number of
patients diagnosed and treated and the outcome of the diseases in terms of complete cure,
remission, relapse or death was collected. Another questionnaire for the program
managers was used in the study to collect data on the facility and personnel level costs for
the TB control programs (included in the Annexure). Market values of the TB drugs was
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collected for estimating the drug costs for patients under various programs. Those who
are involved in the TB control programs on honorary basis, their opportunity costs of the
time were calculated using the average wage rates for service holders using secondary
sources.

3.8 DATA COLLECTION
Given the extent of household level primary data collection in 10 randomly
selected districts a total of two survey teams consisting of sixteen data collectors were
formed with one supervisor, one back checker and six enumerators in each team. The
questionnaires were prepared in consultation with my supervisor and mentors at USC.
The questionnaires were pre-tested at the field level by the selected survey teams before
the actual data collection began.

3.8.1 QUALITY ASSURANCE
The study employed multilevel quality assurance process for data collection.
Researcher will execute a four-step scrutiny process to ensure the reliability and validity
of the information. For each of the steps, certain team members will be given specific
responsibility to manage the quality assurance process.

3.8.2 CROSS CHECK
Enumerators collected quantitative data directly from households. Later,
enumerators went to the households with filled questionnaire where other enumerators
had collected the answers. This cross check by other enumerators helped to recover any
primary mistakes in collecting data.
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3.8.3 ACCOMPANY CHECK AND SPOT CHECK
Field team supervisor carried out next level data check through accompany check
and spot check. Accompany check includes accompanying enumerators during data
collection, validating the information provided by the respondents, throwing of questions,
examining proper coding and collection of information. Field team supervisor also
scrutinized the information through spot check by going to the households after the
enumerators leave the households. Such meticulous checking system ensured the quality
of data effectively.

3.8.4 Back Check
The third level quality assurance was carried out by the team supervisors. Team
supervisors visited households randomly with filled up questionnaires to examine the
accuracy and reliability of information. Three-layer cross checking in the field ensured
high quality data collection.

3.8.5 OTHER QUALITY CHECK AND FEEDBACK
After data compilation, the data set was sent to the PI for his feedbacks and other
quality measures. The Principal Investigator travelled intensely during the period of data
collection and ensured the quality of the data collection.

3.9 DATA ANALYSIS
Data analysis is primarily performed in STATA 14.2. Patient and provider level
costs data are being managed and analyzed. Regression modelling for finding important
predictors for patient costs.

38

For cost-effectiveness analysis R will be used for the ease of estimation. Markov
simulation modeling will be performed in Winbugs and Just Another Gibbs Sampler
(JAGS). Both of these softwares are open source and can easily be used from within R. R
is also an open source software for which many packages are found suitable for costeffectiveness analysis (Sutton, Welton, Cooper, Ades, & Abrams, 2012). BCEA is one of
those packages. It helps to analyze cost-effectiveness within a Bayesian framework
(Baio, 2012)

3.10 EXPECTED OUTCOME OF THE STUDY
Tuberculosis is a deadly tropical disease affecting the people of developing
countries and incurring huge cost on the economy. Thus economic evaluation of this
disease in a developing country setting will provide the researchers, policy makers an
empirical evidence of the extent of the cost burden.

3.11 DISSEMINATION OF RESULTS AND PUBLICATION POLICY
The results of the research will be disseminated to the global audience through
presentations in conferences organized by World Health Organization (WHO),
International Health Economics Association (iHEA), and American Public Health
Association (APHA) etc.
The results will also be communicated with the policy makers and program
managers of TB programs in Bangladesh and abroad. Scientific research articles will be
prepared after analyzing the data and will be published in reputed peer-reviewed journal.
The Principal Investigator of the study, Mohammad Rifat Haider, will take lead in
analyzing the data and writing the article and will be the first author. The supervisor of
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PhD Study, M Mahmud Khan, PhD, and the mentor, Zaina P. Qureshi, PhD, committee
members James W. Hardin, PhD and Md. Abdul Hamid Salim, MBBS will also be coauthors for these studies.
Contribution of other contributors in preparing the papers will also be
acknowledged. The sponsorship of TDR, WHO will be acknowledged by quoting: “This
investigation received financial support from TDR, the Special Programme for Research
and Training in Tropical Diseases, co-sponsored by UNICEF, UNDP, the World Bank
and WHO”.
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CHAPTER 4
STUDY I
4.1 ECONOMIC BURDEN OF TUBERCULOSIS IN BANGLADESH1

1

Haider, M. R. To be submitted.
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Abstract
Background: Tuberculosis (TB) is major scourge for human-kind and causes profound
economic burden. Bangladesh is a high burden TB country by which 12% of its annual
deaths are caused and 362,000 people are infected by TB. This study estimates the
economic burden of TB on the afflicted Bangladeshi population.
Methods: Based on McIntyre’s framework on economic consequences of illness, this
study collects direct and indirect cost for TB care data from 1,000 drug sensitive TB (DSTB) and 145 multi-drug resistant (MDR-TB) patients from all over Bangladesh. Provider
cost for TB care was also collected from the health facilities. Costs for DS-TB and MDRTB patients were estimated using a Generalized Linear Model and summed up with per
patient provider level costs to get the total costs per TB patients.
Results: Mean age of DS-TB patients under the study was 45.2 years while mean age of
MDR-TB patients were 35.5 years. In aggregate, DS-TB patients incurred total average
costs of BDT 21,235 (USD 265) for TB illness; while MDR-TB patients’ average costs
were BDT 34,975 (USD 437). Including provider costs for each patient (USD 9 for
DSTB and USD 2,006 for MDR-TB patients) total average costs for each DS-TB patient
was BDT 22,003 (USD 275) and for each MDR-TB patient was BDT 1,95,449 (USD
2443).
Assuming 57% case notification rate, the actual costs for treating TB patients in 2015
was USD 55.6 million. If all DS-TB patients were treated the cost would have been 1
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billion USD. For MDR-TB treatment, total cost was USD 12.5 million; treating all
MDR-TB patients would have costed USD 23 million.
Conclusions: Results show that DS-TB patients incurred about 50% of their household
annual income for treatment while that goes up to 66% for the MDR-TB patients. Prediagnosis cost constitutes about 63% of total costs for DS-TB patients and 42% of MDRTB patient costs. This figures show the significant economic burden posed by TB and
early diagnosis of the disease can reduce the burden in great extent.
Keywords: Economic Burden, Tuberculosis, Bangladesh, Patient Costs, Provider Costs
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Background
Tuberculosis is an ancient disease and has claimed more life than any other
microbial pathogens in human history (Daniel, 2006). Despite having effective treatment
for TB for more than half a century and an effective vaccine for a century, TB still kills
more people now than it ever has in the history of the world (McMillen, 2015). It is the
human behavior, non-compliance to the relatively long regimen of drugs that provides the
bacteria with opportunity of growing resistance against the anti-TB drugs. Tuberculosis is
also a disease of poverty, that means the poor and congested living conditions facilitate
the bacteria to strive (Davies, 2003, Gandy et al., 2002). Slow progress in control of a
preventable and curable disease over last two decades calls for shift our focus from
biomedical research of inventing new drugs with shorter regimen to community and
patient-driven approach where a paradigm shift is urged for (Stop TB, 2015).
In 2015, Tuberculosis (TB) ranked 18th among the highest burden diseases
globally and it constituted 47% of the global burden attributable to communicable,
maternal, neonatal, and nutritional disorders (Kassebaum et al., 2016). In 2015, 10
million new cases of TB were reported and almost two million people died from TB
worldwide (World Health Organization (WHO), 2016a). In 2015, TB became the top
infectious disease killer by claiming 1.1 million lives by matching the death tolls by
HIV/AIDS (Kassebaum et al., 2016).
Almost 85% of all new cases of Drug Sensitive TB (DS-TB) and multi-drug
resistant TB (MDR-TB) occur in 30 high burden TB countries and Bangladesh is one
them (World Health Organization (WHO), 2015b). In 2015, 362,000 Bangladeshis
developed TB and 73,000 died from it. TB accounted for 12% of all deaths (609,800) that
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occurred in 2015 in Bangladesh (Institute for Health Metrics and Evaluation (IHME),
2016).
The economic burden of TB in Bangladesh is a great concern, since it affects a
sizable number of people each year and causes 12% of the total death. Both disability and
death have grave economic implications in the form of lost income to the persons and
their families and lost Gross Domestic Product (GDP) for the country. The working age
group is more affected by the disease, that also increases the costs associated with the
disease (World Health Organization (WHO), 2016b). Besides causing death TB causes
significant disability among the afflicted population. Not only are older people more
vulnerable to the disease, but their disease is more frequently complicated with adverse
drug events which leads to reduced health related quality of life (Negin, Abimbola, &
Marais, 2015).
Expensive treatment of the disease also put burden on the patients, families, and
the health system of the country. (World Health Organization (WHO), 2016b). Moreover,
almost half (43%) of the affected in Bangladesh are not reported under the national
registries and go untreated (World Health Organization (WHO), 2016a); this makes the
control and elimination of the disease extremely hard and expensive. Emergence of drug
resistant strain also contributes in escalating costs because of high death rates, costly
treatments, and poor outcomes (Fitzpatrick & Floyd, 2012).
This study intends to assess the patient-level costs for both DSTB and MDR-TB,
and the provider-level costs for providing the TB diagnosis and treatment.
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Methods
Conceptual Framework
In cost analysis three types of costs are taken into account, direct costs, indirect
costs and intangible costs due to illness. Direct costs include healthcare costs (hospital,
medication, emergency transportation, outpatient visit charges) and family costs (out-ofpocket payment (OOP), medication, transportation of families etc.). Indirect costs include
the opportunity costs of work-loss days, lost productivity/income on the part of both the
patients and his/her relatives. Intangible costs can arise from the functional limitations,
pains acquired in the process and cannot be quantified and highly subjective in nature
(Centers for Disease Control and Prevention (CDC), 2013). Besides these costs, there is
another important cost incurred by the households through coping strategies, which
includes sale of assets, taking up debt, saving on food or other items, taking a child out of
school to care for the patient or taking up another job (Russell, 2004).
The costs of communicable diseases fall on the households in three distinct
phases: Pre-diagnosis, During Diagnosis/Pre-treatment, and During Treatment. McIntyre
et al. (McIntyre et al., 2006) provided a flow-chart on economic consequences of TB
illness and payment for healthcare (Figure 2.2). According to McIntyre there are four
stages of tuberculosis treatment, e.g., illness experience, treatment seeking behavior,
economic consequences, and coping strategies and social resources. In preliminary
stages, perception of illness and treatment seeking can be affected by the economic status
of the person. If the patient with TB does not seek treatment then only indirect costs are
incurred in form of lost productivity, while if the patient goes for treatment then direct
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costs also incurred on top of indirect costs. Indirect costs further subdivided into
productivity loss of the patient and the caregiver, whereas direct cost is categorized into
financial costs of healthcare (services and medicines) and other financial costs.
Based on the conceptual model of McIntyre et al. (McIntyre et al., 2006) Laokri et
al. (Laokri et al., 2014) provided an extended conceptual framework incorporating
intangible costs, e.g., pain and suffering, and social stigma; elaborating coping costs and
social burdens due to illness; and includes societal economic loss along with illness
poverty trap ensued due to illness (Figure 2.3). This extended model also includes
forgone activities of the informal caregivers as well as those of guardians accompanying
the TB patients for treatment. These foregone activities culminate into labor substitution,
withdrawal of children from school, and informal caregiving activities of the family
members. Guardians lose time and income. Direct costs have been subdivided into
subsidized healthcare costs, non-subsidized healthcare costs, and non-healthcare costs.
Non-subsidized healthcare costs and non-healthcare costs along with income loss of the
guardian can result in (1) Financial resource mobilization, e.g., borrowing, selling assets,
pledging, extra-earnings etc.; (2) Resource reallocation, e.g., dissaving, budget cuts,
deprivation, delayed investment etc. Non-subsidized healthcare costs and non-healthcare
costs can also lead to erratic care pathways which include redundant care visits,
alternative care seeking, diagnosis and treatment delays, and care interruption.
Intangible costs like pain and suffering and social stigma can impose social
consequences like (1) Low awareness: low awareness of disease, denial of illness status,
bad living conditions, fear of losing position, social isolation, lack of family support,
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patient-related delays; (2) Social exclusion: exclusion from services including public
healthcare services, from income and from participation.
Between McIntyre’s and Laokri’s conceptual frameworks, both of which are built
upon the framework proposed by Russell (2004), simpler McIntyre’s framework will be
adopted for this study. Both frameworks are more or less similar, while Laokri’s one is
more detailed and includes pain and suffering, and social stigma. It is difficult to assign
monetary value to intangible costs like pain and stigma. On the other hand, these
intangible phenomena affect the quality of life of the patients. In our adopted quality of
life measurement tool pain and stigma have included to offset their absence in the costs
estimation. It also prevents double counting; once included in costs and again take into
account while measuring quality of life.
Study Design
The study follows a stratified random sampling method. From the 64 districts of
Bangladesh nine districts from the eight divisions (at least one from each division) were
selected based on the high and low burden of TB cases. Then from each district two
upazilas (sub-districts) were selected randomly. From the registry of the Directly
Observed Treatment-Short-course (DOTS) center of the UHCs of these eighteen subdistricts lists of TB patients currently undergoing treatment or recently finished were
collected. Following is the list of all districts and sub-districts covered under the study.
From each sub-district 50 DS-TB patients were selected randomly for interview.
For assessing economic burden of MDR-TB patients and the economic evaluation
of comparator MDR-TB control programs about 168 MDR-TB patients was selected
purposively.
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Study Participants
The inclusion criteria for the study participants were older than 18 years of age,
suffering or recently suffered from pulmonary TB (DS-TB/MDR-TB), and undergoing
treatment or finished treatment within the previous 6 months.
Sample Size
The sample size for estimation of the costs incurred by DS and MDR-TB treatment
will be calculated using the following formula:
𝑍 ∗ 𝑆𝐷 2
𝑛=(
)
𝑑
Where,
Z= 1.96, the right-tail quantile value of a standard normal variable Z at  =0.05
d= margin of error
SD= Standard Deviation of the mean costs
For DS TB in a recent study we find that the patient cost for the treatment was
$224 (Tanzania). This cost does not include the cost for providing the treatment, i.e.,
health care delivery costs. If we guess that the total cost would be $400 including all
other costs. We also assume that the standard deviation would be $400 and with the
margin of error of $50 we get the sample size at 5% significance level is 246. However,
1,000 DS-TB patients were interviewed under the study; out of them 404 undergone
treatment under CHW model and 598 got treatment under CM model.
NTP PMDT Expansion plan, Bangladesh (2013 – 2017) estimates the MDR-TB
treatment cost is $6000. If we take the similar figure as the standard deviation and $1200
as the margin of error, we get the sample size for MDR-TB patients at 5% significance
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level is 96. Under this study, 145 MDR-TB patients were interviewed; 58 patients were
treated with 9 month regimen while 87 patients were under 20-24 month regimen.
Providers
Under the purview of the study 16 DOTs center managers and 3 representatives
from MDR-TB care providing hospitals were interviewed for collecting cost of providing
treatment to DS-TB patients. In each of the TB treatment facilities the facility manger
was interviewed using a pre-set questionnaire.
Variables
Patient Costs
 Direct costs
o Medical
costs
o Non-medical
costs
 Indirect
(opportunity) costs
• Coping costs
• Costs made in the
facility that were not
obligatory to get the
diagnosis
and
treatment (i.e., costs
of food).
• Other
costs:
(in)direct costs made
by
or
for
accompanying
persons (attendants)

Provider Costs
•
•
•
•
•
•
•
•

Prevention
and
Promotion Costs
Contact Tracing
Costs
Diagnosis Costs
Drugs Costs
Treatment Costs
Other TB activities
Costs
Human Resources
Costs
Capital Costs
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Patients’ Socio-economic
Characteristics
• Age
• Sex
• Education
• Occupation
• Religion
• Current health status
• Location
(Rural,
urban, urban slum)
• Wealth (asset) index
• Type of TB patient
(New,
relapse,
failure, transfer in)
• Household
income/number of
earning members

Data Analysis
Data analysis was performed by Stata 14.2 (StataCorp, 2015). Descriptive
statistics like means, standard deviation, frequency, and percentages will be reported.
Multivariable regression analysis will be performed for finding the important variables
for treatment and access costs.
Measurement of Average Total Direct Costs
Average total direct costs will be measured by combining all the out-of-pocket
medical and non-medical costs for TB treatment. Costs for DS-TB and MDR-TB patients
will be separately calculated. These costs include drugs, diagnostic tests, fees,
consultation fees, food costs, travel costs, accompanying person costs. That means direct
costs include all costs incurred directly out-of-pocket for the treatment of TB patient.
Costs incurred by each patient, e.g., both DS-TB and MDR-TB, have been
calculated. Patients were interviewed on each and every visits they made to any type of
provider for the TB illness were tried to track down. For each visit the patients reported
their (including their accompanying persons) incurred direct costs.
Measurement of Average Total Indirect Costs
Average total indirect costs will be measured by foregone income due to inability
to do normal daily activities. These activities can be formal or informal. Valuation of
productivity losses has been done using per capita gross domestic product (GDP) of
Bangladesh (USD 1342/year that means 294 BDT/day). Valuation using GDP is
preferred because this approach gives same weight to rich and poor people’s income.
Regression Analysis
Multivariable regression analysis will be performed using socio-demographic
variables as the predictors. The cost data for both DS-TB and MDR-TB patients were
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skewed to the right with cost amounts concentrating near zero values. However, the costs
are not exactly zeros because all TB patients incurred some costs. Given the distribution
of the costs data, normality assumption for OLS regression has been checked using
histogram and normal probability plot, and heteroscedasticity was tested using the
Breusch-Pagan test. We found that the normality assumption was violated and there was
evidence of heteroscedasticity (unequal variance).
Although log transformation of the cost variable is a common way to deal with
this skewness, it still suffers from the problem of heteroscedasticity and the
transformation and retransformation would lead to biased estimate of cost. Therefore,
estimation of a Generalized Linear Model (GLM) has been preferred because it is
particularly helpful in avoiding the log retransformation problem and it does not require
the normality assumption to hold true. For GLM one has to specify the correct link and
variance (family) function. The modified Park test was used for selecting family, while
the Pregibon link test (checking linearity of response on scale of estimation) was used to
assess the choice of link function, The large sample Pearson correlation test and Modified
Hosmer-Lemeshow test (checks for systematic bias in fit on raw scale) were used for
specifying link. Based on these tests, a GLM model with identity link and inverse
Gaussian family, in which variance is proportional to the cube of mean, was found best
suited for both DS-TB and MDR-TB cost models.
We can specify the model as below:
𝑛

𝑐𝑖,𝑗 = 𝛽0 + 𝛽1 𝑥𝑖,𝑗1 + 𝛽2 𝑥𝑖,𝑗2 + ∑ 𝛼𝑘 𝑧𝑖,𝑗
𝑘
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Here, 𝑐𝑖,𝑗 is the patient cost patient (i=1 to N) and suffering from DS-TB or MDRTB (j=0 or 1). 𝑥𝑖,𝑗1 , 𝑥𝑖,𝑗2 are dummy variables for treatment through CHW model and CM
model for DS-TB treatment costs respectively; while these two represents 20-24 month
regimen and 9 month regimen for MDR-TB treatment model, 𝑧𝑖,𝑗 represents different
covariates to control for across individuals.
Provider Costs
These costs can be called as health system costs as it contains the costs from the
health system perspective. It includes capital costs, personnel costs, drugs cost, laboratory
costs, and programmatic costs. Total cost for each facility has been summed up and then
was divided by the number of total TB patients served by each facilities to come up with
the per patient costs incurred by the provider. In other words, the health system cost will
be described as the cost from the provider side to treat each patient under each type of
treatment modality.
Estimating Economic Burden of TB in Bangladesh
Finally, the total economic burden of TB in Bangladesh has been calculated using
the TB prevalence data. This data was obtained from Global Tuberculosis Report 2015
published by World Health Organization (WHO). Recently a TB prevalence survey has
been conducted by Institute of Epidemiology, Disease Control, and Research (IEDCR) in
Bangladesh. The preliminary findings of that survey found that the prevalence rate was
lower (295 per 100,000 population) than WHO estimate of 362 per 100,000 in 2015. This
rate has also been used to estimate a comparative economic burden of TB in Bangladesh.
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Results
Patient Characteristics
Mean age of DS-TB patients under the study was 45.2 years while mean age of
MDR-TB patients were 35.5 years. Most MDR-TB patients were under the age of 45
years, whereas DS-TB patients were more dispersed among the age groups. In both DSTB and MDR-TB samples majority of the patients were male, had no education, did
informal work or did not work before occurrence of TB, of Islamic faith, and resided in
rural areas. Most of the DS-TB patients were newly diagnosed, while most MDR-TB
patients suffered from relapse or treatment failure. In the same vein, most of the DS-TB
patients had no previous history of TB treatment, but almost two-third of the MDR-TB
patients had previous history of TB treatment and almost one-fifth of the total sample did
not complete the treatment. Since, wealth index was calculated separately among two
samples, one-fifth (20%) of each population belonged to each quintile except the poorest
quintile contained more (22.4%) patient than the poorest one (17.6%) (Table 4.1).
Table 4.1 DSTB and MDR-TB Patient characteristics under the study
Characteristics
N
Age
18-25 Years
26-35 Years
36-45 Years
46-55 Years
56-65 Years
66+ Years
Sex
Female
Male
Education
No Education
Primary

DS-TB Patients
1,000
% (n)

MDR-TB Patients
145
%(n)

14.9 (149)
18.4 (184)
17.5 (175)
20.6 (206)
17.5 (175)
11.1 (111)

29.0 (42)
33.8 (49)
13.8 (20)
9.6 (14)
9.0 (13)
4.8 (7)

37.5 (375)
62.5 (625)

42.1 (61)
57.9 (84)

42.1 (421)
31.7 (317)

33.1 (48)
31.0 (45)
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Secondary
Higher Secondary and
Higher
Occupation before TB
Formal
Agriculture or Household
Jobs
Informal
Did not work
Religion
Other
Islam
Current Health Status
(VAS)
0.-50
51-65
66-80
81-100
Location
Urban
Rural
Urban Slum
Type of TB Patient*
New
Relapse/Failure
Loss to Follow Up
Household Income Before
TB
Previous TB Treatment
No Previous Treatment
Not Completed
Completed
DS-TB Program Model
Community Health Worker
Community Member
MDR-TB Program
Regimen
9 Month Regimen
24 Month Regimen
Wealth Index
Poorest
Poorer
Middle
Richer
Richest

20.6 (206)
5.6 (56)

29.0 (42)
6.9 (10)

11.6 (116)
13.4 (134)

21.4 (31)
8.3 (12)

37.6 (376)
37.4 (374)

33.1 (48)
37.2 (54)

10.6 (106)
89.4 (894)

7.6 (11)
92.4 (134)

23.2 (232)
16.9 (169)
37.9 (379)
22.0 (220)

34.5 (50)
11.0 (16)
30.3 (44)
24.1 (35)

18.2 (182)
77.2 (772)
4.6 (46)

37.9 (55)
47.6 (69)
14.5 (21)

94.2 (909)
4.9 (47)
0.9 (9)
15,282 [24,916]

4.6 (6)
87.7 (114)
7.7 (10)
17,355 [11,307]

94.0 (940)
1.0 (10)
5.0 (50)

35.2 (51)
17.9 (26)
46.9 (68)

40.3 (404)
59.7 (598)

-

-

40.0 (58)
60.0 (87)

22.4 (224)
17.6 (176)
20.0 (200)
20.0 (200)
20.0 (200)

20.0 (29)
20.0 (29)
20.0 (29)
20.0 (29)
20.0 (29)
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Total
* 15 missing for MDR-TB

100 (1,000)

100.0 (145)

Patient Level Average Costs
Direct Costs
In Table 4.2, average direct costs borne by DS-TB and MDR-TB patients have
been illustrated. Direct costs include all the out-of-pocket medical and non-medical costs
for TB treatment. Total average direct costs for DS-TB patients were BDT 20,154 (USD
252) and for MDR-TB the amount was BDT 30,858 (USD 386). The highest costs were
incurred by the patients during the pre-diagnosis phase of the illness. DS-TB patients
spent BDT 13,287 (USD 166) and MDR-TB patients incurred BDT 14844 (USD 186)
before the diagnosis of TB disease was confirmed. TB diagnosis was costly for DS-TB
patients (BDT 1,107; USD 14) than MDR-TB patients (BDT 685; USD 9). Hospital costs
were way higher for the MDR-TB patients (BDT 7,669; USD 96) than DS-TB patients
(BDT 2,515; USD 31). Additional food costs were more or less same for both DS-TB and
MDR-TB patients. Accompanying person’s costs was higher for MDR-TB patients (BDT
2,114.70; USD 26) than DS-TB patients (BDT 380; USD 5). Costs for side-effects of TB
drugs were higher for the MDR-TB patients (BDT 1,647; USD 21) than DS-TB patients
(BDT 435; USD 5). Relocation costs was incurred by only the MDR-TB patients during
hospitalization (initial incentive phase of treatment). On an average, the relocation cost
was BDT 341.24/USD 4.
Indirect Costs
In table 4.2, average indirect costs borne by DS-TB and MDR-TB patients have
also been shown. Indirect costs include the income loss by the patients as well as their
accompanying persons. MDR-TB patients incurred more indirect costs (BDT 1,523; USD
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19) than DS-TB patients (BDT 407; USD 5). Similarly, the persons accompanied MDRTB patients lost more income (BDT 2,594; USD 32) than persons accompanied DS-TB
patients (BDT 674; USD 8). In total, MDR-TB patients incurred more indirect costs
(BDT 4,117; USD 51) than DS-TB patients (BDT 1,081; USD 14).
Total Average Patient Level Costs
In aggregate, DS-TB patients incurred total average costs of BDT 21,235 (USD
265) for TB illness; while MDR-TB patients’ average costs were BDT 34,975 (USD
437).
Table 4.2 Patient Level Average Costs (BDT)
Costs
N
Direct Costs
Before Diagnosis Costs
TB Diagnosis Costs
Follow-up Costs
Drug Collection Costs
Hospital Costs
Additional Food Costs
Accompanying Person
Costs
MDR-TB Relocation Costs
Drug Side-effects Costs
Sub-Total (Direct Costs)
Indirect Costs
Patient Opportunity Costs
(Income Loss)
Accompanying Person
Opportunity Costs
Sub-Total (Indirect Costs)
Total Costs
Provider Level Average Costs

DS-TB Patients
1,000
Mean [SD]

MDR-TB Patients
145
Mean [SD]

13,287.16 [55002.53]
1,106.69 [5725.75]
172.16 [640.63]
14.6 [195.91]
2,515.23 [14813.86]
2,244.01 [1915.92]
380.03 [739.85]

14,844.23 [25589.24]
684.63 [2177.10]
877.17 [1825.46]
1.17 [6.18]
7,669.40 [10521.34]
2,678.39 [1595.63]
2,114.70 [5309.25]

4,34.58 [2998.73]
20,154.43 [60241.68]

341.24 [1386.08]
1,647.28 [5463.01]
30,858.22 [39964.31]

407.07 [378.39]

1,522.86 [942.80]

673.57 [1952.26]

2,593.91 [6765.72]

1,080.64 [2004.40]
21,235.10 [60841.03]

4,116.76 [6887.64]
34,974.098 [43635.95]

In Table 4.3, facility level data was used to illustrate the average per person health
system costs to provide TB treatment. DS-TB treatment facilities did not report any costs
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for prevention and promotional activities, e.g., contact tracing, health promotional
activities, vaccination activities etc. In treating each DS-TB patients the health system
incurred only BDT 768 (USD 9.60), for MDR-TB patients the cost rose to BDT 160,474
(USD 2006). Drugs (BDT 59276; USD 741), human resources (BDT 51826; USD 648),
and diagnostic (BDT 35554; USD 444) were the highest cost incurring areas for MDRTB patients. Similarly, for DS-TB patients the highest cost-incurring areas were drugs
(BDT 439; USD 5), diagnostics cost (BDT 184; USD 2), and human resources (BDT 70;
USD 1).
Table 4.3 Provider Level Average Costs (Per Patient)
Costs
N
Prevention and Promotion
Costs
Diagnostic Costs
Drug Costs
Training Costs
Meeting Costs
Incentive Payment
Human Resources Costs
Capital Costs
Other Costs
Total Costs (BDT)
Total Costs (USD)
Per Patient Total Average Costs

DS-TB Facilities
5648
BDT

MDR-TB Facilities
576
BDT

0.00

524.78

183.51
438.79
10.63
1.34
31.28
69.86
29.37
2.92
767.69
9.60

35,554.08
59,275.55
1,014.58
874.64
3,100.00
51,825.73
8,211.78
92.73
16,0473.86
2,005.92

Average per patient total costs including patient and provider level costs have
been shown in Table 4.4. On an average, each DS-TB patient incurs BDT 22,003 (USD
275) and each MDR-TB patient incurs BDT 1,95,449 (USD 2443).
Table 4.4 Per Patient total average cost (Including patient and provider level costs)
Costs

DS-TB
BDT
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MDR-TB
BDT

21,235.10
Patient Level Costs
(BDT)
Provider Level Costs
767.69
(BDT)
22,002.79
Total Costs (BDT)
275.03
Total Costs (USD)
Bivariate Analysis of Patient Level Cost Data

27,809.67
16,0473.86
19,5448.84
2,443.11

Table 4.5 shows the results from bivariate analysis of patient level cost for both
DS-TB and MDR-TB patients. For DS-TB costs only mean total costs of different
wealth quintiles were significantly different. In case of MDR-TB patients, categories of
previous history of TB treatment and MDR-TB regimen had significantly different mean
total costs.
Table 4.5 Bivariate Analysis of Patient Level Cost for DS-TB and MDR-TB patients
Characteristics
N

Age
18-25 Years
26-35 Years
36-45 Years
46-55 Years
56-65 Years
66+ Years
Sex
Female
Male
Education
No Education
Primary
Secondary
Higher Secondary
and higher
Occupation
Did not work
Formal
Agriculture or
Household Jobs

DS-TB Patients
1,000
Mean
Median p-Value

15,178

9,529

17,788
23,763
22,795
15,993
36,463

8,806
8430
8,887
8,802
9,378

18,092
23,121

8,802
8,849

16,888
21,531
26,083
34,404

7,130
8,646
12,830
21,196

2320
31,086
22,693

0.056a
0.813
(kwallis)

MDR-TB Patients
145
Mean
Median
pValue
0.438
43,3348
26,616
0.269
31,536
23,988
25,703
47,734
35,049

0.206
0.812
0.107
0.000

0.079
0.001

10,095
10,478
7,552
59

18,732
16,135
14,609
19,504
16,476

40,703
30,816

24,217
17,816

25,946
36,153
40,912
48,076

14,923
27,196
18,467
25,419

46,270
32,054
30,992

26,431
26,898
16,102

0.179
0.239
0.289
0.075

0.097
0.133

Informal
15,602
7,533
0.168
Religion
Other
13,532
7,234
0.110
Islam
22,148
9,194
0.205
Location
Urban
26,814
10,416
0.0015
Rural
20,585
8,494
Urban Slum
10,071
8,319
0.108
Previous TB
Treatment
No
20,453
8,515
0.001
Yes
33,484
11,988
0.021
0.069
DS-TB Program
Model
Community Health 16,971
7,574
0.000
Worker
Community
24,102
9,519
Member
MDR-TB
Program Regimen
9 Month Regimen
20-24 Month
Regimen
0.015
Wealth Index
Poorest
12,375
7,267
0.000
Poorer
27,450
7,072
Middle
18,483
8,340
Richer
19,175
9,972
Richest
30,776
12,826
0.238
Comorbidity
No
19,610
8,180
0.006
Yes
24,404
9,752
a
p-values are obtained from univariate analysis

25,150

16,201

19,083
36,280

14,428
18,665

44,143
29,566
28,737

29,782
14,127
17,709

0.210
0.058
0.141
0.003

0.041
45,025
29,523

35,200
16,377

-

-

-

-

0.004

0.006
22,975
42,975

13,406
28,261

30,846
30,180
27,372
32,204
54,273

16,542
16,476
16,147
21,801
30,770

35,146
34,319

18,012
20,607

0.000

0.120
0.071

0.927
0.693

Multivariable Analysis of Patient Level Cost Data
Two separate GLMs were estimated with the patient level cost data for DS-TB
and MDR-TB patients (Table 4.6). The modified Park test showed that best the GLM
model for DS-TB costs belonged utilized the inverse Gaussian family, but for MDR-TB
costs the Gamma family was best suited. The log link was best for both models. Results
from the GLM post-estimation for selecting best model are shown in table 4.7.
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Results show that education is a significant cost driver for both DS-TB and MDRTB patients. With higher education the costs tend to become higher in both cases.
Improved health status (measured by VAS) was associated with decreased expense on TB
care for DS-TB patients. This effect of better health status did not hold true for MDR-TB
patients. Similarly, while location of the patient had no effect in case of MDR-TB
patients, DS-TB patients resided in the urban slums incurred less cost than their urban
counterparts.
Previous TB treatment had a negative effect on MDR-TB patients cost, but it had
no effect on costs of DS-TB patients. Community member model incurred more cost than
the community health care model in case of DS-TB treatment. On the other hand, 20-24
month regimen incurred more cost on MDR-TB patients than 9 month regimen.
Wealth has no effect on cost of MDR-TB patients, while DS-TB patients
belonged to middle, richer, richest quintiles incurred more costs than the poorest patients.
Table 4.6 Multivariable Analysis of Patient Level Cost with Generalized Linear Model
Characteristics
N

Age
18-25 Years
26-35 Years
36-45 Years
46-55 Years
56-65 Years
66+ Years
Sex
Female
Male
Education
No Education
Primary

DS-TB Patients
1,000
Log Link Inverse
Gaussian Family
Coefficient
95% CI

MDR-TB Patients
145
Log Link Gamma Family
Coefficient

95% CI

Ref.
0.25
0.30
0.42
0.36
0.41

-0.19-0.68
-0.15-0.76
-0.03-0.86
-0.14-0.85
-0.18-1.00

Ref.
0.05
-0.30
0.20
0.28
0.16

-0.39-0.48
-0.79-0.23
-0.46-0.87
-0.34-0.90
-0.68-0.99

Ref.
0.18

-0.15-0.52

Ref.
-0.10

-0.48-0.27

Ref.
0.39*

0.08-0.70

Ref.
0.57**

0.15-0.99
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Secondary
Higher Secondary and
higher
Occupation
Did not work
Formal
Agriculture or Household
Jobs
Informal
Religion
Other
Islam
Current Health Status
(VAS)
Location
Urban
Rural
Urban Slum
Previous TB Treatment
No
Yes
DS-TB Program Model
Community Health
Worker
Community Member
MDR-TB Program
Regimen
9 Month Regimen
20-24 Month Regimen
Wealth Index
Poorest
Poorer
Middle
Richer
Richest
Comorbidity
No
Yes
AIC
BIC
Log Likelihood

0.45*
0.93*

0.07-0.84
0.07-1.80

0.59**
0.30

0.15-1.02
-0.41-1.01

Ref.
0.09
0.02

-0.42-0.60
-0.50-0.54

Ref.
-0.33
0.28

-0.80-0.14
-0.44-1.00

-0.31

-0.68- -0.07

-0.49

-0.92-0.07

Ref.
0.28
-0.01*

-0.07-0.62
-0.02- -0.002

Ref.
0.43
-0.004

-0.20-1.05
-0.01-0.005

Ref.
-0.02
-1.07**

-0.46-0.41
-1.74- -0.40

Ref.
0.42
-0.004

-0.19-1.04
-0.58-0.58

Ref.
0.40

-0.23-1.03

Ref.
-0.49**

-0.83- 0.15

Ref.

-

-

-

0.43**

0.18-0.69

-

-

-

-

Ref.
1.17***

0.60- 1.74

Ref.
0.15
0.38*
0.41*
0.54*

-0.18-0.48
0.04-0.72
0.04-0.78
0.03-1.05

Ref.
-0.03
-0.37
-0.32
0.10

-0.52-0.46
-0.93-0.20
-0.95-0.31
-0.63- 0.82

-0.13-0.44
29.30
-5958.78
-13159.45

Ref.
0.02

-0.40-0.44

Ref.
0.15

Table 4.7 Results from GLM post-estimation for selecting best model
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22.91
-515.46
-1636.64

Test

DS-TB Patients
Test
Decision
Statistic
p-Value
0.27
Inverse
Gaussian
Family
0.83
Log Link

Modified Park Test

MDR-TB Patients
Test
Decision
Statistic
p-Value
0.15
Gamma
Family

Pearson Correlation
Test
0.21
Log Link
Pregibon Link Test
0.57
Log Link
Modified HosmerLemeshow Test
Economic Burden of TB Care in Bangladesh

0.15

Log Link

0.12
0.66

Log Link
Log Link

Based on the World TB Report 2016, total 209,438 DS-TB patients were under
treatment in Bangladesh. Assuming 57% case notification rate, we get the actual number
of TB patients in Bangladesh in 2015 was 367,435. Therefore, the actual costs incurred
by Bangladesh have been calculated as USD 55.6 million. Whereas, if all DS-TB patients
were treated the cost would have been 1 billion USD.
For MDR-TB treatment, total USD 12.5 million was incurred in Bangladesh in
2015. If all MDR-TB patients were treated the total cost would have been USD 23
million (Table 4.8).
Table 4.8 Economic Burden of TB care in Bangladesh in 2015
Type of
TB
Patients

Average
cost

Total TB
patients
under
treatment
in 2015

Total actual costs
for TB Care
BDT

USD

Total TB
patients in
2015

Total costs
required for TB
Care
BDT
USD

DS-TB

22,003

209,438

4.45
Billion

55.59
Million

367,435

8.08
101.06
Billion Million

MDRTB

195,449

5,100

0.18
Billion

12.46
Million

9,700

1.90
23.70
Billion Million

4.63
Billion

68.05
Million

Total
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9.98
124.76
Billion Million

Discussions
Study results show that average per DS-TB patient costs were BDT 21,235 (USD
265), which is almost similar to the findings of a recent study (BDT 20,720; USD 224)
(Gospodarevskaya et al., 2014). However, the study reported only treatment cost and
excluded the pre-diagnosis cost incurred by TB patients. Excluding the whooping $166
for pre-diagnosis cost, the actual treatment level costs for DS-TB in Bangladesh from our
study comes to $100. The main difference between the study and our result stems from
the estimation of productivity losses by patients and guardians. That study used the
household level income but we used per capita GDP as the basis for calculation of lost
productivity. Given our sample size of 1,000 in comparison to their 96, we can
confidently claim that our result is more authentic and does not differ significantly
between different types of providers.
Both types of delivery modalities for DS-TB patients in Bangladesh, e.g., CHW
and CM models, ensure patients can get their medicines at their doorsteps or very near to
their houses supervised by community health workers and community members. MDRTB patients also get their medicines from assigned community DOTS providers. Yet, TB
patients incur considerable expenditure for TB treatment. From the results we can see that
a significant portion of the expenditure is incurred before TB diagnosis. It constitutes
about 63% of total costs for DS-TB patients and 42% of MDR-TB patient costs. This
shows that once the patient is diagnosed and under the treatment stream, patient level
costs and health system costs constitute only one-third of the total cost. Delay in TB
diagnosis is the major cost driver for the patients. Patients may visit number of providers
from informal to formal, even are hospitalized in the course, and incur a great loss in
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terms of medical and non-medical costs. This finding is similar to other studies where
pre-diagnosis cost of TB treatment constituted more than half of the total costs (Tanimura
et al., 2014). High pre-diagnosis cost of TB care is a phenomenon ubiquitous in LMICs,
e.g., in Malawi the patients incur a significant pre-diagnosis cost which offset the free TB
care and make the TB treatment unaffordable (Kemp, Mann, Simwaka, Salaniponi, &
Squire, 2007).
The study results slightly differ with the findings from a systematic review done
by Laurence et al. The average provider level cost was $273 in that study (Laurence et
al., 2015) in comparison to $9 per DS-TB patient in ours, since they included
hospitalization cost ($215). But in Bangladesh, the DS-TB treatment protocol does not
require hospitalization, therefore, our results do not include any hospitalization costs and
that makes the two estimates very close. For MDR-TB costs, provider level costs were
calculated $6313 in LMICs and $1218 in LICs, and patient level costs were calculated
$1616 total direct costs in LMICs and $1662 total costs in LICs (Laurence et al., 2015).
In our study we found different results- provider level costs were $2006 and patient level
costs were $437. It may be due to their estimation of life-time productivity loss, which
we confined within the period of illness only.
We found that health system costs for providing treatment costs is nominal ($9
per patient) in Bangladesh. But the high number of patients make the total burden high.
For treating DS-TB patients Bangladesh incurred 55.6 million USD in 2015, and for
MDR-TB patients USD 12.5 million. In total, expenditure for TB treatment in
Bangladesh was 68 million USD. In Bangladesh, total health expenditure was 325,094
million BDT (4,063 million USD) in 2012. Therefore, in 2015 the amount would have
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been 4,545 million USD. So, TB care expenditure constitutes about 1.67% of total
healthcare expenditure in Bangladesh. This figure does not look so ominous, but the
potential of TB treatment is very high in terms of future benefits. In a recent study
commissioned by the Copenhagen Consensus Group, Vassal showed that TB treatment
was ranked first among all priorities because its huge potential in future befits. If one taka
is spent for TB treatment, the economic return would be in the range of 29 to over 162
BDT (Anna Vassal, 2016).
TB also poses great financial hardship on the afflicted population. Often times
poor people are the sufferer and their economic condition does not help them either. In
our study results we see that DS-TB patients incurred about 50% of their household
annual income for TB treatment while that goes up to 66% for the MDR-TB patients.
This catastrophic health expenditure is multiplied in severity due to the absence of any
health insurance or other healthcare financing mechanism in Bangladesh (Nazmul, Abul
Quasem, Howlader, & Kabir, 2015). People tend to resort to sale of assets or savings and
borrowing with or without interest to cope with this catastrophic cost, which, in the long
run, make the household poorer (Khan, Ahmed, & Evans, 2017; Rahman, Gilmour, Saito,
Sultana, & Shibuya, 2013).
Data collected from the DS-TB health facilities show that no cost was incurred for
health promotional and preventive activities in past year. That means there was no such
activities in place. But contact tracing, promotional activities like making people aware of
the signs and symptoms of TB illness, informing the people on the treatment availability
and the successful cure is possible upon completion of treatment, the place where TB
treatment is available etc. are deemed to be instrumental in combating TB in LMICs like
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Bangladesh. There are some top-down promotional activities done from the central level,
but that may not reach the grass-root level. Different means of behavioral change
communication should be introduced; otherwise the ambitious target of reducing TB
deaths by 95% and curbing new cases by 90% from 2015 to 2035 (World Health
Organization (WHO), 2017) would not be achieved.
Urban slum is another hot spot which can serve as the new foci of TB in
Bangladesh. With highest urbanization rate in the world (6.5%) the capital Dhaka city
experiencing a burgeoning urban slum population. This population often resides in the
most inhuman condition and lack basic needs like health, education, and proper housing.
This close proximity of people (200,000.people in 1 square kilometer in Bangladeshi
slums (Angeles et al., 2009)) and poor living conditions facilitate transmission of the TB
bacillus and containment of the disease makes so challenging. We find from our results
that slum dwellers can spend much lower than their urban counterparts and still that
lower spending leaves them as poverty-stricken for rest of their lives due to the long term
effect on their income generating potentials.
Conclusions
Since the lion share of the total costs was incurred before diagnosis, it is
imperative to strengthen the early diagnosis and treatment of TB disease in Bangladesh.
CHW or CM who are involved with the DOTS treatment and act as a DOTS provider
should also act as the counselor for the patients and their family members. DOTS
supporter should also keep eyes open to find any potential TB cases and refer them to the
nearest facility.
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Contract tracing can be another useful way for detecting TB patients. Although it
was a regular activity in the past, during the survey we did not find any such activities
performed nowadays. It is a reminder that we should not move away from the basic
prevention techniques of the public health.
Although, treating DS-TB patients is more beneficial in the long-run, proper
treatment of MDR-TB patient is very important in further spread of the deadly disease.
MDR-TB needs special attention, because of the length of the treatment and potential for
loss to follow up and relapse. Therefore, MDR-TB patients should also be given proper
treatment and special arrangements, like tracking patients uptake of drugs by novel
means, can be thought of.
TB has been cited as the most effective health intervention in terms of costbenefit ratio (Anna Vassal, 2014). It is high time to get all TB patients under treatment
and thereby improve the economy of the country. It will also help us to reach the
ambitious goal of the WHO End TB strategy by 2035.
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CHAPTER 5
STUDY II
5.1 ECONOMIC EVALUATION OF DRUG-SENSITIVE TUBERCULOSIS (DS-TB)
TREATMENT APPROACHES IN BANGLADESH2
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Abstract
Introduction: Bangladesh is a high burden Tuberculosis (TB) country that experienced
362,000 new TB patients and 73,000 TB deaths in 2015. Drug sensitive TB (DS-TB) is
the most prominent type of TB found in Bangladesh and a 6-month drug regimen (2
month intensive and 4 month continuation phase) is prescribed. However, the directly
observed treatment short-course (DOTS) differs in delivery through community health
workers (CHWs) and community members (CMs). This study compares these two
delivery models and conducts a cost-effectiveness analysis.
Methods: The incremental cost-effectiveness ratio (ICER) of treating DS-TB patients, 45
years old on average, through CM versus CHW delivery was compared using a Markov
model with life-time horizon (27 years). The measure of effectiveness, Quality adjusted
life year (QALY) and cost of treatment was collected from 1,000 MDR-TB patients (598
for CM model and 402 from CHW model) in Bangladesh. Transition probabilities
between Markov states were estimated from quarterly outcomes report collected from
health facilities and cost and QALY both were discounted at a rate of 3%. Both
deterministic and probabilistic sensitivity analyses were conducted in a Monte Carlo
Simulation using the R programming language.
Results: Results show that each DS-TB patient under CM treatment model gains 3.61
QALYs with a cost of BDT 131,555. For the DS-TB patients under the CHW model the
cost is 81,650 and the QALY gain is 3.12. The Incremental Cost-Effectiveness Ratio
(ICER) is 103,454, i.e., the CM model is cost-effective if per QALY gain if willingnessto-pay is set to the per capita GDP of Bangladesh (BDT 107,360 in 2015).
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Conclusions: Our study results suggest that a community-based model of DS-TB
treatment is cost-effective even with changed costs and utility values in probabilistic
sensitivity analysis. Community members as DOTS provider are more capable of
reducing stigma related to TB, enhancing patient adherence and thereby reduce costs and
increase utility from the treatment. Community members should also be involved in
contact tracing and prevention activities to increase the effect of the involvement in TB
control.
Keywords: Economic Evaluation, Drug Sensitive Tuberculosis, Cost-effectiveness, Cost,
QALY, Community Based Treatment, Bangladesh
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Introduction
In 2015, tuberculosis (TB) ranked 18th among the highest burden diseases
globally and it constituted 47% of the global burden attributable to communicable,
maternal, neonatal, and nutritional disorders (Kassebaum et al., 2016). During that year,
10 million new cases of TB were reported and almost two million people died from TB
worldwide (World Health Organization (WHO), 2016a). In the same year, TB became
the joint top infectious disease killer by claiming 1.1 million lives and matching the death
tolls by HIV/AIDS (Kassebaum et al., 2016).
Almost 85% of all new cases of TB and multi-drug resistant TB (MDR-TB) occur
in 30 high burden TB countries including Bangladesh (World Health Organization
(WHO), 2015b). According to one estimate in Bangladesh during the whole year of 2015,
approximately 362,000 people developed TB and 73,000 died from it. In Bangladesh, TB
accounted for 12% of all deaths (609,800) that occurred in 2015 (Institute for Health
Metrics and Evaluation (IHME), 2016). Although case notification rate is only 57%,
success of the treatment is high (93%) among DS-TB patients. However, the success rate
is 75% among MDR-TB patients which signifies how difficult to treat drug resistant
strains (World Health Organization (WHO), 2016a). Despite having effective treatment,
patient adherence to TB treatment remains poor because of the long duration of the
regimen (six months for newly diagnosed cases) and the need for daily dosing. Failure to
adhere to the regimen results in MDR-TB (Gandy & Zumla, 2002).
The predominant method of detecting TB at the community level is examining the
sputum sample with Acid Fast Bacilli (AFB) technique. In the case of detection of MDRTB, culture and sensitivity analyses are done in laboratories. Directly Observed
72

Treatment Short-Course (DOTS) strategy has been implemented in Bangladesh since
1993 and all the Upazila Health Complexes (UHCs) have been brought under the
purview of the service from where TB detection and treatment services are given free of
cost. The essence of the strategy is the diagnosed TB patient has to go to the facility
every day for taking the drugs, thus treatment discontinuity and subsequently MDR-TB
cases can be averted (World Health Organization (WHO), 2013d).
The vibrant presence of Non-governmental organizations (NGOs) in the health
sector and TB control endeavor compels the National Tuberculosis Control Program
(NTP) under Ministry of Health and Family Welfare (MoHFW) of Bangladesh to
incorporate them into the public-private partnership (PPP) model of combating TB since
2003. In the recent guideline the role of government and private sector partnership was
reiterated again (Guideline). It was also found in different studies that this PPP model in
TB control was effective in achieving relatively high case detection (Ullah et al., 2012;
Ullah, Newell, Ahmed, Hyder, & Islam, 2006).
For the drug sensitive TB patients, a standard 6-month regimen is followed by all
participating NGOs. However, the mode of delivery is different for different NGOs.
BRAC has employed Community Health Workers (CHWs) besides the DOTS centers to
ensure patient compliance, while Damien Foundation (DF) trained and employed
influential community members to help the patients to be adhered to the treatment
protocol. Another NGO, Salvation Army Bangladesh, is using drug sellers at the
pharmacies as the counselor and drug distributors for the TB patients. Since involving
different people, e.g., family members, neighbors, pharmacists falls under common
strategy of involving community members.
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Using Denver General Hospital data Burman et al. showed that although DOTS is
costly at the outset it turns to be cost-effective than Self-administered Therapy (SAT)
because of higher cure rates (Burman et al., 1997). The outcome variable for this study
was cure rate per cost unit. Using published literature, records, and expert opinions
Baltussen et al. showed that DOTS as well as incremental programs like DOTS plus, Full
combination of DS-TB and MDR-TB strategies all are cost-effective in terms of DALYs
averted per cost unit in high burden TB countries in Africa and South-East Asia
(Baltussen et al., 2005).
A recent study shows that shortening of the DS-TB treatment from six-months to
four-months remain cost-effective option for Brazil, South Africa, Bangladesh and
Tanzania (Gomez et al., 2016). Another study results also support this finding in South
Africa (Knight et al., 2015).
Although several studies conducted economic evaluation between different types
of treatment model or regimen, economic evaluation between CHW and CM models has
not been performed. The two methods of delivering DS-TB care in Bangladesh based on
the service area of particular NGOs provide us with the opportunity to evaluate the costeffectiveness of two methods of delivering DOTS to DS-TB patients. This study aims to
conduct an economic evaluation between CHW and CM models of delivering DS-TB
care with a societal perspective and Quality Adjusted Life Years (QALY) as the outcome.
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Methods
Study Design and Data Sources
The study follows a stratified random sampling method. From the 64 districts of
Bangladesh nine districts from the eight divisions (at least one from each division) were
selected based on the high and low burden of TB cases. Then from each district two
upazilas (sub-districts) will be selected randomly. From the registry of the DOTS center of
the UHCs of these eighteen upazilas, lists of TB patients currently undergoing treatment or
recently completed treatment will be collected. From each upazila 50 DS-TB patients were
selected randomly for interview. The list of all districts and upazilas covered under the
study is shown in Table 3.1.

Institutional level data was also collected for assessing the provider level costs
associated with TB treatment using a pre-set and pre-tested provider questionnaire. We
interviewed the healthcare facility manager to get the annual human resources costs, costs
for training, meeting, incentive payments, capital costs, and other costs. Drug costs and
diagnostic costs are assumed to be equal for both treatment model since both model
follows the same guidelines published by NTP (National Tuberculosis Control Program
(NTP), 2014). Capital costs were annuitized to get the annual costs. Facility quarterly
reports from the year 2015 was used for estimating the total number of patients treated in
each facility. Finally, average per patient costs were calculated for each type of treatment
model.
The DS-TB patients were interviewed using a pre-tested questionnaire adopted
from the Stop-TB questionnaire on patient’s cost (Stop TB Partnership DOTS Expansion
Working Group (TB and Poverty subgroup), 2008).The variables of interest are the
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duration of illness, time elapsed before diagnosis, present status of the illness, how many
healthcare providers has been consulted, the direct costs incurred in each encounter,
duration of DOTS treatment, transportation cost to DOTS center, any friend/relative
accompanying with and the opportunity cost of their time, and the lost work days and
income of the patients among others.
Target Population and Study Sample
This study covers pulmonary form of DS-TB patients aged 18 years or more from
all administrative divisions of Bangladesh. Total 1,000 DS-TB patients’ data was
collected for patient level cost and outcomes (QALY) estimation under this study. Out of
these 1,000 patients, 402 were under CHW treatment model and 598 were under CM
treatment model. Study locations are shown in the Appendix Figure 1A.
Glick (H. A. Glick, 2011) proposed a sample size formula for cost-effectiveness
evaluation of clinical trials. Although our study is not a typical clinical trial, given the
nature of the intervention and the study design we can apply the formula for calculating
the required sample size for our study. The formula calculates the sample size for each of
the two groups with similar standard deviation of costs and effect and same sample size:
2

2

2 (𝑍𝛼 + 𝑍𝛽 ) [𝑠𝑑𝑐2 + (𝑊 ∗ 𝑠𝑑𝑞2 ) − (2 𝑊𝜌 ∗ 𝑠𝑑𝑐 ∗ 𝑠𝑑𝑞 )
𝑛=
(𝑊𝑄 − 𝐶)2
Where:
Zα is the Z-statistic for the level of Type I error (set at 95%)
Zβ is the Z-statistic for the level of Type II error (set at 80%)
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sdq, sdc are the std deviations for each group for treatment effect and cost
respectively
W is the Maximum Willingness to Pay
Q is the expected mean difference in treatment effectiveness
C is the expected mean difference in treatment cost
ρ is the expected correlation of the difference in cost (C) and effect (Q)
This is a measure of the covariance of changes in effectiveness and changes in
cost. Negative covariance, where cost decreases with increasing effectiveness result in a
larger sample size. Positive covariance where cost increases with increasing effectiveness
result in smaller sample sizes.
With 95% confidence interval and 80% power of the test, we assumed that the
standard deviation of costs (sdc) is 400 USD, standard deviation of effect (sdq) is 0.2
QALY, ρ, correlation of difference in cost (C) and effect (Q) is 0.4. The expected mean
difference in treatment effectiveness (Q) is 0.4 QALY and expected mean difference in
treatment cost (C) is 500 USD. We set the willingness-to-pay threshold (W) at the three
times of GDP of Bangladesh which is 3942 USD (BDT 315,360) (Macroeconomics,
2001). We found the sample size for both treatment groups is 405 which is equal to our
study sample size.
Ethical Consideration
The study has already got ethics approval from University of South Carolina in
the USA where the PI is a PhD student. Institutional Board Review (IRB) approval was
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also obtained from Jahangirnagar University in Bangladesh. A third and final approval
was obtained from WHO Research Ethics Review Committee (WHO ERC).
Settings and Locations
DF implements their DS-TB program in 22 districts in the North-Western part of
Bangladesh. The DS-TB patients detected in these areas are treated following same
regimen but the delivery of the DOTS is done by the community members. Whereas, in
rest of the 42 districts all over Bangladesh follows the treatment delivery method by
community health workers. This study collected data from districts of all eight divisions
of Bangladesh.
Study Perspective
The study will be conducted form the societal perspective, which will encompass
all costs incurred by the health care providers, patients, and community.
Comparators
For the DS-TB patients standard 6 months regimen is followed by all participating
NGOs. However, the mode of delivery is different for different NGOs. BRAC has
employed Community Health Workers (CHWs) besides the DOTS centers to ensure
patient compliance, while Damien Foundation (DF) trained and employed influential
community members to help the patients to be adhered to the treatment protocol. Another
NGO, Salvation Army Bangladesh, is using drug sellers at the pharmacies as the
counselor and drug distributors for the TB patients. We treated drug sellers under the
community model. This study will conduct economic evaluation between this two DS-TB
treatment delivery models.
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Time Horizon
The study will take a life-time horizon to capture all costs and outcomes
according to WHO guideline (Edejer, 2003). Since this study includes patients 18 years
and older, we assume they will live through to their life expectancy (72 years in 2015).
Mean age of the patient interviewed was 45 years. Therefore, we repeated the cycle for
27 times to include their whole lifespan.
Discount Rate
The study will follow the WHO discount rate of 3% for both costs and outcomes
(Edejer, 2003).
Choice of Outcome
Quality Adjusted Life Year (QALY) is the chosen outcome for this study.
Measurement of Effectiveness
QALY has been modeled using patient-level EuroQol-5 Dimensions-5 Levels
(EQ-5D-5L) measure of health related quality of life (EuroQol Research Foundation,
2017). We used Zimbabwe score sets for EQ-5D, since Zimbabwe is another developing
country like Bangladesh and we assume the EQ-5D score sets would have been similar
between populations of these two countries. Finally, the QALY measure was estimated
after controlling for patient’s socio-economic factors. Lognormal (log value of QALY as
dependent variable) has been found more suitable model. Recycled prediction has been
used to find out the estimated QALY for each type of patient outcome (e.g., cure, failure,
and default) for both regimens (Glick Book). For death state utility has been assumed
zero.
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Measurement of Costs
Health systems costs were collected from different sources. Prevention and
promotion costs, training costs, meeting costs, human resources costs, capital costs, and
other costs were collected from DS-TB treatment facilities under the purview of the study
using a pre-set provider questionnaire. Heath facility managers, personnel responsible for
financial transactions were interviewed using the questionnaire and relevant costs were
collected. Capital costs were annuitized using 5% interest rate and 10-year lifetime for
Microscopes and Gene Xpert machines, and vehicles. Costs for drugs and diagnostic tests
were assumed to be equal across two treatment modalities since both follows the same
drug regimen and treatment protocol. Per patient cost of delivering DS-TB treatment for
both types of regimen have been estimated dividing costs among the number of treated
patients in one year in those facilities using total number of patients got treatment in
2015. Patient costs were collected through interviews of DS-TB patients using a pre-set
and pre-tested questionnaire prepared on the basis of Stop-TB questionnaire on patient’s
cost (Stop TB Partnership DOTS Expansion Working Group (TB and Poverty subgroup),
2008). The questionnaire was translated in Bengali and the retranslated in English to
validate the translation. Both patient and provider questionnaires were pre-tested and
changes were incorporated before using those in the survey. Total costs of treating a
patient under each regimen was calculated by summing up the patient and provider level
costs. Then the cost was estimated using a Generalized Linear Model with Gamma
variance and log link using data from 1,000 interviewed DS-TB patients who had
complete information on disease outcomes. GLM diagnostics were used to validate the
GLM variance and link. Recycled prediction was used to estimate the costs for each type
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of patient outcome (e.g., cure, failure, default) for both regimens (H. Glick, Doshi,
Sonnad, & Polsky, 2007). For death state costs were assumed to be zero.
Models and Analysis
A dynamic, stochastic, Markov simulation model was used to model the costeffectiveness of the two comparison regimens. Markov models have unique
characteristics which fit the progression of TB well. For example, in a Markov model
states are mutually exclusive, states are complete (i.e. no people are lost) and people
remain in each state for a fixed period of time. Also, a Markov model is preferred over
the decision trees when health event repeats over time, or have longer term health effects,
effect of treatment either stops quickly after initial treatment or continue at an earlier
level, and the risk of different health events does not depend on patient’s prior history.
We can represent the Markov model for DS-TB as Figure 2.4. A more simplistic
decision tree model can be shown as in Figure 5.1:
From the Markov model and decision tree we can find that after starting of the
treatment the DS-TB patient can move to either of the four states, e.g., cure/treatment
complete, failure/relapse, default, and death. Cure state has been defined as those who
had completed treatment protocol without any evidence of failure and had at least three
consecutive negative cultures from samples collected at least 30 days apart in the final 12
month of treatment, or “Treatment Completed”, those who completed treatment
according to treatment protocol but did not meet the definition for cure because of lack of
bacteriological results.
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Cure/Treatment Completed

DOTS by CHW

Retreatment

DOTS by CM
1

DOTS at Health Facility
DOTS by CHW
Fail
Transfer Out

DOTS by CHW
MDR-TB
1
Hospital Treatment
Smear Positive Pulmonary TB
1

Death

DOTS by CM

DOTS at Health Facility

Figure 5.1 Decision Tree of two comparison treatment strategies for DS-TB
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Failure/relapse cases were defined as those who had been treated for DS-TB, were
declared cure or treatment completed at the end of their most recent course of treatment,
and later diagnosed with a recurrent episode of DS-TB. Lost to follow up/ default cases
were defined as those DS-TB patients whose treatment was interrupted for two or more
consecutive months for any reason (National Tuberculosis Control Program (NTP),
2013, 2014).
Here death is the absorbing state, i.e., if a patient is dead he/she can move from
that state to another. If any patient is cured he/she can remain cured, relapse/reinfection
may occur, lost to follow-up (default) or can be dead. On the other hand, the
failed/relapsed patients undergo another cycle of treatment and can culminate into cure,
remain failed, can default, or can be dead as well. Similarly, from default state one can
move over to other three states.
Cost-effectiveness evaluation was performed using heemod package in R
(Filipović-Pierucci, Zarca, & Durand-Zaleski, 2017). The BCEA package was also used
to validate the results form analysis with heemod package (Filipović-Pierucci et al.,
2017). Cost and utility data was modeled using STATA 14.2 (StataCorp, 2015).
Measurement of Transition Probabilities
As mentioned earlier, cost-effectiveness analysis of these two regimens has not
been undertaken yet. However, the programmatic outcome for the two treatment
strategies has been derived from the quarterly reports on the health outcomes after 12-15
months of completion of treatment, which were collected from the health facilities. Using
the reports from 2015, total number of patients and their transition between different
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states have been calculated. Transitional probabilities were estimated from these numbers
of DS-TB patients in different states using Markov simulation as an evidence synthesis
technique (Sutton, Welton, & Cooper, 2012). R has been used for the analysis along with
r2jags package for estimating the transitional probabilities for two treatment regimens
(Su & Yajima, 2012).
From these two studies the transitional probabilities for first two cycles were
estimated and furnished in Table 5.1.
Table 5.1 Transitional Probabilities of DS--TB Treatment Regimens
Input variable
CM
Cure to Cure (tpC2C)
0.609
Cure to Failure (tpC2F)
0.126
Cure to Default (tpC2Def)
0.127
Cure to Death (tpC2Death)
0.138
Failure to Cure (tpF2C)
0.354
Failure to Failure (tpF2F)
0.209
Failure to Default (tpF2Def)
0.209
Failure to Death (tpF2Death)
0.228
Default to Cure (tpDef2C)
0.250
Default to Failure (tpDef2F)
0.252
Default to Default (tpDef2Def)
0.250
Default to Death (tpDef2Death)
0.248

CHW
0.529
0.133
0.170
0.168
0.268
0.244
0.240
0.248
0.245
0.255
0.250
0.250

Parameters
Patient level cost for each regimen as well as the per patient provider costs are
shown in Table 5.2.
Table 5.3 shows parameters for the cost-effectiveness analysis along with their
distributions. Parameters mainly consist of transitional probabilities for transition
between different states, costs for treating each type of states, and the utility of each
states. Apart from this initial age was determined as the mean age of the interviewed
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population (45 years). Time horizon was therefore fixed at 27 years, accounting for the
rest of the general life expectancy of Bangladeshi people (life expectancy at birth in
Bangladesh is 72 years (The World Bank, 2017b)). Both age and cycle parameters were
kept fixed for the model.
Costs parameters follow gamma distribution as mentioned earlier and measured in
2015 Bangladeshi Taka (BDT). Utility values are measured in QALY and their
distributions were lognormal.
Table 5.2 Patient, Provider and Total Costs for two regimens of DS-TB treatment in
Bangladesh
Costs
CHW
CM
A. Patient Level Costs
Mean (BDT)
Mean (BDT)
Direct Costs
Before Diagnosis Costs
10,894.24
14,895.78
TB Diagnosis Costs
777.37
1,328.08
Follow-up Costs
213.55
144.33
Drug Collection Costs
2.81
22.49
Hospital Costs
1,421.63
3,250.39
Additional Food Costs
1,926.06
2,457.74
Accompanying Person Costs
365.7
389.66
MDR-TB Relocation Costs
Drug Side-effects Costs
438.33
432.11
16,039.69
22,920.58
Total Direct Costs
Indirect Costs
Patient Opportunity Costs (Income Loss)
432.8
396.63
Accompanying Person Opportunity Costs
508.28
784.68
941.08
1,181.31
Total Indirect Costs
Total Patient Level Costs
16,980.77
24,101.89
B. Provider Level Costs
Prevention and Promotion Costs
Not reported
Not reported
Diagnostic Costs
Same
Same
Drug Costs
Same
Same
Training Costs
6.23
44.02
85

Meeting Costs
Incentive Payment
Human Resources Costs
Capital Costs
Other Costs
Total Provider Level Costs
Total Costs

0.70
100.99
1,827.20
36.56
2.29
19,73.97

5.67
13.21
1,592.01
94.41
11.26
1,760.56

18,954.74

25,862.45

Table 5.3 Input Parameters for Cost-Effectiveness Analysis of DS-TB Treatments

a

Variable
Category
Starting age of
cohort (mean)
Time horizon

Distributiona Value

Cost of Cure
(CM)
Cost of Failure
(CM)
Cost of Default
(CM)
Cost of Cure
(CHW)
Cost of Failure
(CHW)
Cost of Default
(CHW)
Utility of Cure
(CM)
Utility of
Failure (CM)
Utility of
Default (CM)
Utility of Cure
(CHW)
Utility of
Failure (CHW)
Utility of
Default (CHW)
Discount Rate

Gamma

Low

High

Reference

Fixed

45 Years

-

-

Study Data

Fixed

27 Years

-

-

Lognormal

BDT
25,095
BDT
31,849
BDT
34,132
BDT
17,719
BDT
22,488
BDT
24,100
0.783

BDT
20,076
BDT
25,479
BDT
27,306
BDT
14,175
BDT
17,990
BDT
19,280
0.626

BDT
30,114
BDT
38,219
BDT
40,958
BDT
21,263
BDT
26,985
BDT
28,920
0.940

World
Bank
Study Data

Lognormal

0.738

0.590

0.886

Study Data

Lognormal

0.742

0.594

0.890

Study Data

Lognormal

0.776

0.621

0.931

Study Data

Lognormal

0.732

0.586

0.878

Study Data

Lognormal

0.736

0.589

0.883

Study Data

3%

0%

6%

Gamma
Gamma
Gamma
Gamma
Gamma

Fixed

In Probabilistic Sensitivity Analysis
Results
86

Study Data
Study Data
Study Data
Study Data
Study Data
Study Data

Edejer,
2003

Base Case Results
Base case results show that over the 27 cycles each DS-TB patient under CM treatment
model gains 3.61 QALYs with a cost of BDT 131,555. For the DS-TB patients under the
CHW model the cost is 81,650 and the QALY gain is 3.12. The Incremental CostEffectiveness Ratio (ICER) is 103,454, i.e., the CM model is cost-effective if per QALY
gain one can afford more than BDT 131,454 (Table 5.4).
Table 5.4 Base Case Results
Treatment Model
CM
CHW

Cost Per Patient
(BDT)
131,555
81,650

QALY Gained

ICER

3.61
3.12

103,454

Deterministic Sensitivity Analysis
Parameters were varied on different scales for high and low values and univariate
sensitivity analysis was performed to assess the robustness of the findings. A tornado plot
has been prepared to illustrate the effect of change in each variable. Based on the findings
in one-way sensitivity analysis, input parameters were varied accordingly to see their
impact in probabilistic sensitivity analysis.
In the tornado plot, shown in the Figure 5.2, we find that the most influential
parameters were utility of cure state for CM model, followed by utility of cure state of
CHW model, costs of cure state of CM model, utility of loss to follow-up state of CHW
model, and utility of loss to follow-up state of CM model. according to the more effects
on the results.
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Figure 5.2 Tornado Plot of Deterministic Sensitivity Analysis
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Probabilistic Sensitivity Analysis
In probabilistic sensitivity analysis, the costs values and utility values for each
state were varied by 20%. Initially, the base case Markov model with all parameters with
their values and distribution was run for 1000 iterations and the base case results were
assessed using incremental cost effectiveness ratio (ICER), Cost-effectiveness
Acceptability Curve (CEAC), and Expected Value of Perfect Information (EVPI).
Incremental Cost-effectiveness Ratio (ICER)
From the results reported in the Table 6 shows that over life-time the CM method
costs BDT 197,680; while CHW model costs BDT 76,836. At the same time QALY
gained by CM model is 6.13 whereas in CHW model QALY gain is 2.91. Therefore, the
resultant ICER is BDT 37,487 per QALY gained. It shows that CM method is costeffective if willingness to pay is more than BDT 37,487 (Table 5.5). Results shown in the
cost effectiveness plane also shows that the ICER is in the North-East Quadrant (Figure
5.4).
Table 5.5 ICER from Probabilistic Model
Treatment
Model
CM
CHW

Cost Per
Patient (BDT)
197,680
76,836

QALY Gained

ICER

EVPI

6.13
2.91

37,487

18,388

Cost-Effectiveness Acceptability Curve (CEAC)
Since the ICER for each QALY gain is BDT 37,480, cost-effectiveness
acceptability curve for CM and CHW crosses over at that point. After the value CM
becomes more cost-effective and thereby acceptable (Figure 5.5).
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Figure 5.4 Cost-Effectiveness Plane
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Figure 5.5 Cost-Effectiveness Acceptability Curve
Expected Value of Perfect Information (EVPI)
EVPI is the absolute limit of the value of further research that would completely
eliminate the uncertainty around the parameters in the model. EVPI value of BDT 18,388
shows that with reducing uncertainty around the parameters would require only BDT
18,388. It is also evident from the figure 6 that with EVPI peaks between BDT 300,00
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and BDT 400,000. It signifies that with increasing willingness-to-pay EVPI also
increases till certain value, then it declines.
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Figure 5.6 Expected Value of Perfect Information (EVPI) Curve
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Discussions
The study results show that the CM method of DS-TB treatment is cost-effective
in Bangladesh from a societal perspective. ICER form base case analysis is BDT 103,454
(USD 1293) which is even lower than per capita GDP of Bangladesh in 2015, which is
USD 1342. The deterministic sensitivity analysis shows that the utility garnered from the
cure status of CM method is the principal factor behind the result. Even when we
changed the utility value by 20% (within a range of 0 and 1), we found that the CM
method remains cost-effective.
Several studies have also been conducted to assess the cost-effectiveness of
DOTS program itself. DOTS was found cost-effective in developing country settings,
Thailand (Hunchangsith et al., 2012), Egypt and Syria (Vassall et al., 2002), Botswana
(Moalosi et al., 2003), Haiti (Jacquet et al., 2006), Uganda (Okello et al., 2003), Brazil
(Mohan et al., 2007). These studies invariably documented that the DOTS strategy or
involving the communities in the care process is cost-effective over SAT. In Malawi it
was shown that community based DOTS was cost-effective than the usual hospital-based
model (Floyd, Skeva, Nyirenda, Gausi, & Salaniponi, 2003).
Very few studies compared between community member DOTS model and
community health worker DOTS model. In a study conducted in Thailand, the results
show that community member model is dominant, while ICER was USD 1,100 for each
DALY gained in health worker model (Hunchangsith et al., 2012). In some countries,
randomized controlled trials (RCT) were conducted to find the efficacy of DOTS model.
In Nepal, both family based DOTS and Community based DOTS were found to be
capable of attaining international targets for treatment success (Newell, Baral, Pande,
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Bam, & Malla, 2006). In Senegal, it was found that the package based on improved
patient counseling and communication, decentralization of treatment, patient choice of
DOT supporter, and reinforcement of supervision led to improved patient outcomes
(Thiam et al., 2007).
Community members can be anyone in the community. Neighbors are mostly
selected by DF to cater drugs daily to the DS-TB patients. Salvation Army in Dhaka city
deployed drug sellers in the vicinity to provide anti-TB drugs to the DS-TB patients on
regular basis. This idea of involving community is not novel; The Union prefers the
integration of community members in the treatment procedure (Aït-Khaled et al., 2010).
Most important objective of the DOTS model was to enhance the adherence to the TB
drug regimen (World Health Organization & Stop TB Initiative, 2010). In Bangladesh, it
has been found that community based models works better than the hospital-based model
(Islam et al., 2002). But comparison between community member model and community
health workers have not been done to move forward with the best and cost-effective
model.
From costs figures for the two methods, we see that patients incur more costs for
DS-TB treatment in case of CM model. Patients’ costs were higher for before diagnosis
costs, diagnosis costs, hospital costs, and additional food costs. On the other hand,
providers with CM model spend more on training, while CHW model spend more on
incentives to the CHWS. Each CHW gets a remuneration of BDT 500 for successful
completion of the DS-TB regimen. Interestingly, no facility reported any costs for
prevention activities. Also note that, present treatment guidelines for DS-TB does not
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require any hospitalization. These show that CM model lacks in early diagnosis of the
patients which leads to undue hospitalization and more costs.
However, CM model is successful in reducing stigma related to TB disease. It has
been documented in several studies that effective stigma reducing strategies are focused
on individual and community levels (Heijnders & Van Der Meij, 2006). Stigma related to
TB disease and its care is widespread in Bangladesh and women are the worst sufferer
(Somma et al., 2008). Community member’s involvement reduce the chance of spread of
the news of TB infection and thereof avoid gossiping, undue fear of transmitting the
disease and potential discrimination. If community health workers do not divulge the
news of TB disease, her daily presence in a particular house is a telltale sign for
neighbors which leads to discrimination for the TB patient. Therefore, CHW models are
not adequate to ensure the adherence and proper treatment which is evident in the utility
value of CM method.
This study has several limitations. Although for transitional probabilities we used
quarterly reports from 18 facilities under the survey, the reported outcomes were not
verified like controlled trial settings. This can make the results biased. Cost and
effectiveness data from the patients may suffer from the recall bias, although we included
only those patients who completed their treatment not more than six months.
Despite these limitations, this study tried to collect the patient and provider level
data comprehensively using pre-set questionnaires. To our best knowledge, it is also the
first study to conduct economic evaluation between CHW and CM model of DS-TB
treatment in developing country setting.
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Community based DOTS is getting acceptance worldwide due to its proven
efficacy. However, early diagnosis and treatment of TB cases is still a far cry due to lack
of knowledge about TB in general population and absence of any proper prevention
programs. This indicates the importance of deploying community members in
disseminating the knowledge about TB signs and symptoms which may facilitate early
diagnosis of the disease as well as reduce the stigma associated with TB disease.
In conclusion, the evidence of cost-effectiveness of CM method encourages us to
adopt this model all over Bangladesh. More involvement of the community members of
all sort will help prevent the transmission of the disease, early diagnosis will lead to early
cure at low costs, and treatment adherence will help us to attain the End TB strategy by
2035.
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CHAPTER 6
STUDY III
6.1 ECONOMIC EVALUATION OF MULTI DRUG-RESISTANT TUBERCULOSIS
(MDR-TB) TREATMENT APPROACHES IN BANGLADESH3

3

Haider, M. R. To be submitted.
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Introduction: Worldwide Tuberculosis (TB) control has been halted by the emergence
of multi-drug resistant TB (MDR-TB). Bangladesh has also experienced surge in the
number of MDR-TB cases with a 29% of MDR-TB cases were found among the retreatment of pulmonary TB cases in 2015. In Bangladesh, two MDR-TB treatment
regimens (9-month and 20-24 month) are practiced and this study intends to conduct
economic evaluation between those two.
Methods: The incremental cost-effectiveness ratio (ICER) of treating MDR-TB patients,
35 years old on average, by the 9-month regimen versus the 20-24-month regimen was
compared using a Markov model with life-time horizon (37 years). The measure of
effectiveness, Quality adjusted life year (QALY) and cost of treatment was collected
from 145 MDR-TB patients (58 undergone the 9-month treatment and 87 from the 20-24month regimen) in Bangladesh. Transition probabilities between Markov states were
estimated from two published studies and cost and QALY both were discounted at a rate
of 3%. Deterministic and probabilistic sensitivity analyses were conducted in a Monte
Carlo Simulation using R.
Results: Based on the study data, each patient under the 9-month regimen gained 6.21
QALY with a total cost of BDT 987,418. Whereas, each patient under CHW model
gained 5.74 QALY by incurring costs of BDT 1,501,221. Therefore, the 9-month
regimen is clearly dominating over the 20-24-month regimen because it costs less while it
gains more QALY.
Conclusions: Our study results suggest that the shorter 9-month regimen remains costeffective in Bangladesh setting with changing costs and utility parameters varied in the
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probabilistic sensitivity analysis. MDR-TB treatment is itself cost-effective in developed
countries and with cost-effective shorter regimen both treatment adherence and efficacy
of the treatment will be improved.
Keywords: Economic Evaluation, Multi Drug Resistant Tuberculosis, Costeffectiveness, Cost, QALY, Bangladesh Regimen, Bangladesh
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Introduction
Tuberculosis (TB) is a deadly tropical disease caused by Mycobacterium
tuberculosis, a bacillus which typically affects lungs (pulmonary tuberculosis) in addition
to other parts of the human body. Tuberculosis is prevalent in the temperate region of the
world and this tropical disease is endemic in South-East Asian and African countries.
India and China, the two largest countries in terms of population, had the highest number
of cases (26% and 12% respectively) in 2012. Bangladesh, a South Asian country with
hot tropical weather, also harbors the disease in huge numbers of afflicted people.
Bangladesh is a high burden TB country and its number of Multi-Drug Resistant TB
(MDR-TB) patients is on the rise (World Health Organization (WHO), 2016a).
The world has experienced a slow gain in TB control in recent years and that
progress has been halted by the emergence of MDR-TB and Extremely Drug Resistant
TB (XDR-TB) strains. Bangladesh has also experienced a surge in the number of MDRTB cases with a 29% of MDR-TB cases found among the re-treatment of pulmonary TB
cases in 2015 (World Health Organization (WHO), 2016a).
Bangladesh follows a model involving community health workers or community
members to provide drugs regularly to the patients undergoing drug sensitive TB
(DSTB). Under the public private partnership models different Non-governmental
organizations (NGOs) are responsible for directly observed treatment short-course
(DOTs). Any lack of adherence may result in menacing drug resistant strains, MDR or
XDR TB; treatment for both the conditions are costly and time consuming. The current
WHO guidelines prescribed treatment regimen is of 20-24 months, while the shortest
effective MDR-TB treatment regimen spans over nine months (Deun et al., 2010). The
100

prolonged treatment schedule may result in more incidence of treatment discontinuation.
WHO in cooperation with STOP TB Partnership came up with a response plan in 20072008 and Bangladesh is one of the seven countries using shorter treatment regimens for
MDR-TB in June 2013 (World Health Organization (WHO), 2013c).
National Tuberculosis Control Program (NTP) in Bangladesh follows the 20-24month treatment regimen for MDR-TB patients. The NTP follows the Programmatic
Management of Drug-resistant TB (PMDT) guideline (Falzon et al., 2011) and the
treatment is supervised and administered by DOTS providers (National Tuberculosis
Control Program (NTP), 2013)
Damien Foundation (DF) runs their own protocol of treatment for MDR-TB
patients, which span over 9 months and differs in drug composition as well. DF generally
admits the MDR-TB patients in one of their three hospitals located in Jalchatra of
Madhupur in Tangail district, Shomvuganj in Mymensingh district and at Anantapur in
Netrakona district for four months of intensive phase; which is followed by the
continuation phase of five months for which drugs are administered at patients’ home by
DOTs providers (Damien Foundation Bangladesh, 2015). DF has initiated a shorter
regimen treatment of 9 months in 1997 (Van Deun et al., 2010), which eventually came
to known as “Bangladesh” regimen (Aung et al., 2014). In a recent publication in 2014,
DF researchers presented their findings from their observation study that 84.4% of the
patients undergone the shorter regimen had bacteriologically favorable outcomes up to
two years after treatment completion (Aung et al., 2014). This success of Bangladesh
regimen inspired United Sates Agency for International Development (USAID), the
International Union Against Tuberculosis and Lung Disease (the Union), and Janssen
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Research & Development, LLC to commission a clinical trial to find out the effectiveness
of the regimen in other countries like Ethiopia, Mongolia, South Africa, and Vietnam
(International Union Against Tuberculosis and Lung Disease (The Union), 2017).
Although several studies showed the cost-effectiveness of MDR-TB treatment as
a whole in developed and developing country settings (Diel, Nienhaus, Lampenius,
Rüsch-Gerdes, & Richter, 2014; Diel, Vandeputte, et al., 2014; Fitzpatrick & Floyd,
2012), no study was conducted to perform economic evaluation of two regimens, the 9month regimen (shorter) and current WHO recommended the 20-24-month regimen
(current). This study aims to fill the void in conducting the cost-effectiveness evaluation
of these two treatment regimens from a societal perspective (including both patients and
payer perspectives) using Quality Adjusted Life Years (QALYs) as the outcome for
effectiveness, which qualifies this as a cost-utility study in health economics parlance
(Drummond, Sculpher, Claxton, Stoddart, & Torrance, 2015).
Methods
Study Design and Data Sources
The study follows a purposive sampling method for interviewing MDR-TB
patients. According to the recent estimates in 2014 number of laboratory-confirmed
MDR-TB patients was 954 in Bangladesh and the prevalence of MDR-TB is 5,100 in
2015 (World Health Organization (WHO), 2016a). In our study area, it is understandable
that the number will be significantly lower. Therefore, we collected the information of
the MDR-TB patients from the TB control programs and reach those who were accessible
(Brazier et al., 2002).
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Institution-level data has been collected for assessing the provider level costs
associated with TB treatment. Number of patients diagnosed and treated in 2015 has been
collected from the secondary sources such as the World TB report published by WHO
and the Annual TB report of NTP, Bangladesh. Drug costs have been collected from the
STOP TB Global Drug Facility website. Costs for diagnostic tests have been estimated
after consulting with local experts who are knowledgeable of the MDR-TB programs in
Bangladesh and also know the market price of different tests.
Cost Of Illness (COI) includes direct, indirect and tangibles costs incurred by the
patients (Centers for Disease Control and Prevention (CDC), 2013) and in this study the
TB patients will be traced and interviewed for the detail cost descriptions. The variables
of interest are the duration of illness, time elapsed before diagnosis, present status of the
illness, how many healthcare providers has been consulted, the direct costs incurred in
each encounter, duration of DOTS treatment, transportation cost to DOTS center, any
friend/relative accompanying with and the opportunity cost of their time, and the lost
work days and income of the patients among others. The programmatic cost has been
collected using a pre-set questionnaire and using annuitization for capital costs per patient
costs were calculated for each regimen.
The study will seek data on tuberculosis burden on the population of Bangladesh
from different sources, e.g., published reports, program documentations and various
surveys and the incidence of TB will be extracted from those sources. To find the QALYs
gained through the program we interviewed patients using EuroQoL 5D-5L questionnaire
and used the tariff provided by EuroQol.
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Target Population and Study Sample
This study covers the adult (more than 18 years old) MDR-TB patients all over
Bangladesh. 145 MDR-TB patients’ data was used for patient level cost and outcomes
(QALY) estimation for this study. Out of these 145 patients, 58 were under the 9-month
regimen and 87 were under the 20-24-month regimen, who were under treatment in four
MDR-TB treatment facilities (two for each regimens). Table 1 shows the number of
patients interviewed under each regimen and the districts to which they belonged. In the
Appendix Figure 1 the geographic location of the study districts is shown.
Glick (H. A. Glick, 2011) proposed a sample size formula for cost-effectiveness
evaluation of clinical trials. Although our study is not a typical clinical trial, given the
nature of the intervention and the study design we can apply the formula for calculating
the required sample size for our study. The formula calculates the sample size for each of
the two groups with similar standard deviation of costs and effect and same sample size:
2

2

2 (𝑍𝛼 + 𝑍𝛽 ) [𝑠𝑑𝑐2 + (𝑊 ∗ 𝑠𝑑𝑞2 ) − (2 𝑊𝜌 ∗ 𝑠𝑑𝑐 ∗ 𝑠𝑑𝑞 )
𝑛=
(𝑊𝑄 − 𝐶)2
Where:
Zα is the standard normal quantile for the level of Type I error (set at 95%)
Zβ is the standard normal quantile for the level of Type II error (set at 80%)
sdq, sdc are the std deviations for each group for treatment effect and cost
respectively
W is the Maximum Willingness to Pay
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Q is the expected mean difference in treatment effectiveness
C is the expected mean difference in treatment cost
ρ is the expected correlation of the difference in cost (C) and effect (Q)
This is a measure of the covariance of changes in effectiveness and changes in
cost. Negative covariance, where cost decreases with increasing effectiveness result in a
larger sample size. Positive covariance where cost increases with increasing effectiveness
result in smaller sample sizes.
With 95% confidence interval and 80% power of the test, we assumed that the
standard deviation of costs (sdc) is 100 USD, standard deviation of effect (sdq) is 0.25
QALY, ρ, correlation of difference in cost (C) and effect (Q) is 0.5. The expected mean
difference in treatment effectiveness (Q) is 0.15 QALY and expected mean difference in
treatment cost (C) is 1000 USD. We set the willingness-to-pay threshold (W) at the three
times of GDP of Bangladesh which is 3942 USD (BDT 315,360) (Macroeconomics,
2001). We found the sample size for one group is 70 and another is 104 with a 2:1 sample
size ratio.
Settings and Locations
DF implements their MDR program in 22 districts in the North-west part of
Bangladesh. The MDR-TB patients detected in these areas are treated following the 9month regimen. Whereas, in rest of the 42 districts all over Bangladesh follows the 2024-month regimen. Thus this study covers the whole country.
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Ethical consideration
The study has already got ethics approval from University of South Carolina in
the USA where the PI is a PhD student. Institutional Board Review (IRB) approval will
also be taken from Jahangirnagar University in Bangladesh. A third and final approval
was obtained from WHO Research Ethics Review Committee (WHO ERC).
Study Perspective
The study will be conducted form the societal perspective, which will encompass
all costs incurred by the health care providers, patients, and community.
Comparators
The two distinct programs carried out by NTP and DF will be the comparators in
this study. DF runs a 9-month regimen which administers high-dose Gatifloxacin (GFX),
Ethambutol (EMB), Pyrazinamide (PZA), and Clofazimine (CFZ) throughout,
supplemented during the minimum 4-month intensive phase by Kanamycin (KM),
Prothionamide (PTH), and Isoniazide (INH) (Aung et al., 2014).
NTP follows the 20-24-month regimen which includes Kanamycin (KM),
Ofloxacin (OFX), Pyrazinamide (PZA), Ethonamide (ETO), and Cycloserine (CS) in 610 months (on average 8 month) long intensive phase and Ofloxacin (OFX),
Pyrazinamide (PZA), Ethonamide (ETO), and Cycloserine (CS) in 13-18 months (on
average 12 months) of continuation phase of treatment (National Tuberculosis Control
Program (NTP), 2013).
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Time Horizon
The study will take a life-time horizon to capture all costs and outcomes
according to WHO guideline (Edejer, 2003). Since this study includes patients 18 years
and older, we assume they will live through to their life expectancy (72 years in 2015).
Mean age of the patient interviewed was 35 years. Therefore, we repeated the cycle for
37 times to include their whole lifespan.
Discount Rate
The study will follow the WHO discount rate of 3% for both costs and outcomes
(Edejer, 2003).
Choice of Outcome
Quality Adjusted Life Year (QALY) is the chosen outcome for this study.
Measurement of Effectiveness
QALY has been modeled using patient-level EuroQol-5 Dimensions-5 Levels
(EQ-5D-5L) measure of health related quality of life (EuroQol Research Foundation,
2017). We used Zimbabwe score sets for EQ-5D, since Zimbabwe is another developing
country like Bangladesh and we assume the EQ-5D score sets would have been similar
between populations of these two countries. Finally, the QALY measure was estimated
after controlling for patient’s socio-economic factors. Lognormal (log value of QALY as
dependent variable) has been found more suitable model. Recycled prediction has been
used to find out the estimated QALY for each type of patient outcome (e.g., cure, failure,
and default) for both regimens (Glick Book). For death state utility has been assumed
zero.
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Measurement of Costs
Health systems costs were collected from different sources. Prevention and
promotion costs, training costs, meeting costs, human resources costs, capital costs, and
other costs were collected from MDR-TB treatment facilities under the purview of the
study using a pre-set provider questionnaire. Heath facility managers, personnel
responsible for financial transactions were interviewed using the questionnaire and
relevant costs were collected. Capital costs were annuitized using 5% interest rate and 10year lifetime for Microscopes and Gene Xpert machines, and vehicles. Costs for drugs
were derived from the Stop TB Global Drug Repository (Stop TB Partnership, 2017) and
per patient drug costs were calculated for each regimen (Appendix Table 1 and Table 2).
Diagnostic tests costs were derived from expert knowledge from the officials working in
MDR-TB program in Bangladesh (Appendix Table 3 and Table 4). Per patient cost of
delivering MDR-TB treatment for both types of regimen have been estimated dividing
costs among the number of treated patients in one year in those facilities using Annual
Tuberculosis Report by NTP, Bangladesh (National Tuberculosis Control Program
(NTP), 2015). Patient costs were collected through interviews of MDR-TB patients using
a pre-set questionnaire prepared on the basis of Stop-TB questionnaire on patient’s cost
(Stop TB Partnership DOTS Expansion Working Group (TB and Poverty subgroup),
2008). The questionnaire was translated English to Bengali and then retranslated back
into English to validate the translation. Both patient and provider questionnaires were
pre-tested and changes were incorporated before using those in the survey. Total costs of
treating a patient under each regimen was calculated by summing up the patient and
provider level costs. Then the cost was modeled using a Generalized Linear Model with
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Gamma family and log link using data from 145 interviewed MDR-TB patients who had
complete information on disease outcomes. GLM diagnostics were used to validate the
GLM family and link. Recycled prediction was used to estimate the costs for each type of
patient outcome (e.g., cure, failure, default) for both regimens (H. Glick et al., 2007). For
death state costs were calculated as zero.
Models and Analysis
A dynamic, stochastic, Markov simulation model was used to estimate the costeffectiveness of the two comparison regimens. Markov model has some unique
characteristics which fit the progression of TB well. For example, in Markov model states
are mutually exclusive, states are complete (i.e. no people are lost) and people remain in
that state for a fixed period of time. Also, Markov model is preferred over the decision
trees when health event repeats over time, or have longer term health effects, effect of
treatment either stops quickly after initial treatment or continue at an earlier level, and the
risk of different health events does not depend on patient’s prior history.
A simplistic decision tree model can be shown in Figure 6.1:
From the Markov model and decision tree we find that after starting of the
treatment the MDR-TB patient can move to either of the four states, e.g., cure/treatment
complete, failure/relapse, default, and death. Cure state has been defined as those who
had completed treatment protocol without any evidence of failure and had at least three
consecutive negative cultures from samples collected at least 30 days apart in the final 12
month of treatment, or “Treatment Completed”, those who completed treatment
according to treatment protocol but did not meet the definition for cure because of lack of
bacteriological results.
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Figure 6.1 Decision Tree of two comparison treatment strategies for MDR-TB
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Failure/relapse cases were defined as those whose treatment was needed to be terminated
or at least change of two anti-TB drugs due to lack of conversion, bacteriological
reversion in the continuation phase, evidence of additional acquired resistance, or adverse
drug reaction. Lost to follow up/ default cases were defined as those MDR-TB patients
whose treatment was interrupted for two or more consecutive months for any reason
(National Tuberculosis Control Program (NTP), 2013).
Here death is the absorbing state, i.e., if a patient is dead he/she can move from
that state to another. If any patient is cured he/she can remain cured, relapse/reinfection
may occur, lost to follow-up (default) or can be dead. On the other hand, the
failed/relapsed patients undergo another cycle of treatment and can culminate into cure,
remain failed, can default, or can be dead as well. Similarly, from default state one can
move over to other three states.
Cost-effectiveness evaluation was performed using heemod package in R
(Filipović-Pierucci et al., 2017). BCEA package was also used to validate the results form
analysis with heemod package (Filipović-Pierucci et al., 2017). Cost and utility data was
modeled using STATA 14.2 (StataCorp, 2015).
Measurement of Transition Probabilities
As mentioned earlier, cost-effectiveness analysis of these two regimens has not
been undertaken yet. However, the programmatic outcome for the two treatment
strategies has been derived from two papers. One paper reported the results of the
standardized treatment spanning 20-24 month (Van Deun et al., 2004). Another paper
published recently reported the results of the alternative regimens of 9 month (Aung et
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al., 2014). Both studies were conducted in Bangladesh. Transitional probabilities were
estimated from these two studies using Markov simulation as an evidence synthesis
technique (Sutton, Welton, & Cooper, 2012). R has been used for the analysis along with
r2jags packages for estimating the transitional probabilities for two treatment regimens
(Su & Yajima, 2012).
From these two studies the transitional probabilities for first two cycles were
estimated and furnished in Table 6.1.
Table 6.1 Transition Probabilities of MDR-TB Treatment Regimens
Input variable
20-24-Month Regimena
9-Month Regimenb
Cure to Cure (tpC2C)
0.813
0.846
Cure to Failure (tpC2F)
0.071
0.043
Cure to Default (tpC2Def)
0.024
0.080
Cure to Death (tpC2Death)
0.092
0.031
Failure to Cure (tpF2C)
0.143
0.119
Failure to Failure (tpF2F)
0.431
0.486
Failure to Default (tpF2Def)
0.139
0.040
Failure to Death (tpF2Death)
0.287
0.355
Default to Cure (tpDef2C)
0.088
0.023
Default to Failure (tpDef2F)
0.087
0.499
Default to Default (tpDef2Def)
0.637
0.365
Default to Death (tpDef2Death)
0.188
0.113
a
Source: (Aung et al., 2014)
b
Source: (Van Deun et al., 2004)
Parameters
Patient level cost for each regimen as well as the per patient provider costs are
shown in Table 6.2.
Table 6.3 shows parameters for the cost-effectiveness analysis along with their
distributions. Parameters mainly consist of transitional probabilities for transition
between different states, costs for treating each type of states, and the utility of each
states. Apart from this initial age was determined as the mean age of the interviewed
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population (35 years). Time horizon was therefore fixed at 37 years, accounting for the
rest of the general life expectancy of Bangladeshi people (life expectancy at birth in
Bangladesh is 72 years (The World Bank, 2017b)). Both age and cycle parameters were
kept fixed for the model. Transmission of secondary infection was assumed to be .003
annually based on the findings of a study that 0.03 new secondary cases may develop
among the MDR-TB population (Sloot, Schim van der Loeff, Kouw, & Borgdorff, 2014).
Costs parameters follow a gamma distribution as mentioned earlier and are
measured in 2015 Bangladeshi Taka (BDT). Utility values are measured in QALY and
their distributions were lognormal.
Table 6.2 Patient, Provider and Total Costs for two regimens of MDR-TB treatment in
Bangladesh
Costs
DS-TB Patients MDR-TB Patients
A. Patient Level Costs
Mean
Mean
Direct Costs
Before Diagnosis Costs
13287.16
14844.23
TB Diagnosis Costs
1106.69
684.63
Follow-up Costs
172.16
877.17
Drug Collection Costs
14.6
1.17
Hospital Costs
2515.23
7669.4
Additional Food Costs
2244.01
2678.39
Accompanying Person Costs
380.03
2114.7
MDR-TB Relocation Costs
0
341.24
Drug Side-effects Costs
434.58
1647.28
20154.46
30858.21
Total Direct Costs
Indirect Costs
Patient Opportunity Costs (Income Loss)
407.07
1522.86
Accompanying Person Opportunity Costs
673.57
2593.91
1080.64
4116.77
Total Indirect Costs
Total Patient Level Costs
21235.10
34974.98
B. Provider Level Costs
Prevention and Promotion Costs
202.02
652.17
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Diagnostic Costs
Drug Costs
Training Costs
Meeting Costs
Incentive Payment
Human Resources Costs
Capital Costs
Other Costs
Total Provider Level Costs
Total Costs

17825.00
42761.50
2608.70
2608.70
3100.00
23728.70
22100.92
345.73
115731.41
136966.51

38300.00
61833.27
767.68
808.08
3100.00
28267.15
10101.01
101.01
143480.23
178455.21

Table 6.3 Input Parameters for Cost-Effectiveness Analysis
Variable
Category
Starting age of
cohort (mean)
Time horizon
Cost of Cure (2024 Month)
Cost of Failure
(20-24 Month)
Cost of Default
(20-24 Month)
Cost of Cure (9
Month)
Cost of Failure (9
Month)
Cost of Default (9
Month)
Utility of Cure
(20-24 Month)
Utility of Failure
(20-24 Month)
Utility of Default
(20-24 Month)
Utility of Cure (9
Month)
Utility of Failure
(9 Month)
Utility of Default
(9 Month)

Distributiona

Value

Fixed
Fixed
Gamma

Low

High

35 Years

-

-

Study Data

BDT
151740
BDT
149920
BDT
162744
BDT
98084
BDT
96905
BDT
105376
0.524

BDT
238046
BDT
258390
BDT
251222
BDT
153870
BDT
167023
BDT
162568
1.00

(LE Data)
Study Data

Lognormal

37 Years
BDT
194893
BDT
204155
BDT
206983
BDT
125977
BDT
131964
BDT
133972
0.777

Lognormal

0.710

0.428

0.99

Study Data

Lognormal

0.757

0.543

0.971

Study Data

Lognormal

0.813

0.560

1.00

Study Data

Lognormal

0.746

0.464

1.00

Study Data

Lognormal

0.793

0.579

1.00

Study Data

Gamma
Gamma
Gamma
Gamma
Gamma
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Reference

Study Data
Study Data
Study Data
Study Data
Study Data
Study Data

Discount Rate

Fixed

Probability of
Binomial
Secondary
transmission (per
year)
a
In Probabilistic Sensitivity Analysis

3%

0%

6%

0.03

0

0.06

Edejer,
2003
Germany
Paper

Results
Base Case Results
The base case results show that after 37 cycles (years) each patient under the 9month regimen gained 6.21 QALY with a total cost of BDT 987,418. Whereas, each
patient under CHW model gained 5.74 QALY by incurring costs of BDT 1,501,221
(Table 5). Therefore, the 9-month regimen is clearly dominating the 20-24-month
regimen because it costs less while it gains more QALY.
Table 6.5 Base Case Results
Regimen
9 Month (DF)
20-24 Month (NTP)

Cost Per Patient
(BDT)
987,418
1,501,221

QALY Gained

ICER

6.21
5.74

-1,086,095
(Dominates)

Deterministic Sensitivity Analysis
Parameters were varied on different scales for high and low values and univariate
sensitivity analysis was performed to see the robustness of the findings. A tornado plot
has been prepared to see the effect of change in each variable. Based on the findings in
one-way sensitivity analysis, input parameters were varied accordingly to see their impact
in probabilistic sensitivity analysis.
In tornado plot, shown in the Figure 6.2, we find that the most influential
parameters were costs of cure state of the 20-24-month regimen, cost of cure state of the
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9-month regimen, costs of failure state of 9 month regimen, cost of failure state of the 2024-month regimen according to the more effects on the results. Among the utility values
utility of cure state of the 9-month regimen has more effect than utilities of other states.
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Figure 6.2 Tornado Plot of Deterministic Sensitivity Analysis
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Probabilistic Sensitivity Analysis
In probabilistic sensitivity analysis, the costs values and utility values for each
state were varied by 20%. At first the base case Markov model with all parameters with
their values and distribution was run for 1000 iterations and the base case results were
assessed in the form of incremental cost effectiveness ratio (ICER), Cost-effectiveness
Acceptability Curve (CEAC), and Expected Value of Perfect Information (EVPI).
Incremental Cost-effectiveness Ratio (ICER)
From the results reported in the Table 5 shows that over life-time the 9-month
regimen costs about BDT 942,315 while the 20-24-month standard regimen costs BDT
1,434,254. At the same time QALY gained by the 9-month regimen is 6.00 whereas in
the 20-24-month regimen QALY is gained 5.51. Therefore, the resultant ICER is -BDT
997,257 per QALY gained. It shows that 9 month regimen dominates the 20-24-month
regimen (Table 5). Results shown in the cost effectiveness plane also shows that the
ICER is in the North-West Quadrant which makes the 9-month regimen dominant over
the 20-24-month regimen (Figure 6.4).
Table 6.5 ICER from Probabilistic Model
Regimen
9 Month (DF)
20-24 Month
(NTP)

Cost Per
Patient (BDT)
942,315
1,434,254

QALY Gained

ICER

EVPI

6.00
5.51

-997,257
(Dominates)

13,719

Cost-Effectiveness Acceptability Curve (CEAC)
CEAC has been shown in Figure 6.3. Since the 9-month regimen dominates over
the 20-24-month regimen, the CEAC for the 9-month regimen is over 0.75 form the
beginning. With increasing willingness-to-pay CEAC value gets bigger. On the other
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hand, it decreases for the 20-24-month regimen for higher values (Figure 6.4).
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Figure 6.3 Cost-Effectiveness Plane
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Figure 6.4 Cost-Effectiveness Acceptability Curve
Expected Value of Perfect Information (EVPI)
EVPI is the absolute limit of the value of further research that would completely
eliminate the uncertainty around the parameters in the model. EVPI value of BDT 13,
719 shows that with reducing uncertainty around the parameters would require only BDT
13,719. It is also evident from the Figure 6 that with increasing willingness-to-pay the
EVPI decreases and offsets the need of further research due to the small gains.
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Discussions
The study results show that the 9-month “Bangladesh” regimen is cost-effective
from a societal perspective. Bangladesh regimen has more cure rate and it provides more
utility to the patient than those who undergone the 20-24-month regimen which WHO
currently endorse. However, in 2012 a clinical trial named the STREAM (Standardized
Treatment Regimen of Anti-Tuberculosis Drugs for Patients with MDR TB) in Ethiopia,
Mongolia, South Africa, and Vietnam had been initiated (International Union Against
Tuberculosis and Lung Disease (The Union), 2017). The primary objective of the first
stage of the trial is to evaluate the effectiveness of the shorter “Bangladesh” regimen in
other settings (Moodley & Godec, 2016). Damien Foundation initiated the
Fluoroquinolone based shorter regimen and tested over 12-year period (Van Deun et al.,
2010); but the study lacks in terms of it was only an observational study and more
patients opted out from participation in the study; patients with HIV were not included;
and cohorts were enrolled consecutively, i.e., various regimens were tested in various
time periods, and cohort sizes were not predetermined (TBFACTS.ORG, 2017). Since in
the published description of the trial does not mention any undertaking of costeffectiveness analysis alongside the clinical trial this study provides an important
evidence of cost-effectiveness for the shorter regimen.
Several studies have also been conducted to assess the cost-effectiveness of
different MDR-TB treatment regimens. Fitzpatrick et al. (2012) conducted a systemic
review of studies which used primary data and outcome which eventually includes only
four studies conducted in Estonia, Peru, the Philippines, and Tomsk, Russia. Cost per
DALY averted with second line drugs were $598, $163, $143, $745 respectively. The
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cost per DALY averted was lower than GDP per capita in all 14 WHO sub-regions
considered. In other studies, Diel and colleagues showed that the treatment of MDR-TB
is cost-effective in Germany (Diel, Nienhaus, et al., 2014)and European Union (EU)
countries combined (Diel, Vandeputte, et al., 2014).
Our study results suggest that shorter regimen is cost-effective in Bangladesh
setting. Since Bangladesh is developing country, the findings can be emulated in other
developing countries. There is already evidence that MDR-TB treatment is itself costeffective in developed countries; with shorter regimen treatment adherence will increase
in efficacy of the treatment. Although STREAM trial will evaluate the incidence of
adverse drug reactions among the shorter and current regimens, in this study we found
that the adverse drug events were less among the patients undergoing shorter regimen.
Both shorter duration of treatment and lesser adverse drug reactions translated into more
QALY for the shorter regimen and eventually made the shorter regimen cost-effective.
This study has several limitations. For transitional probabilities we used one study
for each treatment regimens due to lack of published study. This made the results biased.
Results from the STREAM study will help to fill this void and the clinical trial results can
be used for future studies. Cost and effectiveness data from the patients may suffer from
the recall bias, especially for the patients under the 20-24-month regimen. Health care
facility level cost data were also collected from four facilities (two for each regimen) may
suffer from biased estimates.
Despite these limitations, this study tried to collect the patient and provider level
data comprehensively using pre-set questionnaires. To our best knowledge, it is also the
122

first study to conduct economic evaluation between shorter and current regimens of
MDR-TB treatment.
Growing evidence of efficacy compels the policy makers to adopt the shorter
regimen as the approved regimen in near future. Results of this study makes the case for
shorter regimen stronger with the evidence of cost-effectiveness which is often
considered as the pivotal consideration for allocating scarce resources.
We can conclude that the evidence of cost-effectiveness of shorter regimen of
MDR-TB and the efficacy of the regimen from other studies reflect that it is high time to
adopt the shorter regimen as the prescribed treatment for MDR-TB treatment. This will
prevent the deadly disease to spread among the vulnerable population worldwide and
help us to reach the End TB strategy goals.
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APPENDIX A- STUDY III SUPPLEMENTAL INFORMATION
Table A.1 MDR-TB Drug Costs
Short
Daily
Drug
Form Dose (mg) Price Dose (mg) Daily dose Price
Kanamycin
Km
1000 79.25
500
0.79
Moxifloxacin
Mfx
400 mg
39
400
0.39
Prothionamide
Pto
250 13.39
500
0.27
Levofloxacin
Lfx
750 10.00
750
0.10
Cycloserine
Cs
250 28.80
500
0.58
Ethionamdie
Eto
250
7.77
500
0.16
Clofazimine
Cfz
100 103.86
100
1.04
Pyrazinamide
Z
500 17.305
1000
0.05
High dose Isoniazid (H)
H
300 12.76
900
0.06
Ethambutol
Eto
400 20.29
400
0.03
Table A.2 Drug Costs for MDR-TB Treatment Regimes
Phase
20-24-month regimen
Intensive Z-KM-Eto-Cs-Ofx/Lvx
Continu
Z-Eto-Cs-Ofx/Lvx
ation

Phase

9-month regimen
Km-Mfx-Pto-Cfz-ZIntensive Hhigh-dose-E
Continu
Mfx-Cfz-Z-E
ation

Duration Price (Each Price
(month)
Day)
(Period)
BDT
8
1.68
402.10
14
Duration
(month)

0.89
Total
Price (Each
Day)

4
5
Total

134

370.82
772.916 61833
Price
(Period)
BDT

2.60

311.69

1.49

222.83
534.5187

42762

Table A.3 Diagnostic Test Costs for 20-24-Month Regimen

SL

During
Total Amount
At base line
Intensive Phase in 8* Month
or before Rate
(Injectable
(Investigation
starting the (Tk)
Period- usually Rate X
treatment
8 month*)
Frequency)

Laboratory
Investigations

Pure Tone
1 Audiometry
(PTA)

Must

750

Monthly

2 S. Creatinine

Must

350

Monthly**

3 S. Electrolyte

Must

900

Monthly**
Every 1-3
Monthly

2850

Every 6
Monthly
Need based on
symptoms /
Clinical
Decision**
Need based on
symptoms /
Clinical
Decision**
Need based on
symptoms /
Clinical
Decision*
Every 6
Monthly
Need based on
symptoms /
Clinical
Decision**

900

4

S. Bilirubin,
SGPT, ALP

Must

950

5

Thyroid Function
Must
Test (TSH)

900

6

Complete Blood
Must
Count (CBC)

450

7 S. Uric Acid

Must

400

Must

250

Must

450

Pregnancy Test
10 (Female at Child Must
Bearing Age)

300

8

Random Blood
Sugar (RBS)

9 Chest X Ray

Expenditure at
Baseline/Patient

6000

2800

7200

900

800

500

450

During
Continuation Phase
(Oral Medication
only-Usually 12
month***)
No clear decision
regarding this!

Need based on
symptoms / Clinical 1400
Decision**
Need based on
symptoms / Clinical 3600
Decision**
Need based on
symptoms / Clinical 3800
Decision**
Every 6 Monthly

Need based on
symptoms / Clinical 1600
Decision**
Need based on
symptoms / Clinical 1000
Decision**
Every 6 Monthly

900

Need based on
symptoms / Clinical
Decision**

Expenditure at
5700 Intensive
22400
Phase/Patient

Expenditure in
Continuation
Phase/Patient

4 Month

5 Month

Continuation
(22400/8)*5 Phase

(15900/12)*5

135

1800

Need based on
symptoms / Clinical 1800
Decision**

Table A.4 Diagnostic Test cost for 9-Month Regimen

Intensive
Phase

Total Amount
in 12* Month
(Investigation
Rate X
Frequency)

Total
17825

15900

APPENDIX B- PATIENT QUESTIONNAIRE (DS-TB)

Face Sheet for DRUG SENSITIVE TB Patient Interview
IDENTIFICATION
DIVISION:
DISTRICT:
UPAZILA:
NAME AND TYPE OF THE FACILITY:
(Union Health Center =01, Upazila Health Complex =02, District
Hospital =03)
HEALTH FACILITY CODE:
TYPE OF THE PROVIDER:
(BRAC =01, Damien Foundation =02, Other (Please specify)=03)
RESPONDENT:
(Patient=01, Friend/Guardian=02, Other (Please specify)=03)
SEX OF THE RESPONDENT:
(Male=01, Female= 02)
SEX OF THE PATIENT:
(Male=01, Female= 02)
NAME OF THE DOT PROVIDER:
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INTERVIEWER VISITS
1

2

3

FINAL VISIT

DATE
INTERVIEWER’S
NAME & CODE

RESULT
CODE

RESULT CODE*
RESULT
CODE
*RESULT CODES:
01

COMPLETED

03

POSTPONED

05

PARTLY COMPLETED

02

NOT AVAILABLE

04

REFUSED

96

OTHER, SPECIFY________________

SUPERVISOR

FIELD EDITOR

OFFICE EDITOR

KEYED BY

Collect information from only those patients who have completed their treatment
within last two months.
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Section 1: Patient Information
(TO BE FILLED BY INTERVIEWER TRANSFERING INFORMATION FROM THE TB CARD)

Options
Consent obtained from
patient or caregiver?

No.

101

Questions and
filters

Yes……………………………….1
No…………………………………2

Skip
Coding categories

Response

Patient age
Years
Months

102

Patient Sex

Male……………………………1
Female..……………………….2

103

BCG Vaccine

No
Scar……………………………1
Scar Seen……………………….2

104

Type of TB

Pulmonary smear positive..……1
Pulmonary smear negative…….2
Xpert MTB/RIF Positive………...3
Extra-Pulmonary ………………...4
Please Specify_______________
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105

Type of Patient

New…………………….…….1
Failure………………...……..2
Transfer in..…………………3
Relapse……………………..4
Treatment after loss to follow
up/default.……………….….5
Other ………………..………6
Specify________________

106

Referred by which
type of provider?

Private Practitioner (Graduate)…1
Private Practitioner (NonGraduate)………………………..2
Govt. field staff…………………..3
Shasthya Sebika (SS)/Non-govt.
field staff (NGFS)……………….4
Village Doctor (VD)……………..5
Community Volunteer………….6
Govt. Hospital…………………..7
Private Hospital………………...8
Community Health Care Provider
(CHCP)………………………….9
TB Patient………………………
Other____________________10
Please specify

107

Results of sputum
Examination

108

Treatment Regimen

Month
0
2/3
3/4
5
6/8

Smear 1

Smear 2

Cat I……………………………1
Cat II…………………………..2
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Xpert Result

Weight (kg)

109

Treatment outcome

Cured…………………….…….1
Treatment completed....……..2
Died………....…………………3
Treatment failure……………..4
Lost to follow
up/Default.…………………….5
Transfer Out…………..………6
Not Evaluated…………………7

110

HIV Status

Positive…………………….…….1
Negative………………......……..2
Not Tested…....…………………3
Unknown………….……………..4
Declined.…………………….….5

111

Type of Drug
Reaction

112

Date of starting
treatment

Day
Month
Year

113

Date of treatment
completion

Day
Month
Year
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Section 2.0: Previous treatment
PATIENT INTERVIEW SECTION

Start time: Hours |__|__| Minutes |__|__|

No.

Questions and filters

Coding categories

201

Have you ever had TB
treatment before?

Yes……………………………1

If 2

No…………………………….2

►

CROSS-CHECK WITH
INFORMATION FROM
PATIENT CARD
202

Have you completed your
previous TB treatment?

Why did not you complete
your previous treatment?

Yes……………………………1

If 1

No…………………………….2

►
301

A. Distance to the facility
B. Lack of money for treatment
costs

[For each option, record 1
if the option is mentioned
and record 2 if the option
has not been mentioned.]

Skip

301

CROSS-CHECK WITH
INFORMATION FROM
PATENT CARD

203

Response

C. Drug Side Effects
D. Moved/Migrated
E. Thought that no more
treatment was necessary
E. Other
Please
Specify________________
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Section 3: Delay, Prediagnostic & Diagnostic Costs
No.

Questions and filters

Coding categories

301

What symptoms did you
experience that led you to
seek treatment for your
most recent illness with
TB?

a. Cough

Response

b. Evening rise of
temperature/low grade fever
c. Night sweats
d. Coughing up blood
e. Weight loss

[For each option, record 1
if the option is mentioned
and record 2 if the option
has not been mentioned.]
302

How long did you
experience these symptoms
before you went to seek
treatment?

[For each option, record
number of weeks if
mentioned yes in the
previous question.]

f. Other
Specify_____________________
a. Cough

Weeks

b. Evening rise of
temperature/low grade fever

Weeks

c. Night sweats

Weeks

d. Coughing up blood

Weeks

e. Weight loss

Weeks

f. Other

Weeks

Specify_____________________
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Skip

Section 3.1 First Visit
303

After you experienced
the symptoms, which
provider did you go to
first?

Community Clinic…………….…….1
Union Subcenter………….....……..2
Upazila Health Complex…..………3
District Hospital……..……………..4
Pharmacy & Drug Store……….….5
Homoeopath………………..………6
Private Hospital……..……………..7
Village Doctor………………………8
Traditional Healer………………….9
Other………………………..………10
Specify______________________

304

What was the distance to
the provider from your
home?

Kilometer

305

What was the travel time
to reach this provider?

Hour
Minute

306

What was the waiting
and consultation time
with the provider?

Hour
Minute

307

308

309

What was the registration
(ticket) cost paid by you?
In TAKA

IF not known put 99999

What was the
consultation fee you have
paid? In TAKA

IF not known put 99999

What was the cost you
paid for diagnostic tests?
In TAKA

IF not known put 99999

IF no registration cost 000

IF no consultation fee 000

IF no cost for tests 000
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310

What was the cost for xray? In TAKA

IF not known put 99999
IF no cost for x-ray 000

311

What was the costs of
drugs? In TAKA

IF not known put 99999
IF no cost for drugs 000

312

313

What was travel costs?

IF not known put 99999

(INCLUDE ALL
TRAVEL RELATED
COSTS: RETURN
TRAVEL, TRAVEL
FOR LABORATIRY
TESTS, DTUGS, COST
FOR
ACCOMPANYING
PERSONS) In TAKA

IF no travel cost 000

What was the food costs?
In TAKA

IF not known put 99999
IF no food cost 000

314

What was cost for
accommodation?

IF not known put 99999
IF no accommodation cost 000
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Section 3.2 Second Visit
No.

Questions and filters

Coding categories

315

Once you experience
the symptoms to which
provider did you go
after you have seen the
provider type
_________________?

Community Clinic…………….…….1

(MENTION THE
FIRST VISIT’S
PROVIDER TYPE)

Pharmacy & Drug Store……….….5

Response

Union Subcenter………….....……..2
Upazila Health Complex…..………3
District Hospital……..……………..4

Homoeopath………………..………6
Private Hospital……..……………..7
Village Doctor………………………8
Traditional Healer………………….9
Other………………………..………10
Specify______________________

316

What was the distance
to the provider from
your home?

Kilometer

317

What was the travel
time to reach this
provider?

Hour
Minute

318

What was the waiting
and consultation time
with the provider?

Hour
Minute

319

320

321

What was the
registration (ticket) cost
paid by you? In TAKA

IF not known put 99999

What was the
consultation fee you
have paid? In TAKA

IF not known put 99999

What was the cost you
paid for diagnostic
tests? In TAKA

IF not known put 99999

IF no registration cost 000

IF no consultation fee 000

IF no cost for tests 000
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Skip

322

What was the cost for
x-ray? In TAKA

IF not known put 99999
IF no cost for x-ray 000

323

What was the costs of
drugs? In TAKA

IF not known put 99999
IF no cost for drugs 000

324

325

What was travel costs?

IF not known put 99999

(INCLUDE ALL
TRAVEL RELATED
COSTS: RETURN
TRAVEL, TRAVEL
FOR LABORATIRY
TESTS, DTUGS,
COST FOR
ACCOMPANYING
PERSONS) In TAKA

IF no travel cost 000

What was the food
costs? In TAKA

IF not known put 99999
IF no food cost 000

326

What was cost for
accommodation?

IF not known put 99999
IF no accommodation cost 000
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Section 3.3 Third Visit
No.

Questions and filters

Coding categories

327

Once you experience the
symptoms to which
provider did you go after
you have seen the
provider type
_________________?

Community Clinic…………….…….1

(Mention the second
visit’s provider type)

Pharmacy & Drug Store……….….5

Response

Union Subcenter………….....……..2
Upazila Health Complex…..………3
District Hospital……..……………..4

Homoeopath………………..………6
Private Hospital……..……………..7
Village Doctor………………………8
Traditional Healer………………….9
Other………………………..………10
Specify______________________
328

What was the distance to
the provider from your
home?

Kilometer

329

What was the travel time
to reach this provider?

Hour
Minute

330

What was the waiting
and consultation time
with the provider?

Hour
Minute

331

332

333

What was the
registration (ticket) cost
paid by you? In TAKA

IF not known put 99999

What was the
consultation fee you
have paid? In TAKA

IF not known put 99999

What was the cost you
paid for diagnostic tests?
In TAKA

IF not known put 99999

IF no registration cost 000

IF no consultation fee 000

IF no cost for tests 000
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Skip

334

What was the cost for xray? In TAKA

IF not known put 99999
IF no cost for x-ray 000

335

What was the costs of
drugs? In TAKA

IF not known put 99999
IF no cost for drugs 000

336

337

What was travel costs?

IF not known put 99999

(INCLUDE ALL
TRAVEL RELATED
COSTS: RETURN
TRAVEL, TRAVEL
FOR LABORATIRY
TESTS, DTUGS, COST
FOR
ACCOMPANYING
PERSONS) In TAKA

IF no travel cost 000

What was the food
costs? In TAKA

IF not known put 99999
IF no food cost 000

338

What was cost for
accommodation?

IF not known put 99999
IF no accommodation cost 000
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Section 3.4 Fourth Visit
No.

Questions and filters

Coding categories

339

Once you experience
the symptoms to which
provider did you go
after you have seen the
provider type
_________________?

Community Clinic…………….…….1

(Mention the third
visit’s provider type)

Pharmacy & Drug Store……….….5

Response

Union Subcenter………….....……..2
Upazila Health Complex…..………3
District Hospital……..……………..4

Homoeopath………………..………6
Private Hospital……..……………..7
Village Doctor………………………8
Traditional Healer………………….9
Other………………………..………10
Specify______________________
340

What was the distance
to the provider from
your home?

Kilometer

341

What was the travel
time to reach this
provider?

Hour
Minute

342

What was the waiting
and consultation time
with the provider?

Hour
Minute

343

344

345

What was the
registration (ticket) cost
paid by you? In TAKA

IF not known put 99999

What was the
consultation fee you
have paid? In TAKA

IF not known put 99999

What was the cost you
paid for diagnostic
tests? In TAKA

IF not known put 99999

IF no registration cost 000

IF no consultation fee 000

IF no cost for tests 000
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Skip

346

What was the cost for
x-ray? In TAKA

IF not known put 99999
IF no cost for x-ray 000

347

What was the costs of
drugs? In TAKA

IF not known put 99999
IF no cost for drugs 000

348

349

What was travel costs?

IF not known put 99999

(INCLUDE ALL
TRAVEL RELATED
COSTS: RETURN
TRAVEL, TRAVEL
FOR LABORATIRY
TESTS, DTUGS,
COST FOR
ACCOMPANYING
PERSONS) In TAKA

IF no travel cost 000

What was the food
costs? In TAKA

IF not known put 99999
IF no food cost 000

350

What was cost for
accommodation?

IF not known put 99999
IF no accommodation cost 000
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Section 3.5 Fifth Visit
No.

Questions and filters

Coding categories

351

Once you experience
the symptoms to which
provider did you go
after you have seen the
provider type
_________________?

Community Clinic…………….…….1

(Mention the fourth
visit’s provider type)

Pharmacy & Drug Store……….….5

Response

Union Subcenter………….....……..2
Upazila Health Complex…..………3
District Hospital……..……………..4

Homoeopath………………..………6
Private Hospital……..……………..7
Village Doctor………………………8
Traditional Healer………………….9
Other………………………..………10
Specify______________________
352

What was the distance
to the provider from
your home?

Kilometer

353

What was the travel
time to reach this
provider?

Hour
Minute

354

What was the waiting
and consultation time
with the provider?

Hour
Minute

355

356

357

What was the
registration (ticket) cost
paid by you? In TAKA

IF not known put 99999

What was the
consultation fee you
have paid? In TAKA

IF not known put 99999

What was the cost you
paid for diagnostic
tests? In TAKA

IF not known put 99999

IF no registration cost 000

IF no consultation fee 000

IF no cost for tests 000
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Skip

358

What was the cost for
x-ray? In TAKA

IF not known put 99999
IF no cost for x-ray 000

359

What was the costs of
drugs? In TAKA

IF not known put 99999
IF no cost for drugs 000

360

361

What was travel costs?

IF not known put 99999

(INCLUDE ALL
TRAVEL RELATED
COSTS: RETURN
TRAVEL, TRAVEL
FOR LABORATIRY
TESTS, DTUGS,
COST FOR
ACCOMPANYING
PERSONS) In TAKA

IF no travel cost 000

What was the food
costs? In TAKA

IF not known put 99999
IF no food cost 000

362

What was cost for
accommodation?

IF not known put 99999
IF no accommodation cost 000
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Section 3.6 Sixth Visit
No.

Questions and filters

Coding categories

363

Once you experience
the symptoms to which
provider did you go
after you have seen the
provider type
_________________?

Community Clinic…………….…….1

(Mention the fifth
visit’s provider type)

Pharmacy & Drug Store……….….5

Response

Union Subcenter………….....……..2
Upazila Health Complex…..………3
District Hospital……..……………..4

Homoeopath………………..………6
Private Hospital……..……………..7
Village Doctor………………………8
Traditional Healer………………….9
Other………………………..………10
Specify______________________
364

What was the distance
to the provider from
your home?

Kilometer

365

What was the travel
time to reach this
provider?

Hour
Minute

366

What was the waiting
and consultation time
with the provider?

Hour
Minute

367

368

369

What was the
registration (ticket) cost
paid by you? In TAKA

IF not known put 99999

What was the
consultation fee you
have paid? In TAKA

IF not known put 99999

What was the cost you
paid for diagnostic
tests? In TAKA

IF not known put 99999

IF no registration cost 000

IF no consultation fee 000

IF no cost for tests 000
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Skip

370

What was the cost for
x-ray? In TAKA

IF not known put 99999
IF no cost for x-ray 000

371

What was the costs of
drugs? In TAKA

IF not known put 99999
IF no cost for drugs 000

372

373

What was travel costs?

IF not known put 99999

(INCLUDE ALL
TRAVEL RELATED
COSTS: RETURN
TRAVEL, TRAVEL
FOR LABORATIRY
TESTS, DTUGS,
COST FOR
ACCOMPANYING
PERSONS) In TAKA

IF no travel cost 000

What was the food
costs? In TAKA

IF not known put 99999
IF no food cost 000

374

What was cost for
accommodation?

IF not known put 99999
IF no accommodation cost 000
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Section 3.7 Seventh Visit
No.

Questions and filters

Coding categories

375

Once you experience
the symptoms to which
provider did you go
after you have seen the
provider type
_________________?

Community Clinic…………….…….1

(Mention the sixth
visit’s provider type)

Pharmacy & Drug Store……….….5

Response

Union Subcenter………….....……..2
Upazila Health Complex…..………3
District Hospital……..……………..4

Homoeopath………………..………6
Private Hospital……..……………..7
Village Doctor………………………8
Traditional Healer………………….9
Other………………………..………10
Specify______________________
376

What was the distance
to the provider from
your home?

Kilometer

377

What was the travel
time to reach this
provider?

Hour
Minute

378

What was the waiting
and consultation time
with the provider?

Hour
Minute

379

380

381

What was the
registration (ticket) cost
paid by you? In TAKA

IF not known put 99999

What was the
consultation fee you
have paid? In TAKA

IF not known put 99999

What was the cost you
paid for diagnostic
tests? In TAKA

IF not known put 99999

IF no registration cost 000

IF no consultation fee 000

IF no cost for tests 000
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Skip

382

What was the cost for
x-ray? In TAKA

IF not known put 99999
IF no cost for x-ray 000

383

What was the costs of
drugs? In TAKA

IF not known put 99999
IF no cost for drugs 000

384

385

What was travel costs?

IF not known put 99999

(INCLUDE ALL
TRAVEL RELATED
COSTS: RETURN
TRAVEL, TRAVEL
FOR LABORATIRY
TESTS, DTUGS,
COST FOR
ACCOMPANYING
PERSONS) In TAKA

IF no travel cost 000

What was the food
costs? In TAKA

IF not known put 99999
IF no food cost 000

386

What was cost for
accommodation?

IF not known put 99999
IF no accommodation cost 000
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Section 3.8 Eighth Visit
No.

Questions and filters

Coding categories

387

Once you experience
the symptoms to which
provider did you go
after you have seen the
provider type
_________________?

Community Clinic…………….…….1

(Mention the seventh
visit’s provider type)

Pharmacy & Drug Store……….….5

Response

Union Subcenter………….....……..2
Upazila Health Complex…..………3
District Hospital……..……………..4

Homoeopath………………..………6
Private Hospital……..……………..7
Village Doctor………………………8
Traditional Healer………………….9
Other………………………..………10
Specify______________________
388

What was the distance
to the provider from
your home?

Kilometer

389

What was the travel
time to reach this
provider?

Hour
Minute

390

What was the waiting
and consultation time
with the provider?

Hour
Minute

391

392

393

What was the
registration (ticket) cost
paid by you? In TAKA

IF not known put 99999

What was the
consultation fee you
have paid? In TAKA

IF not known put 99999

What was the cost you
paid for diagnostic
tests? In TAKA

IF not known put 99999

IF no registration cost 000

IF no consultation fee 000

IF no cost for tests 000
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Skip

394

What was the cost for
x-ray? In TAKA

IF not known put 99999
IF no cost for x-ray 000

395

What was the costs of
drugs? In TAKA

IF not known put 99999
IF no cost for drugs 000

396

397

What was travel costs?

IF not known put 99999

(INCLUDE ALL
TRAVEL RELATED
COSTS: RETURN
TRAVEL, TRAVEL
FOR LABORATIRY
TESTS, DTUGS,
COST FOR
ACCOMPANYING
PERSONS) In TAKA

IF no travel cost 000

What was the food
costs? In TAKA

IF not known put 99999
IF no food cost 000

398

What was cost for
accommodation?

IF not known put 99999
IF no accommodation cost 000
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Section 4.0: Treatment Costs
Section 4.1 Cost Related to DOT
No.

Questions and filters

Coding categories

401

From where did you get
your TB drugs?

Health facility………………….…….1

Response

Home……………………….....……..2
Community…………………..………3
Pharmacy……………..……………..4
Workplace……………….……….….5
Other………………………..………9
Specify______________________

402

How often do you
travel to the health
facility / hospital for
picking up your TB
drugs?

403

How long does it take
to go to the place for
picking up the drugs
(ONE WAY)?

Times/month

A. On Foot

Hour
Minute

B. By Transport

Hour
Minute

404

405

How long does one of
these visits take on
average, including time
on the road and waiting
time (total turnaround
time)?
From your home to the
facility, how much does
it cost if you take
transport? (both ways)

Hour
Minute

IF not known put 99999
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Skip

406

407

408

If you go to a facility to
pick up your drugs,
how much do you
spend on food on that
day? (on the road,
while waiting, lunch
etc.)

IF not known put 99999

Do you have to pay
administration fees
when picking up your
TB drugs?

Yes……………………………1

If 2

No…………………………….2

►

What was the
administration cost?

IF not known put 99999

409

IF no administration cost 000
409

410

Do you have to pay for
accommodation when
picking up your TB
drugs?

Yes……………………………1

If 2

No…………………………….2

►

What was the
accommodation cost?

IF not known put 99999

411

IF no accommodation cost 000

Section 4.2 Cost related to Follow Up Tests
411

Did you ever have to
go to the health facility
in addition to your
regular visits for

Yes……………………………1

If 2

No…………………………….2

►
414

follow up tests since
the beginning of
treatment?
412

If yes, how many
times?

413

If yes, did you have to
pay any additional
costs any time during
the entire period?

414

Times
Yes……………………………1

If 2

No…………………………….2

►
421

If so, what kind of costs
and how much did you
A. Fees

160

pay last time (In
TAKA)?
B. Sputum Test

C. X -ray
IF not known put
99999
IF no cost put 000

D. TB Drugs

E. Other Drugs

F. Others
415

How long does one of
these follow-up visits
take on average,
including time on the
road, waiting time and
tests (total turnaround
time)?

Hour
Minute

Section 5.0: Cost related to accompanied persons (Friends/Guardian)
No.

Questions and filters

Coding categories

501

Does any
family/friend/DOT
supporter accompany you
on any visits before
diagnosis and/or during
diagnosis?

Yes……………………………1

If 2

No…………………………….2

►

502

If YES, on how many visits
has your family/friend/DOT
supporter accompanied you
or gone with you before
diagnosis and/or during
diagnosis?

503

What was the cost for prediagnosis/diagnosis visits of

Response

Skip

507

Times

A. Transport Cost

161

your accompanying person
in Taka)?

B. Food Cost
C. Accommodation Cost

IF not known put 99999
IF no cost put 000
504

Does your accompanying
person earn?

Yes……………………………1

If 2

No…………………………….2

►
506

505

If earn, how much the
person earn per day (in
TAKA)?
IF not known put 99999

506

Why did someone
accompany you?

A. Distance
B. Security
C. Administrative barrier

[For each option, record 1
if the option is mentioned
and record 2 if the option
has not been mentioned.]

D. Too ill to travel alone
E. Was required for treatment
F. Other
Please
Specify________________

507

Does any
family/friend/DOT
supporter accompany you
on any visits during
treatment (taking drugs)?

508

If YES, on how many visits
has your family/friend/DOT
supporter accompanied you
or gone with you during
treatment?

509

What was the cost for visits
of your accompanying

Yes……………………………1

If 2

No…………………………….2

►
601

Times

A. Transport Cost
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person during your
treatment in TAKA)?

B. Food Cost
C. Accommodation Cost

IF not known put 99999
IF no cost put 000
510

Does your accompanying
person earn?

Yes……………………………1

If 2

No…………………………….2

►
512

511

If earn, how much the
person earn per day (In
TAKA)?

512

Why did someone
accompany you?

A. Distance
B. Security concern
C. Administrative barrier

[For each option, record 1
if the option is mentioned
and record 2 if the option
has not been mentioned.]

D. Too ill to travel alone
E. Was required for treatment
F. Other

IF not known put 99999

Please
Specify________________

Section 6.0: Hospitalization Costs
No.

Questions and filters

Coding categories

Response

Skip

601

Have you been hospitalized
before (but due to TB) or
during your TB treatment?

Yes……………………………1

If 2

No…………………………….2

►
701

602

603

If YES, how many times
were you hospitalized for
this illness?

Times

A. Hospital Administration Fees
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How much did you pay
during your last stay at the
hospital (In TAKA)?

B. Hospital stay charges

IF not known put 99999

D. Transport (Both Ways)

IF no cost put 000

C. Food (Not provided by the
hospital)

E. Drugs
F. Diagnostic Tests
G. Others

604

Did any attendant/caregiver
stay with you at the
hospital?

Yes……………………………1

If 2

No…………………………….2

►
701

605

If YES, how many days
he/she stay with you (sleep
there)?

606

Were there any extra costs
for your relative/friend for
staying at the hospital?

Days

Yes……………………………1

If 2

No…………………………….2

►
506

607

What was the cost for the
accompanying person
during your hospitalization
(stayed at night)? In TAKA

A. Transport Cost
B. Food Cost
C. Accommodation Cost

IF not known put 99999
D. Other Cost

608

Does your accompanying
person earn?

Yes……………………………1
No…………………………….2
Don’t Know.………………….3

If 2
/3
►
610
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609

If earn, how much the
accompanying person earn
per day?

610

Did any other family/friend
visit you while in hospital?

Yes……………………………1

If 2

No…………………………….2

►
701

611

If YES, How many people
visited you?

Days

612

On an average, how many
times did each of these
person visit you?

Times

613

What was the cost for
EACH VISIT of them (IN
TAKA)?

IF not known put 99999

A. Transport Cost
B. Food Cost
C. Accommodation Cost
D. Other Cost

614

How long were the visits
including traveling time?

Hour
Minute

Section 7.0: Other Costs, Other Illnesses and Coping Costs
Section 7.1 Other Costs
No.

Questions and filters

Coding categories

701

Did you buy any
supplements for your diet
because of the TB illness,
for example vitamins,
meat, energy drinks, soft
drinks, fruits or
medicines?

Yes……………………………1

If 2

No…………………………….2

►

If YES, how much did you
spend approximately on

A. Meat

702

Response

Skip

703
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each of these items each
month (in TAKA)?

B. Fish
C. Fruits

IF not known put 99999

D. Drinks
E. Vegetables
F. Vitamins/Herbs
G. Others

Section 7.2 Other illnesses
703

Do you have any chronic
illness for which you are
receiving treatment?

Yes……………………………1

If 2

No…………………………….2

►
707

704

If YES, which disease do
you have?

A. Diabetes
B. Heart Disease
C. High Blood Pressure

[For each option, record 1
if the option is mentioned
and record 2 if the option
has not been mentioned.]

D. Cancer
E. Arthritis
F. Other
Specify
G. Other
Specify

705

706

Are there any additional
costs for you because of
this other illness besides
the costs that you have
already mentioned?

Yes……………………………1

If 2

No…………………………….2

►

If YES, how much are
these additional costs on
average per month? In
TAKA

A. Drugs

707

B. Diagnostic tests
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C. Transport
IF not known put 99999
D. Fees
E. Others
707

How much did you spend
on healthcare on average
per month BEFORE the
TB illness? In TAKA

IF not known put 99999

708

How much did you spend
on healthcare on average
per month AFTER the TB
illness? In TAKA

IF not known put 99999

Section 7.3 Coping Costs
709

710

Has your illness with TB
resulted in a financial
burden?

Yes……………………………1

Did you borrow any
money to cover costs due
to the TB illness?

Yes……………………………1

If 2

No…………………………….2

►

No…………………………….2

715
711

If YES, how much did you
borrow? In TAKA

IF not known put 99999

712

From whom did you
borrow?

A. Family
B. Neighbor

[For each option, record 1
if the option is mentioned
and record 2 if the option
has not been mentioned.]

C. Friend
D. Bank
E. Cooperative
F. NGO
G. Money lender
H. Others
Specify______________________
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713

Have you already paid
back the borrowed
money?

Yes……………………………1

If 2

No…………………………….2

►
716

714

How are you planning to
pay back the money?

In
Full……………………………1

If 2
►

In Installment..………………….2
716
715

If you are paying in
installment, what is the
monthly installment? In
TAKA

IF not known put 99999

716

Have you sold any of your
property to finance the
cost of the TB illness?

Yes……………………………1

If 2

No…………………………….2

►
718

717

How much money did you
get from the sale of each
of these properties?

A. Land
B. Livestock
C. Transport/Vehicle

IF not known put 99999

D. Household item
E. Farm produce
F. Jewelry
G. Savings (FDR)
H. Other
Specify

718

Have you employed any
household help for your
illness?

Yes……………………………1

If 2

No…………………………….2

►
801
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719

How much do you pay
monthly to the household
help? In TAKA

IF not known put 99999

Section 8.0 Patient Income and Patient’s Household Income
Section 8.1 Personal Income
No.

Questions and filters

Coding categories

801

Who is the primary
income earner of the
household?

Patient…………………….…….1

Response

Skip

Patient’s Wife.…………...……..2
Patient’s Husband..……………3
Patient’s Mother………………..4
Patient’s Father…………..…….5
Patient’s Son….………………..6
Patient’s Daughter..……..…….7
Other ………………..………….8
Specify________________

802

What is the highest level
of Education (In years) of
these individuals?

A. Patient

B. Primary Income Earner (If Other
than patient)
[For each option, record
the number of years spent
studying. if the person is
illiterate/did not go to
school record “0”]

C. Household Head (If Other than
patient)
B. Spouse of Household Head (If
Other than patient)

803

Are you involved in
income earning activities?

Yes, formal work…………………1

If 4

Yes, agricultural and other
household work………………….2

►
809

Yes, informal work………………3
No…………………………………4
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804

If No, why are you not
involved in any income
earning activities?

Cannot work due to illness …….1
Stopped working after contracting
TB …….……...…………...……..2
Retired…………………….…….3
Student……...…………...……..4
Other……………....……………5
Specify-----------------------------

805

Have you left your job
due to your TB illness?

Yes…………………….…….1

If 2

No……...…………...……..2

►
809

806

If YES, how many months
ago did you leave your
job?

807

What was your monthly
income when you were
working? In TAKA

IF not known put 99999

808

How regularly did you
work before you became
ill with TB?

Throughout the year…….…….1

Months

Seasonal/part of the year.……..2
Day Labor………....……………3
Other……………....……………4
Specify-----------------------------

170

809

What was your main
occupation before your
illness with TB?

Service…………………….…….1
Agriculture…...…………...……..2
Household work…....……………3
Construction……………….…….4
Garments worker………...……..5
Transport…....…………..………6
Student…………………….…….7
Retired…...…………...………….8
Other………….…....……………9
Specify-----------------------------

810

811

Did you have to change
jobs when you became ill
with TB?

Yes…………………….…….1

What is your main
occupation after your
illness with TB?

Service…………………….…….1

No……...…………...……..2

Agriculture…...…………...……..2
Household work…....……………3
Construction……………….…….4
Garments worker………...……..5
Transport…....…………..………6
Student…………………….…….7
Retired…...…………...………….8
Other………….…....……………9
Specify-----------------------------

812

How many hours did you
work on average per day
BEFORE you became ill
with TB?

Hours

813

How many hours do you
work on average NOW
per day?

Hours
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If answer to 812 differs
from answer to 813:Is the
change related to the TB
illness?

Yes…………………….…….1

If 2

No……...…………...……..2

►

815

What was your estimated
personal income per
month BEFORE the TB
illness? In TAKA

IF not known put 99999

816

What is your estimated
personal income per
month NOW? In TAKA

IF not known put 99999

817

Is someone doing the
work you used to do after
your illness?

Spouse…………………….…….1

814

818

Son…………...…………...……..2
Daughter……..…....……………3
Friend…….……………….…….4
Nobody…………………...……..5
Other………….…....……………9
Specify-----------------------------

818

Do you have children of
or below school age?

Yes…………………….…….1

If 2

No……...…………...……..2

►
822

819

Are all of your children
attending school
regularly?

Yes…………………….…….1

If 1

No……...…………...……..2

►
822

820

821

Did your children go to
school regularly before
your recent illness with
TB?

Yes…………………….…….1

If your children do not go
to school, indicate the
reasons for not attending
school regularly?

A. Needs to help around the house

No……...…………...……..2

B. No money for school fess
C. Also sick
D. Has to work to earn
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822

[For each option, record 1
if the option is mentioned
and record 2 if the option
has not been mentioned.]

E. Take care of patient

Has the TB illness
affected your social or
private life in any way?

Yes…………………….…….1

If 2

No……...…………...……..2

►

F. Other
Specify___________________

823
823

If YES, how was your
social life affected?

A. Divorce
B. Loss of job
C. Dropped out of school

[For each option, record 1
if the option is mentioned
and record 2 if the option
has not been mentioned.]

D. Separated from spouse
E. Disruption of sexual life
F. Sick child
G. Other
Specify___________________

8824

What is your religion?

Islam…………………….…….1
Hindu………...…………...……..2
Christian……..…....……………3
Buddhism.……………….…….4
Other………….…....……………5
Specify-----------------------------

Section 8.2 Household Income
825

How much do you
estimate was the average
income of your household
per month BEFORE the
TB illness? (for all
persons in the house,
including patient; includes
welfare payments,
government assistance or

A. Patient’s income
B. Income of rest of the household

C. Govt. assistance
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other social support)? In
TAKA

D. Other

IF not known put 99999
826

How much do you
estimate was the average
income of your household
per month NOW? (for all
persons in the house,
including patient; includes
welfare payments,
government assistance or
other social support)? In
TAKA

A. Patient’s income
B. Income of rest of the household
D. Govt. assistance
E. Other

IF not known put 99999
827

How many people
regularly sleep in your
house? (including patient)

828

How many members of
the household are
employed for
wage/salary? (including
patient)

829

Besides yourself, does
anyone else of your
household receive
treatment for TB?

830

Yes…………………….…….1

If 2

No……...…………...……..2

►
823

If YES, how many
household members are
suffering from TB?
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Section 9.0 Socioeconomic Indicators
Section 9.0 Questions about the household
901

What is the main
source of lighting
for the
household?

RESPONSES

Electrical mains .................................... 01
Solar electricity .................................... 02
Generator .............................................. 03
Gas…………………………………………..….04
Kerosine/Oil lamp ................................ 05
Candles / Torch .................................... 06
Coleman (Kerosene/Pressure lanterns)…….07
Improvised lamp ................................... 08
Others ................................................... 96
Specify ____________________________

No source of lighting ............................ 98
902

What is the main
source of water
for drinking and
food preparation
for the
household?

903

What type of fuel
is mainly used in
your household
for cooking?

Piped into household ............................01
Piped to yard/plot .................................02
Piped into neighborhood.......................03
Protected well .......................................04
Unprotected well ..................................05
Protected Spring ..................................06
Unprotected Spring ..............................07
River/stream .........................................08
Pond/lake/dam ......................................10
Communal tank ....................................11
Rainwater..............................................12
Tank truck / Water cart .........................13
Bottled water .......................................14
Other____________________ .............96
(Specify)
Not reported ..........................................99
Gas ........................................................ 01
Stove with kerosene .............................. 02
Firewood ............................................... 03
Charcoal ............................................... 04
Dung ..................................................... 05
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Skip

Electricity ............................................ 06
Biogas ................................................... 07
Straw/shrubs/grass ................................ 08
Saw dust ............................................... 09
Others ................................................... 96
Specify _____________________________

904

What kind of
toilet facility do
people in your
house mainly
use?

905

Main
material of the
floor for the
principal
residence
structure

906

Main
material of the
roof of the
principal
residence

Own flush toilet ...................................... 01
Shared flush toilet ................................... 02
Ventilated improved pit latrine ............... 03
Pit latrine with slab ................................. 04
Pit latrine without slab / open pit ............ 05
Bowl/Bucket system ............................... 06
Closet oversea/river ................................ 07
No facility/bush/seashore ....................... 08
Other____________________ .............. 96
(Specify)
Not reported ..................................... …. 99
Natural Floor:
Earth ....................................................... 11
Sand ........................................................ 12
Rudimentary:
Wood planks ......................................... 21
Palm/bamboo ........................................ 22
Finished:
Polished wood ...................................... 31
Vinyl/asphalt strips ............................... 32
Marble/Ceramic tiles ............................ 33
Floor tile ............................................... 34
Cement / Concrete/ ............................... 35
Brick ..................................................... 36
Carpet ................................................... 37
Unpolished............................................ 38
Other____________________ ............ 96
(Specify)
Not reported ................................... …. 99
Natural roofing
No roof ................................................. 11
Thatch/palm leaf ................................... 12
Rudimentary roofing
Bamboo ............................................... 21
Wood planks ........................................ 22
Cardboard ............................................ 23
Finished roofing
Tin / Metal ........................................... 31
Wood ................................................... 32
Ceramic Tiles ...................................... 33

176

Cement / Concrete ............................... 34
Other____________________ ............ 96
(Specify)
907

Main
material of the
exterior walls of
principal
residence

908

What type of fuel
does your
household mainly
use for cooking?

Natural Walls
No walls ................................................ 11
Cane/Palm/Trunks ................................ 12
Dirt ....................................................... 13
Rudimentary walls
Bamboo with mud / matting ................. 21
Stone with mud ..................................... 22
Mud ...................................................... 23
Fibro ..................................................... 24
Plywood ................................................. 25
Cardboard ............................................. 26
Finished walls
Tin / Metal sheets ................................. 31
Cement / Concrete ................................ 32
Brick ..................................................... 31
Stone with lime/cement ........................ 33
Bricks ................................................... 34
Wood planks/shingles ........................... 35
Other____________________ ............... 96
(Specify)
ELECTRICITY . . . . . . . . . . . . . . . . . . . . . . 01

If 95

LPG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 02

►

NATURAL GAS . . . . . . . . . . . . . . . . . . . . . . 03

911

BIOGAS . . . . . . . . . . . . . . . . . . . . . . . . . . . . 04
KEROSENE . . . . . . . . . . . . . . . . . . . . . . . . . 05
COAL, LIGNITE . . . . .. . . . . . . . . . . . . . . . . . 06
CHARCOAL . . . . . . . . . . . . . . . . . . . . . . . . . 07
WOOD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 08
STRAW/SHRUBS/GRASS . . . . . . . . . . . . . . 09
AGRICULTURAL CROP . . . . . . . . . . . . . . . . 10
ANIMAL DUNG . . . . . . . . . . . . . . . . . . . . . . 11
NO FOOD COOKED
IN HOUSEHOLD . . . . . . . . . . . . . . . . . . . . . 95
OTHER 96
(SPECIFY)
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IN THE HOUSE . . . . . . . . . . . . . . . . . . . . . . . . 1
IN A SEPARATE BUILDING . . . . . . . . . . . . 2
OUTDOORS . . . . . . . . . . . . . . . . . . . . . . . . . . 3
OTHER 6
(SPECIFY)

909

Is the cooking
usually done in
the house, in a
separate building,
or outdoors?

910

Do you have a
separate room
which is used as a
kitchen?

Yes…………………….…….1

Does your
household own
any homestead?

Yes…………………….…….1

911

912

913

No……...…………...……..2

No……...…………...……..2

Does your household or any member of the household own the items?
Yes No
Electricity connection? A. Electricity .....................................
1
2
Solar Electricity?
B. Solar electricity…………….
1
2
A radio?
C. Radio.............................................
1
2
A television?
D. Television .....................................
1
2
A mobile phone?
E. Mobile phone ................................
1
2
A non-mobile phone?
F. Non-mobile phone .........................
1
2
A refrigerator?
G. Refrigerator ..................................
1
2
A DVD/VCD player?
H. DVD/VCD player .........................
1
2
An electric fan?
I. Fan .................................................
1
2
An Almirah/wardrobe? J. Almirah ........................................
1
2
A water pump
K. Water Pump .................................
1
2
An IPS?Generator
L. Generator/IPS...............................
1
2
An air conditioner
M. AC ...............................................
1
2
A computer/laptop?
N. Computer/Laptop..........................
1
2
In your opinion, is your
High income……………………………………1
household a high income
Middle income………………………………….2
household, a middle income
household or a poor household?

Low
income……………………………………..3

914

How many people live in your
household?

Total household size

915

How many adult members (15
years or older)

Number of adults in the household

916

How many children (less than
15 years)

Number of children in the household
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Responses

917

918

How many separate sleeping
rooms are there for the use of
your household members in
your residence?
What is your current place of
residence?

Number of rooms

Urban……………………………………1
Urban slum…………………….……….2
Rural……………………………………..3
Other……………………………………..4
Specify__________________________

919

If the government could provide
you with some service to ease
the burden of TB on you and
your household, what would you
prefer to have?
DO NOT READ. INDICATE
THE ITEMS MENTIONED. IF
NOT IN THE LIST, ADD ANY
NEW GOVT. SERVICE
MENTIONED.

920

Transport vouchers..………………………1
Food vouchers…………………….……….2
More efficient service……………………..3
Other……………………………………..4
Specify____________________________

How much would you be willing
to pay for not becoming ill with
TB in the first place? In TAKA
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Section 10.0 Performance of the Facility
The next part of the survey is about the quality of TB care that you received during your visits to
this facility. Please answer the questions in this part of the survey about this facility only. Do not
include any other facilities in your answer.
No.

Questions and
filters

Skip
Coding categories

Response

Section 10.1 Availability of TB Services
1001

1002

Are the waiting
time(s) before being
served by health
providers of this
facility acceptable
to you?

Never…………………….…….1

How often are you
attended to by the
same health
providers in this
facility?

Never…………………….…….1

Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

1003

1004

How often are the
service hours of this
facility
inconvenient for
you to get your TB
treatment?

Never…………………….…….1

How often are
drugs not available
when you require
them?

Never…………………….…….1

Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

1005

How often do you
experience
difficulties in
obtaining TB
services in this
facility because of
language barriers?

Never…………………….…….1
Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

180

1006

How often do you
have to go to
another health unit
for TB services or
treatment?

Never…………………….…….1
Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

1007

Is this health
facility easy to
reach (distance)?

Never…………………….…….1
Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

1008

How often are TB
services available
during the working
hours of this
facility?

Never…………………….…….1
Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

1009

How often are the
relevant health
providers you come
to see in this facility
available?

Never…………………….…….1
Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

Section 10.2 Communication and Information
1010

1011

1012

Do the health
providers in this
facility tell you
when you stop
spreading TB to
others?

Yes…………………….…….1

Do the health
providers in this
facility tell you that
TB can be cured?

Yes…………………….…….1

Do the health
providers in this
facility tell you
about the
importance of
observed treatment?

Yes…………………….…….1

No……...…………...……..2

No……...…………...……..2

No……...…………...……..2
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1013

1014

1015

1016

1017

Do the health
providers in this
facility tell you
about the side
effects of TB
drugs?

Yes…………………….…….1

Do the health
providers in this
facility tell you
about the need for
sputum tests at
given points during
your treatment
schedule?

Yes…………………….…….1

Do the health
providers in this
facility tell you
about the duration
of the TB
treatment?

Yes…………………….…….1

During your visits
to this facility, do
health providers tell
you about how to
store your drugs
obtained for your
treatment?

Yes…………………….…….1

Does the health
provider in this
facility tell you
when next to come
back for TB
services?

Yes…………………….…….1

No……...…………...……..2

No……...…………...……..2

No……...…………...……..2

No……...…………...……..2

No……...…………...……..2

Section 10.3 Patient – Provider interaction and counselling
1018

During your visits
to this facility, how
often does the
health provider treat
you with respect?

Never…………………….…….1
Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4
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1019

1020

1021

1022

1023

1024

During your visits
to this facility, how
often does the
health provider
listen carefully to
you?

Never…………………….…….1

During your visits
to this facility, how
often do health
providers explain
things in a way you
can understand?

Never…………………….…….1

During your visits
to this facility, how
often do you have
sufficient time to
discuss your
problems?

Never…………………….…….1

During your visits
to this facility, how
often do health
providers discuss
with you how to
deal with your
problems?

Never…………………….…….1

During your visits
to this facility, how
often do you
experience
discrimination
because you have
TB?

Never…………………….…….1

During your visits
to this facility, how
often is your
privacy respected
during
examination?

Never…………………….…….1

Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4
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1025

Do health providers
at this facility tell
you how TB can
affect your every
day life?

Never…………………….…….1
Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

Section 10.4 Infrastructure
1026

How often is this
facility clean?

Never…………………….…….1
Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

1027

How often is there
safe drinking water
in this facility?

Never…………………….…….1
Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

1028

How often are the
toilets in this
facility usable?

Never…………………….…….1
Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

1029

How often do you
find enough
comfortable places
to sit on in this
facility?

Never…………………….…….1
Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

Section 10.5 Professional Competence
1030

Does this facility
offer services to
examine your
sputum?

Yes…………………….…….1
No……...…………...……..2
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1031

1032

1033

1034

1035

1036

Does this facility
offer home based
TB treatment?

Yes…………………….…….1

Were you
physically
examined during
your first visit to
this health facility?

Yes…………………….…….1

Was your sputum
examined when you
were diagnosed
with TB?

Yes…………………….…….1

How many working
days were there
between your first
sputum submission
and the time you
got your results?

0-2 Working days……….…….1

In case of germs in
your sputum that
cause TB, were
your close contacts
examined by the TB
facility?

Yes…………………….…….1

How often is there a
treatment observer
checking on your
daily intake of TB
drugs?

Never…………………….…….1

No……...…………...……..2

No……...…………...……..2

No……...…………...……..2

3-4 Working days ……...……..2
More than 5 Working days...…3

No……...…………...……..2

Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

Section 10.6 Affordability
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1037

1038

How often do you
have to pay for your
regular TB services
(e.g. sputum tests,
TB-drugs, X-rays,
etc.)?

Never…………………….…….1

How often do you
have to pay a tip in
order to receive TB
services?

Never…………………….…….1

Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

1039

How often do costs
(e.g. transport)
prevent you from
getting to the health
facility?

Never…………………….…….1
Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

Section 10.7 Support
1040

How often do you
receive transport
support from the
health facility?

Never…………………….…….1
Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

1041

How often do you
receive food
support from the
health facility?

Never…………………….…….1
Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

1042

How often do you
receive financial
assistance from the
health facility?

Never…………………….…….1
Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

Section 10.8 Stigma
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1043

1044

1045

Does the health
provider talk to you
the same way you
are spoken to when
you receive services
other than TB?

Never…………………….…….1

Does the health
provider welcome
you into the health
facility when you
visit for TB
services?

Never…………………….…….1

Does the health
provider turn
his/her face away
when speaking with
you?

Never…………………….…….1

Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

1046

Do you feel that
you are treated with
dignity when you
visit the health
facility?

Never…………………….…….1
Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

Section 11.0 Quality of Life
Section 11.1 Health Related Quality of Life (FACIT-TB Questionnaire)
How would you describe your
level of feeling for the following
statements: (record the number
in the right column)

No
t
At
All

Slight
ly

Moderately

Quite
A Bit

Extrem
ely

A. Physical well-being
1101

I feel ill

1

2

3

4

5

1102

I get tired easily

1

2

3

4

5
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Response

1103

I have a lack of energy

1

2

3

4

5

1104

I have pain

1

2

3

4

5

1105

I feel weak all over

1

2

3

4

5

1106

I feel fatigued

1

2

3

4

5

1107

I have been short of
breath

1

2

3

4

5

1108

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1113

I have nausea-“a sense
of vomiting outbreak”
Because of my physical
condition, I have
trouble meeting the
needs of my family
I am bothered by fever
(episode of high body
temperature)
I am forced to spend
time in bed
I have discomfort or
pain in my stomach area
I have had itching

1

2

3

4

5

1114

I have a loss of appetite

1

2

3

4

5

1115

I have been coughing

1

2

3

4

5

I am bothered by side
effects of treatment
Dusts Worsen my
1117
symptoms
B. Social and economic
well-being

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1109

1110

1111
1112

1116

1118
1119
1120

1121
1122

I feel close to my
friends
I get emotional support
from my family
I am satisfied with my
family communication
about my illness
My family has accepted
my illness
I feel close to my
partner (or the person
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who is my main
support)
I get support from my
1123
friends
My physical condition
1124
and/or medical
treatment cause me
financial difficulties
C. Emotional wellbeing/Stigma of having
TB
I worry that my
1125
condition will get worse
I worry about dying
1126

1133

I am concerned about
what the future holds
for me
I am embarrassed by
my illness
It is hard to tell other
people about my
infection
I am losing hope in the
fight against my illness
I am bothered by the
change in weight
I worry about spreading
my infection
I feel nervous

1134

I feel sad

1127

1128
1129

1130
1131
1132

I am satisfied with how
I am coping with my
illness
D. Functional well-being

1135

1136

1137
1138
1139
1140

I am content with the
quality of my life right
now
My work (include work
at home) is fulfilling
I am able to work
(include work at home)
I am able to enjoy life
I am enjoying the things
I usually do for fun

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5
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1141
1142

I have accepted my
illness
I am sleeping well

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

E. Spiritual well-being
1143
1144

1145

I find strength in my
faith or spiritual belief
My illness has
strengthened my faith
or spiritual belief
My life is still
productive

Section 11.2 EQ-5D-5L Questionnaire

Under each heading, please tick the ONE box that best describes your health TODAY.
Sl

Category

Options

Response

1146

Mobility

I have no problems in walking
about.................................1
I have slight problems in walking
about.............................2
I have moderate problems in walking
about......................3
I have severe problems in walking
about...........................4
I am unable to walk
about..................................................5

1147

Self-Care

I have no problems washing or dressing
myself...............1
I have slight problems washing or
dressing myself...........2
I have moderate problems washing or
dressing myself....3
I have severe problems washing or
dressing myself........4
I am unable to wash or dress
myself.................................5
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1148

Usual Activities I have no problems doing my usual
activities....................1
(e.g., work,
study,
I have slight problems doing my usual
housework,
activities................2
family or
I have moderate problems doing my
leisure
usual activities.........3
activities)
I have severe problems doing my usual
activities.............4
I am unable to do my usual
activities.................................5

1149

Pain/Discomfor
t

I have no pain or
discomfort...............................................
1
I have slight pain or
discomfort...........................................2
I have moderate pain or
discomfort....................................3
I have severe pain or
discomfort........................................4
I have extreme pain or
discomfort......................................5

1150

Anxiety/Depres
sion

I am not
anxious/depressed....................................
...........1
I am slightly
anxious/depressed....................................
.....2
I am moderately
anxious/depressed..................................3
I am severely
anxious/depressed....................................
..4
I am extremely
anxious/depressed....................................
5
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Section 11.3 SF-6D Questionnaire

Under each heading, please tick the ONE box that best describes your health TODAY.
Sl

Category

Options

Respon
se

115
1

Physical
Functioning

My health does not limit me in vigorous
activities..................................1
My health limits me a little in vigorous
activities.....................................2
My health limits me a little in moderate
activities...................................3
My health limits me a lot in moderate
activities......................................4
My health limits me a little in bathing and
dressing...............................5
My health limits me a lot in bathing and
dressing..................................6

115
2

Role
Limitation

I have no problems with your work or other regular daily
activities as a result of your physical health or any emotional
problems......................1
I am limited in the kind of work or other activities as a result
of your physical
health..............................................................................................2
I accomplish less than you would like as a result of emotional
problems..............................................................................................
..........3
You are limited in the kind of work or other activities as a
result of your physical health and accomplish less than you
would like as a result of emotional
problems.....................................................................................4

115
3

Social
Functioning

My health limits my social activities none of the
time..................................1
My health limits my social activities a little of the
time.................................2
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My health limits my social activities some of the
time..................................3
My health limits my social activities most of the
time...................................4
My health limits my social activities all of the
time.......................................5
115
4

Pain

I have no
pain................................................................................................1
I have pain, but it does not interfere with my normal work (both
outside the home and
housework)...................................................................................2
I have pain that interferes with your normal work (both outside the
home and housework) a little
bit.............................................................................3
I have pain that interferes with your normal work (both outside the
home and housework)
moderately.........................................................................4
I have pain that interferes with your normal work (both outside the
home and housework) quite a
bit...........................................................................5
I have pain that interferes with your normal work (both outside the
home and housework)
extremely..........................................................................6

115
5

Mental Health

I feel tense or downhearted and low none of the
time.................................1
I feel tense or downhearted and low a little of the
time................................2
I feel tense or downhearted and low some of the
time................................3
I feel tense or downhearted and low most of the
time.................................4
I feel tense or downhearted and all of the
time............................................5

115
6

Vitality

I have a lot of energy all of the
time..............................................................1
I have a lot of energy most of the
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time.........................................................2
I have a lot of energy some of the
time........................................................3
I have a lot of energy a little of the
time........................................................4
I have a lot of energy none of the
time..........................................................5

Section 11.4 Visual Analog Scale
1157 Visual Analog Scale Score
1158

Comments by interviewer on the interview

1159

INTERVIEWERS: CHECK YOUR FILLED IN QUESTIONNAIRE CAREFULLY
BEFORE LEAVING THE RESPONDENTS AND END YOUR INTERVIEW BY
GIVING THANKS TO THE RESPONDENT.
RECORD THE END TIME OF THE
INTERVIEW:
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Hour
Minutes

APPENDIX C – PATIENT QUESTIONNAIRE (MDR-TB)

Face Sheet for MULTI-DRUG RESISTANT TB(MDR-TB) Patient
Interview
IDENTIFICATION
DIVISION:
DISTRICT:
UPAZILA:
NAME AND TYPE OF THE FACILITY:
(NIDCH =01, District Chest Hospital =02, Damien Foundation Hospital
=03, Other=04, Please Specify)
HEALTH FACILITY CODE:
DRUG REGIMEN FOLLOWED:
(21 MONTH REGIMEN =01, 9 MONTH REGIMEN =02)
RESPONDENT:
(Patient=01, Friend/Guardian=02, Other (Please specify)=03)
SEX OF THE RESPONDENT:
(Male=01, Female= 02)
SEX OF THE PATIENT:
(Male=01, Female= 02)
NAME OF THE DOT PROVIDER:
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INTERVIEWER VISITS
1

2

3

FINAL VISIT

DATE
INTERVIEWER’S NAME
& CODE

RESULT
CODE

RESULT CODE*
RESULT
CODE
*RESULT CODES:
01

COMPLETED

03

POSTPONED

05

PARTLY COMPLETED

02

NOT AVAILABLE

04

REFUSED

96

OTHER, SPECIFY____________________

OFFICE
EDITOR

KEYED BY

SUPERVISOR

FIELD EDITOR

Take information for only those patients (>18 years of age) who are undergoing the
treatment or have completed their treatment within last two months.
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Section 1: Patient Information
(TO BE FILLED IN BY THE INTERVIEWER WITH HELP OF PATIENT TB CARD; FILL IN ALSO IF
INTERVIEW IS REFUSED FRO NON-RESPONSE ANALYSIS)

Options
Consent obtained from patient
or caregiver?

No
.

Questions and filters

10
1

Patient age

Yes……………………………….1
No…………………………………2

Coding categories

Response

Years
Male ………………....……1

10
2

Patient Sex

10
3

Site

10
4

History of contact with
TB/ DR TB Patient

Yes………………………………1

10
5

IF YES, Relation and
duration

WRITE DOWN FROM PATIENT CARD

10
6

Medical Diagnosis other
than TB

WRITE DOWN FROM PATIENT CARD

Female….. ……………….2
Pulmonary ………………....……1
Extra-Pulmonary ……………….2
Please Specify_______________

No………………………………..2
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10
7

Registration Status

10
8

Type of Resistance

CAT I Non converter……….…….1
CAT I Failure.………………..…..2
Treatment After loss to follow-up- CAT
I…………………………..…3
CAT I Relapse…………………..4
CAT I Non converter……….…….5
CAT II Failure……………………6
Treatment After loss to follow-up- CAT
Ii…………………………..…7
CAT I Relapse…………………..8
Close contact of DR TB with
S/S………………………………..9
Transfer In……………………10
HIV Infected Patient………….11
Pulmonary-clinically diagnosed,
new/previously treated……….12
Extra pulmonary, new/previously
treated………………………….13
Unknown TB treatment history..14
New (Pulmonary), bacteriologically
confirmed…..15
MDR TB/XDR
TB/Polyresistance………………1
Monoresistance…………………2

10
9

Previous TB Treatment
Episode including DR TB

No.

Start Date

Regimen

Outcome

Drugs:
First Line Drugs:
H=Isoniazid
R=Rifampicin
E=Ethambutol
Z=Pyrizinamide
S=Streptomycin
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Second Line Drugs:
Km=Kanamycin
Ofx=Ofloxacin
Lfx=Levofloxacin
Eto=Ethionamide
Cs=Cycloserine
PAS=Para-aminosalicyclic Acid
Cm=Capreomycin
Clf=Clofazimine
Lzd=Linezoli
Trd=Terizidone
Amx/Clv=Amxicillin+Clavulanate
Acid
Mfx=Moxifloxacin
Other…………………………………

11
0

Regimen and Drug Doses
*Date: Date treatment
started and doses, Change
of doses (if any)

11
1

Results of sputum
Examination

Date
*

Z
(mg
)

Km
(gm)

Ofx/Lf
x (mg)

Eto
(mg
)

Cs
(mg
)

Cm
(gm)

PAS
(gm)

Date
*

Clf
(mg
)

Amx/Cl
v (gm)

Trd
(mg)

Lzd
(mg
)

Mfx
(mg
)

Othe
r

Comment
s

Month
0
1

[Notation method:
2

No AFB =0
1-9 AFB per 100 HPF=
Scanty (report number of
AFB)
10-99 AFB per 100 HPF=
+
1-10 AFB per HPF= ++
>10 AFB=+++]

3

Week

Date of sample collection

1
2
3
4
1
2
3
4
1
2
3
4

4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
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Result

11
2

Adverse Drug Reaction

Date

11
3

Results of Culture

Month

[Notation Method:
No growth reported=0
Fewer than 10
colonies=report number
of colonies (1-9)
10-100 Colonies=+
More than 100
colonies=++
Innumerable or confluent
growth=+++
Non-tuberculous
mycobacteria= NTM
Contaminated=contaminat
ed]

Adverse Drug
Reaction

Date of
sample
collection

0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
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Suspected
Drug

Result

Measure Taken

11
4

Drug Susceptibility
Testing (DST) Results

Method

Date

S

H

R

E

Km

Method

Date

Ofx/Lfx

Eto

Other

Other

Other

[Notation:
R=Resistant
S=Susceptible
C=Contaminated
Unk=Unknown]

Method:
Xpert MTB/RIF……..1
Line Probe Assay (LPA2
Liquid Culture………...3
Solid Culture (L-J)……4
11
5

In which phase of the
treatment are you
currently on?

Injectable phase of 21 months regimen…1
Continuation phase of 21 months
regimen…2
Injectable phase of 9 months regimen…3
Continuation phase of 9 months regimen…4

11
6

How long are you on this
phase of treatments?
Months

11
7

HIV Status

Positive…………….…….1
Negative………......……..2
Not Tested…....…………3
Unknown…….……………..4
Declined.…………………….….5
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11
8

Final outcome (If
treatment is completed)

Cured…………………….…….1
Treatment completed....……..2
Died………....…………………3
Treatment failure……………..4
Default.…………………….….5
Transfer Out…………..………6

11
9

Date of starting treatment

Day
Month
Year

12
0

Date of completion of
treatment

Day
Month
Year
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Section 2.0: Previous treatment
PATIENT INTERVIEW SECTION
Minutes |__|__|

Start time: Hours |__|__|

No.

Questions and filters

Coding categories

Response

201

Have you ever had TB
treatment before?

Yes……………………………1

If 2

No…………………………….2

►

CROSS-CHECK WITH
INFORMATION FROM
PATENT CARD
202

Skip

301

What is your TB treatment
history

Cat I Treatment
failure……………1

If
1,2,5

CROSS-CHECK WITH
INFORMATION FROM
PATENT CARD

Cat II Treatment
failure..………….2

►
301

Transfer to Cat-IV during nonMDR treatment……………3

If 3
►

Treatment after default..………….4
204
TB relapse……………………….5
Other……………………………...6
Specify ____________________
203

Your treatment card
indicated that you had
default treatment. Why
was previous treatment not
completed?

A. Distance to the facility
B. Lack of money for treatment
costs
C. Drug Side Effects
D. Moved/Migrated

[For each option, record 1
if the option is mentioned
and record 2 if the option
has not been mentioned.]
204

E. Other
Please Specify________________

If on Cat IV treatment,
how long have you been
on TB treatment before
you were diagnosed with
MDR-TB?

Months

203

Section 3: Delay, Prediagnostic & Diagnostic Costs
No.

Questions and filters

Coding categories

301

What symptoms did you
experience that led you to
seek treatment for your most
recent illness with TB?

a. Cough

Response

b. Evening rise of temperature/low
grade fever
c. Coughing up blood
d. Weight loss

302

[For each option, record 1 if
the option is mentioned and
record 2 if the option has not
been mentioned.]

e. Other

How long did you experience
these symptoms before you
went to seek treatment?

a. Cough

Weeks

b. Evening rise of temperature/low
grade fever

Weeks

c. Coughing up blood

Weeks

d. Weight loss

Weeks

e. Other

Weeks

[For each option, record
number of weeks if mentioned
yes in the previous question.]

Specify_____________________

Specify_____________________

204

Skip

Section 3.1 First Visit
303

After you experienced the
symptoms, which provider
did you go to first?

Community
Clinic…………….…….1
Union Subcenter………….....……..2
Upazila Health Complex…..………3
District Hospital……..……………..4
Pharmacy & Drug Store……….….5
Homoeopath………………..………6
Private Hospital……..……………..7
Traditional Healer………………….8
Other………………………..………9
Specify______________________

304

What was the distance to the
provider from your home?

Kilometer

305

What was the travel time to
reach this provider?

Hour
Minute

306

What was the waiting and
consultation time with the
provider?

Hour
Minute

307

308

309

What was the registration
(ticket) cost paid by you? In
TAKA

IF not known put 99999

What was the consultation
fee you have paid? In
TAKA

IF not known put 99999

What was the cost you paid
for diagnostic tests? In
TAKA

IF not known put 99999

IF no registration cost 000

IF no consultation fee 000

IF no cost for tests 000
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310

What was the cost for x-ray?
In TAKA

IF not known put 99999
IF no cost for x-ray 000

311

What was the costs of
drugs? In TAKA

IF not known put 99999
IF no cost for drugs 000

312

313

What was travel costs?

IF not known put 99999

(INCLUDE ALL TRAVEL
RELATED COSTS:
RETURN TRAVEL,
TRAVEL FOR
LABORATIRY TESTS,
DTUGS, COST FOR
ACCOMPANYING
PERSONS) In TAKA

IF no travel cost 000

What was the food costs? In
TAKA

IF not known put 99999
IF no food cost 000

314

What was cost for
accommodation?

IF not known put 99999
IF no accommodation cost 000

206

Section 3.2 Second Visit
No.

Questions and filters

Coding categories

315

Once you experience the
symptoms to which
provider did you go after
you have seen the
provider type
_________________?

Community
Clinic…………….…….1

(MENTION THE FIRST
VISIT’S PROVIDER
TYPE)

Response

Union Subcenter………….....……..2
Upazila Health Complex…..………3
District Hospital……..……………..4
Pharmacy & Drug Store……….….5
Homoeopath………………..………6
Private Hospital……..……………..7
Traditional Healer………………….8
Other………………………..………9
Specify______________________

316

What was the distance to
the provider from your
home?

Kilometer

317

What was the travel time
to reach this provider?

Hour
Minute

318

What was the waiting
and consultation time
with the provider?

Hour
Minute

319

320

321

What was the registration
(ticket) cost paid by you?
In TAKA

IF not known put 99999

What was the
consultation fee you have
paid? In TAKA

IF not known put 99999

What was the cost you
paid for diagnostic tests?
In TAKA

IF not known put 99999

IF no registration cost 000

IF no consultation fee 000

IF no cost for tests 000
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Skip

3322

What was the cost for xray? In TAKA

IF not known put 99999
IF no cost for x-ray 000

323

What was the costs of
drugs? In TAKA

IF not known put 99999
IF no cost for drugs 000

324

325

What was travel costs?

IF not known put 99999

(INCLUDE ALL
TRAVEL RELATED
COSTS: RETURN
TRAVEL, TRAVEL
FOR LABORATIRY
TESTS, DTUGS, COST
FOR
ACCOMPANYING
PERSONS) In TAKA

IF no travel cost 000

What was the food costs?
In TAKA

IF not known put 99999
IF no food cost 000

326

What was cost for
accommodation?

IF not known put 99999
IF no accommodation cost 000
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Section 3.4 Fourth Visit
No.

Questions and filters

Coding categories

339

Once you experience the
symptoms to which
provider did you go
after you have seen the
provider type
_________________?

Community
Clinic…………….…….1

(MENTION THE
THIRD VISIT’S
PROVIDER TYPE)

Response

Union Subcenter………….....……..2
Upazila Health Complex…..………3
District Hospital……..……………..4
Pharmacy & Drug Store……….….5
Homoeopath………………..………6
Private Hospital……..……………..7
Traditional Healer………………….8
Other………………………..………9
Specify______________________

340

What was the distance
to the provider from
your home?

Kilometer

341

What was the travel
time to reach this
provider?

Hour
Minute

342

What was the waiting
and consultation time
with the provider?

Hour
Minute

343

344

345

What was the
registration (ticket) cost
paid by you? In TAKA

IF not known put 99999

What was the
consultation fee you
have paid? In TAKA

IF not known put 99999

What was the cost you
paid for diagnostic tests?
In TAKA

IF not known put 99999

IF no registration cost 000

IF no consultation fee 000

IF no cost for tests 000
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Skip

346

What was the cost for xray? In TAKA

IF not known put 99999
IF no cost for x-ray 000

347

What was the costs of
drugs? In TAKA

IF not known put 99999
IF no cost for drugs 000

348

349

What was travel costs?

IF not known put 99999

(INCLUDE ALL
TRAVEL RELATED
COSTS: RETURN
TRAVEL, TRAVEL
FOR LABORATIRY
TESTS, DTUGS, COST
FOR
ACCOMPANYING
PERSONS) In TAKA

IF no travel cost 000

What was the food
costs? In TAKA

IF not known put 99999
IF no food cost 000

350

What was cost for
accommodation?

IF not known put 99999
IF no accommodation cost 000
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Section 3.5 Fifth Visit
No.

Questions and filters

Coding categories

351

Once you experience the
symptoms to which
provider did you go
after you have seen the
provider type
_________________?

Community
Clinic…………….…….1

(MENTION THE
FOURTH VISIT’S
PROVIDER TYPE)

Response

Union Subcenter………….....……..2
Upazila Health Complex…..………3
District Hospital……..……………..4
Pharmacy & Drug Store……….….5
Homoeopath………………..………6
Private Hospital……..……………..7
Traditional Healer………………….8
Other………………………..………9
Specify______________________

352

What was the distance
to the provider from
your home?

Kilometer

353

What was the travel
time to reach this
provider?

Hour
Minute

354

What was the waiting
and consultation time
with the provider?

Hour
Minute

355

356

357

What was the
registration (ticket) cost
paid by you? In TAKA

IF not known put 99999

What was the
consultation fee you
have paid? In TAKA

IF not known put 99999

What was the cost you
paid for diagnostic tests?
In TAKA

IF not known put 99999

IF no registration cost 000

IF no consultation fee 000

IF no cost for tests 000
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Skip

358

What was the cost for xray? In TAKA

IF not known put 99999
IF no cost for x-ray 000

359

What was the costs of
drugs? In TAKA

IF not known put 99999
IF no cost for drugs 000

360

361

What was travel costs?

IF not known put 99999

(INCLUDE ALL
TRAVEL RELATED
COSTS: RETURN
TRAVEL, TRAVEL
FOR LABORATIRY
TESTS, DTUGS, COST
FOR
ACCOMPANYING
PERSONS) In TAKA

IF no travel cost 000

What was the food
costs? In TAKA

IF not known put 99999
IF no food cost 000

362

What was cost for
accommodation?

IF not known put 99999
IF no accommodation cost 000
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Section 3.6 Sixth Visit
No.

Questions and filters

Coding categories

363

Once you experience the
symptoms to which
provider did you go after
you have seen the
provider type
_________________?

Community
Clinic…………….…….1

(MENTION THE FIFTH
VISIT’S PROVIDER
TYPE)

Response

Union Subcenter………….....……..2
Upazila Health Complex…..………3
District Hospital……..……………..4
Pharmacy & Drug Store……….….5
Homoeopath………………..………6
Private Hospital……..……………..7
Traditional Healer………………….8
Other………………………..………9
Specify______________________

364

What was the distance to
the provider from your
home?

Kilometer

365

What was the travel time
to reach this provider?

Hour
Minute

366

What was the waiting
and consultation time
with the provider?

Hour
Minute

367

3368

369

What was the registration
(ticket) cost paid by you?
In TAKA

IF not known put 99999

What was the
consultation fee you have
paid? In TAKA

IF not known put 99999

What was the cost you
paid for diagnostic tests?
In TAKA

IF not known put 99999

IF no registration cost 000

IF no consultation fee 000

IF no cost for tests 000
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Skip

370

What was the cost for xray? In TAKA

IF not known put 99999
IF no cost for x-ray 000

371

What was the costs of
drugs? In TAKA

IF not known put 99999
IF no cost for drugs 000

372

373

What was travel costs?

IF not known put 99999

(INCLUDE ALL
TRAVEL RELATED
COSTS: RETURN
TRAVEL, TRAVEL
FOR LABORATIRY
TESTS, DTUGS, COST
FOR
ACCOMPANYING
PERSONS) In TAKA

IF no travel cost 000

What was the food costs?
In TAKA

IF not known put 99999
IF no food cost 000

374

What was cost for
accommodation?

IF not known put 99999
IF no accommodation cost 000
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Section 3.7 Seventh Visit
No.

Questions and filters

Coding categories

375

Once you experience the
symptoms to which
provider did you go
after you have seen the
provider type
_________________?

Community
Clinic…………….…….1

(MENTION THE SIXTH
VISIT’S PROVIDER
TYPE)

Response

Union Subcenter………….....……..2
Upazila Health Complex…..………3
District Hospital……..……………..4
Pharmacy & Drug Store……….….5
Homoeopath………………..………6
Private Hospital……..……………..7
Traditional Healer………………….8
Other………………………..………9
Specify______________________

376

What was the distance
to the provider from
your home?

Kilometer

377

What was the travel
time to reach this
provider?

Hour
Minute

378

What was the waiting
and consultation time
with the provider?

Hour
Minute

379

380

381

What was the
registration (ticket) cost
paid by you? In TAKA

IF not known put 99999

What was the
consultation fee you
have paid? In TAKA

IF not known put 99999

What was the cost you
paid for diagnostic tests?
In TAKA

IF not known put 99999

IF no registration cost 000

IF no consultation fee 000

IF no cost for tests 000
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Skip

382

What was the cost for xray? In TAKA

IF not known put 99999
IF no cost for x-ray 000

383

What was the costs of
drugs? In TAKA

IF not known put 99999
IF no cost for drugs 000

384

385

What was travel costs?

IF not known put 99999

(INCLUDE ALL
TRAVEL RELATED
COSTS: RETURN
TRAVEL, TRAVEL
FOR LABORATIRY
TESTS, DTUGS, COST
FOR
ACCOMPANYING
PERSONS) In TAKA

IF no travel cost 000

What was the food
costs? In TAKA

IF not known put 99999
IF no food cost 000

386

What was cost for
accommodation?

IF not known put 99999
IF no accommodation cost 000
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Section 3.8 Eighth Visit
No.

Questions and filters

Coding categories

387

Once you experience the
symptoms to which
provider did you go
after you have seen the
provider type
_________________?

Community
Clinic…………….…….1

(MENTION THE
SEVENH VISIT’S
PROVIDER TYPE)

Response

Union Subcenter………….....……..2
Upazila Health Complex…..………3
District Hospital……..……………..4
Pharmacy & Drug Store……….….5
Homoeopath………………..………6
Private Hospital……..……………..7
Traditional Healer………………….8
Other………………………..………9
Specify______________________

388

What was the distance
to the provider from
your home?

Kilometer

389

What was the travel
time to reach this
provider?

Hour
Minute

390

What was the waiting
and consultation time
with the provider?

Hour
Minute

391

392

393

What was the
registration (ticket) cost
paid by you? In TAKA

IF not known put 99999

What was the
consultation fee you
have paid? In TAKA

IF not known put 99999

What was the cost you
paid for diagnostic tests?
In TAKA

IF not known put 99999

IF no registration cost 000

IF no consultation fee 000

IF no cost for tests 000
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Skip

394

What was the cost for xray? In TAKA

IF not known put 99999
IF no cost for x-ray 000

395

What was the costs of
drugs? In TAKA

IF not known put 99999
IF no cost for drugs 000

396

397

What was travel costs?

IF not known put 99999

(INCLUDE ALL
TRAVEL RELATED
COSTS: RETURN
TRAVEL, TRAVEL
FOR LABORATIRY
TESTS, DTUGS, COST
FOR
ACCOMPANYING
PERSONS) In TAKA

IF no travel cost 000

What was the food
costs? In TAKA

IF not known put 99999
IF no food cost 000

398

What was cost for
accommodation?

IF not known put 99999
IF no accommodation cost 000
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Section 4.0: Treatment Costs
Section 4.1 Cost Related to DOT
No.

Questions and filters

Coding categories

401

From where did you get
your TB drugs?

Health facility………………….…….1

Response

Home……………………….....……..2
Community…………………..………3
Pharmacy……………..……………..4
Workplace……………….……….….5
Other………………………..………9
Specify______________________

402

How often do you
travel to the health
facility / hospital for
picking up your TB
drugs?

403

How long does it take
to go to the place for
picking up the drugs
(ONE WAY)?

Times/
month

A. On Foot

Hour
Minute

B. By Transport

Hour
Minute

404

405

How long does one of
these visits take on
average, including time
on the road and waiting
time (total turnaround
time)?
From your home to the
facility, how much does
it cost if you take
transport? (BOTH
WAYS)

Hour
Minute

IF not known put 99999
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Skip

406

If you go to a facility to
pick up your drugs,
how much do you
spend on food on that
day? (on the road,
while waiting, lunch
etc.)

IF not known put 99999

407

Do you have to pay
administration fees
when picking up your
TB drugs?

Yes……………………………1

If 2

No…………………………….2

►

What was the
administration cost?

IF not known put 99999

408

409

IF no administration cost 000
409

410

Do you have to pay for
accommodation when
picking up your TB
drugs?

Yes……………………………1

If 2

No…………………………….2

►

What was the
accommodation cost?

IF not known put 99999

411

IF no accommodation cost 000

Section 4.2 Cost related to Follow Up Tests
411

Did you ever have to
go to the health facility
in addition to your
regular visits for

Yes……………………………1

If 2

No…………………………….2

►
414

follow up tests since
the beginning of
treatment?
412

If yes, how many
times?

413

If yes, did you have to
pay any additional
costs any time during
the entire period?

414

Times
Yes……………………………1

If 2

No…………………………….2

►
421

If so, what kind of costs
and how much did you
A. Fees
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pay last time (In
TAKA)?
B. Sputum Test

IF not known put
99999

C. X -ray

IF no cost put 000
D. TB Drugs

E. Other Drugs

F. Others
415

How long does one of
these follow-up visits
take on average,
including time on the
road, waiting time and
tests (total turnaround
time)?

Hour
Minute

Section 5.0: Cost related to accompanied persons (Friends/Guardian)
No.

Questions and filters

Coding categories

501

Does any
family/friend/DOT
supporter accompany you
on any visits before
diagnosis and/or during
diagnosis?

Yes……………………………1

If 2

No…………………………….2

►

502

If YES, on how many visits
has your family/friend/DOT
supporter accompanied you
or gone with you before
diagnosis and/or during
diagnosis?

503

What was the cost for prediagnosis/diagnosis visits of

Response

Skip

507

Times

A. Transport Cost
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your accompanying person
in Taka)?

B. Food Cost
C. Accommodation Cost

IF not known put 99999
IF no cost put 000
504

Does your accompanying
person earn?

Yes……………………………1

If 2

No…………………………….2

►
506

505

If earn, how much the
person earn per day (in
TAKA)?

IF not known put 99999

506

Why did someone
accompany you?

A. Distance
B. Security
C. Administrative barrier

[For each option, record 1
if the option is mentioned
and record 2 if the option
has not been mentioned.]

D. Too ill to travel alone
E. Was required for treatment
F. Other
Please
Specify________________

507

Does any
family/friend/DOT
supporter accompany you
on any visits during
treatment (taking drugs)?

508

If YES, on how many visits
has your family/friend/DOT
supporter accompanied you
or gone with you during
treatment?

509

What was the cost for visits
of your accompanying
person during your
treatment in TAKA)?

Yes……………………………1

If 2

No…………………………….2

►
601

Times

A. Transport Cost
B. Food Cost

222

C. Accommodation Cost
IF not known put 99999
IF no cost put 000
510

Does your accompanying
person earn?

Yes……………………………1

If 2

No…………………………….2

►
512

511

If earn, how much the
person earn per day (In
TAKA)?

512

Why did someone
accompany you?

A. Distance
B. Security
C. Administrative barrier

[For each option, record 1
if the option is mentioned
and record 2 if the option
has not been mentioned.]

D. Too ill to travel alone
E. Was required for treatment
F. Other
Please
Specify________________

Section 6.0: Hospitalization Costs
No.

Questions and filters

Coding categories

Response

Skip

601

Have you been hospitalized
before (but due to TB) or
during your TB treatment?

Yes……………………………1

If 2

No…………………………….2

►
701

602

If YES, how many times
were you hospitalized for
this illness?

603

How much did you pay
during your last stay at the
hospital (In TAKA)?

Times

A. Hospital Administration Fees
B. Hospital stay charges

223

C. Food (Not provided by the
hospital)
IF not known put 99999
D. Transport (Both Ways)
IF no cost put 000
E. Drugs
F. Diagnostic Tests
G. Others
604

Did any attendant/caregiver
stay with you at the
hospital?

Yes……………………………1

If 2

No…………………………….2

►
701

605

If YES, how many days
he/she stay with you (sleep
there)?

606

Were there any extra costs
for your relative/friend for
staying at the hospital?

Days

Yes……………………………1

If 2

No…………………………….2

►
506

607

What was the cost for the
accompanying person
during your hospitalization
(stayed at night)? In TAKA

A. Transport Cost

IF not known put 99999

C. Accommodation Cost

B. Food Cost

IF no cost put 000
D. Other Cost

608

Does your accompanying
person earn?

Yes……………………………1
No…………………………….2
Don’t Know.………………….3

If 2
/3
►
610

224

609

If earn, how much the
accompanying person earn
per day?
IF not known put 99999

610

Did any other family/friend
visit you while in hospital?

Yes……………………………1

If 2

No…………………………….2

►
701

611

If YES, How many people
visited you?

Days

612

On an average, how many
times did each of these
person visit you?

Times

613

What was the cost for
EACH VISIT of them (IN
TAKA)?

IF not known put 99999
IF no cost put 000

614

A. Transport Cost
B. Food Cost
C. Accommodation Cost
D. Other Cost

How long were the visits
including traveling time?

Hour
Minute
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Section 7.0: Other Costs, Other Illnesses and Coping Costs
Section 7.1 Other Costs
No.

Questions and filters

Coding categories

701

Did you buy any
supplements for your diet
because of the TB illness,
for example vitamins,
meat, energy drinks, soft
drinks, fruits or
medicines?

Yes……………………………1

If 2

No…………………………….2

►

If YES, how much did you
spend approximately on
each of these items each
month (in TAKA)?

A. Meat

702

Response

Skip

703

B. Fish
C. Fruits

IF not known put 99999
D. Drinks
E. Vegetables
F. Vitamins/Herbs
G. Others
703

Did you have to move to
be able to receive (MDR)
TB treatment?

Yes……………………………1

If 2

No…………………………….2

►
705

704

If YES: how much did
you pay for relocation? (In
TAKA)

IF not known put 99999
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705

706

707

Did you experience any
adverse events during the
treatment of (MDR-) TB?
(Adverse events are any
additional health problems
that occur during(MDR-)
TB treatment and that may
be related to the treatment)

Yes……………………………1

If 2

No…………………………….2

►

If YES: Was treatment
required of these events?
This includes changes in
TB drug regimen!

Yes……………………………1

IF YES, How much did
you spend on treatment of
adverse events and/or
changes in the TB drug
regimen approximately?

A. Drugs

708

No…………………………….2

B. Fees
C. Transport
D. Accommodation
E. Costs borne by guardian/friends
F. Others

Section 7.2 Other illnesses
708

Do you have any chronic
illness for which you are
receiving treatment?

Yes……………………………1

If 2

No…………………………….2

►
712

709

If YES, which disease do
you have?

A. Diabetes
B. Heart Disease
C. High Blood Pressure

[For each option, record 1
if the option is mentioned
and record 2 if the option
has not been mentioned.]

D. Cancer
E. Arthritis
F. Other
Specify
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G. Other
Specify
710

711

Are there any additional
costs for you because of
this other illness besides
the costs that you have
already mentioned?

Yes……………………………1

If 2

No…………………………….2

►

If YES, how much are
these additional costs on
average per month? In
TAKA

A. Drugs

712

B. Diagnostic tests
C. Transport

IF not known put 99999
D. Fees
E. Others
712

How much did you spend
on healthcare on average
per month BEFORE the
TB illness? In TAKA

713

How much did you spend
on healthcare on average
per month AFTER the TB
illness? In TAKA

Section 7.3 Coping Costs
714

715

Has your illness with TB
resulted in a financial
burden?

Yes……………………………1

Did you borrow any
money to cover costs due
to the TB illness?

Yes……………………………1

If 2

No…………………………….2

►

No…………………………….2

720
716

If YES, how much did you
borrow? In TAKA

IF not known put 99999

A. Family
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717

From whom did you
borrow?

B. Neighbor
C. Friend

[For each option, record 1
if the option is mentioned
and record 2 if the option
has not been mentioned.]

D. Bank
E. Cooperative
F. NGO
G. Money lender
H. Others
Specify______________________

718

Have you already paid
back the borrowed
money?

Yes……………………………1

If 2

No…………………………….2

►
721

719

How are you planning to
pay back the money?

In
Full……………………………1

If 2
►

In Installment..………………….2
721
720

If you are paying in
installment, what is the
monthly installment? In
TAKA

IF not known put 99999

721

Have you sold any of your
property to finance the
cost of the TB illness?

Yes……………………………1

If 2

No…………………………….2

►
723

722

How much money did you
get from the sale of each
of these properties?

A. Land
B. Livestock
C. Transport/Vehicle

IF not known put 99999

D. Household item
E. Farm produce
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F. Jewelry
G. Savings (FDR)
H. Other
Specify
723

Have you employed any
household help for your
illness?

Yes……………………………1

If 2

No…………………………….2

►
801

724

How much do you pay
monthly to the household
help? In TAKA

IF not known put 99999
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Section 8.0 Patient Income and Patient’s Household Income
Section 8.1 Personal Income
No.

Questions and filters

Coding categories

801

Who is the primary income
earner of the household?

Patient…………………….…….1

Response

Skip

Patient’s Wife.…………...……..2
Patient’s Husband..……………3
Patient’s Mother………………..4
Patient’s Father…………..…….5
Patient’s Son….………………..6
Patient’s Daughter..……..…….7
Other ………………..………….8
Specify________________

802

What is the highest level of
Education (In years) of
these individuals?

A. Patient

B. Primary Income Earner (If Other
than patient)
[For each option, record
the number of years spent
studying. if the person is
illiterate/did not go to
school record “0”]

C. Household Head (If Other than
patient)
B. Spouse of Household Head (If
Other than patient)

803

Are you involved in
income earning activities?

Yes, formal work…………………1

If 4

Yes, agricultural and other
household work………………….2

►
809

Yes, informal work………………3
No…………………………………4
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804

If No, why are you not
involved in any income
earning activities?

Cannot work due to illness …….1
Stopped working after contracting
TB …….……...…………...……..2
Retired…………………….…….3
Student……...…………...……..4
Other……………....……………5
Specify-----------------------------

805

Have you left your job due
to your TB illness?

Yes…………………….…….1

If 2

No……...…………...……..2

►
809

806

If YES, how many months
ago did you leave your
job?

807

What was your monthly
income when you were
working? In TAKA

IF not known put 99999

808

How regularly did you
work before you became
ill with TB?

Throughout the year…….…….1

Months

Seasonal/part of the year.……..2
Day Labor………....……………3
Other……………....……………4
Specify-----------------------------
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809

What was your main
occupation before your
illness with TB?

Service…………………….…….1
Agriculture…...…………...……..2
Household work…....……………3
Construction……………….…….4
Garments worker………...……..5
Transport…....…………..………6
Student…………………….…….7
Retired…...…………...………….8
Other………….…....……………9
Specify-----------------------------

810

811

Did you have to change
jobs when you became ill
with TB?

Yes…………………….…….1

What is your main
occupation after your
illness with TB?

Service…………………….…….1

No……...…………...……..2

Agriculture…...…………...……..2
Household work…....……………3
Construction……………….…….4
Garments worker………...……..5
Transport…....…………..………6
Student…………………….…….7
Retired…...…………...………….8
Other………….…....……………9
Specify-----------------------------

812

How many hours did you
work on average per day
BEFORE you became ill
with TB?

Hours

813

How many hours do you
work on average NOW per
day?

Hours
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If answer to 812 differs
from answer to 813:Is the
change related to the TB
illness?

Yes…………………….…….1

If 2

No……...…………...……..2

►

815

What was your estimated
personal income per month
BEFORE the TB illness?
In TAKA

IF not known put 99999

816

What is your estimated
personal income per month
NOW? In TAKA

IF not known put 99999

817

Is someone doing the work
you used to do after your
ilnness?

Spouse…………………….…….1

814

818

Son…………...…………...……..2
Daughter……..…....……………3
Friend…….……………….…….4
Nobody…………………...……..5
Other………….…....……………9
Specify-----------------------------

818

Do you have children of or
below school age?

Yes…………………….…….1

If 2

No……...…………...……..2

►
822

819

Are all of your children
attending school regularly?

Yes…………………….…….1

If 1

No……...…………...……..2

►
822

820

821

Did your children go to
school regularly before
your recent illness with
TB?

Yes…………………….…….1

If your children do not go
to schoo1, indicate the
reasons for not attending
school regularly?

A. Needs to help around the house

No……...…………...……..2

B. No money for school fess
C. Also sick
D. Has to work to earn
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822

[For each option, record 1
if the option is mentioned
and record 2 if the option
has not been mentioned.]

E. Take care of patient

Has the TB illness affected
your social or private life
in any way?

Yes…………………….…….1

If 2

No……...…………...……..2

►

E. Other
Specify___________________

823
823

If YES, how was your
social life affected?

A. Divorce
B. Loss of job
C. Dropped out of school

[For each option, record 1
if the option is mentioned
and record 2 if the option
has not been mentioned.]

D. Separated from spouse
E. Disruption of sexual life
F. Sick child
G. Other
Specify___________________

824

What is your religion?

Islam…………………….…….1
Hindu………...…………...……..2
Christian……..…....……………3
Buddhism.……………….…….4
Other………….…....……………5
Specify-----------------------------

Section 8.2 Household Income
825

How much do you
estimate was the average
income of your household
per month BEFORE the
TB illness? (for all
persons in the house,
including patient; includes

A. Patient’s income
B. Income of rest of the household
C. Govt. assistance
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welfare payments,
government assistance or
other social support)? In
TAKA

D. Other

IF not known put 99999
826

How much do you
estimate was the average
income of your household
per month NOW? (for all
persons in the house,
including patient; includes
welfare payments,
government assistance or
other social support)? In
TAKA

A. Patient’s income
B. Income of rest of the household
c. Govt. assistance
D. Other

IF not known put 99999
827

How many people
regularly sleep in your
house? (including patient)

828

How many members of the
household are employed
for wage/salary?
(including patient)

829

Besides yourself, does
anyone else of your
household receive
treatment for TB?

830

Yes…………………….…….1

If 2

No……...…………...……..2

►
823

If YES, how many
household members are
suffering from TB?
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Section 9.0 Socioeconomic Indicators
Section 9.0 Questions about the household
901

What is the main
source of lighting
for the
household?

RESPONSES

Electrical mains .................................... 01
Solar electricity .................................... 02
Generator .............................................. 03
Gas…………………………………………..….04
Kerosine/Oil lamp ................................ 05
Candles / Torch .................................... 06
Coleman (Kerosene/Pressure lanterns)…….07
Improvised lamp ................................... 08
Others ................................................... 96
Specify ____________________________

No source of lighting ............................ 98
902

What is the main
source of water
for drinking and
food preparation
for the
household?

903

What type of fuel
is mainly used in
your household
for cooking?

Piped into household ............................01
Piped to yard/plot .................................02
Piped into neighborhood.......................03
Protected well .......................................04
Unprotected well ..................................05
Protected Spring ..................................06
Unprotected Spring ..............................07
River/stream .........................................08
Pond/lake/dam ......................................10
Communal tank ....................................11
Rainwater..............................................12
Tank truck / Water cart .........................13
Bottled water .......................................14
Other____________________ .............96
(Specify)
Not reported ..........................................99
Gas ........................................................ 01
Stove with kerosene .............................. 02
Firewood ............................................... 03
Charcoal ............................................... 04
Dung ..................................................... 05
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Skip

Electricity ............................................ 06
Biogas ................................................... 07
Straw/shrubs/grass ................................ 08
Saw dust ............................................... 09
Others ................................................... 96
Specify _____________________________

904

What kind of
toilet facility do
people in your
house mainly
use?

905

Main
material of the
floor for the
principal
residence
structure

906

Main
material of the
roof of the
principal
residence

Own flush toilet ...................................... 01
Shared flush toilet ................................... 02
Ventilated improved pit latrine ............... 03
Pit latrine with slab ................................. 04
Pit latrine without slab / open pit ............ 05
Bowl/Bucket system ............................... 06
Closet oversea/river ................................ 07
No facility/bush/seashore ....................... 08
Other____________________ .............. 96
(Specify)
Not reported ..................................... …. 99
Natural Floor:
Earth ....................................................... 11
Sand ........................................................ 12
Rudimentary:
Wood planks ......................................... 21
Palm/bamboo ........................................ 22
Finished:
Polished wood ...................................... 31
Vinyl/asphalt strips ............................... 32
Marble/Ceramic tiles ............................ 33
Floor tile ............................................... 34
Cement / Concrete/ ............................... 35
Brick ..................................................... 36
Carpet ................................................... 37
Unpolished............................................ 38
Other____________________ ............ 96
(Specify)
Not reported ................................... …. 99
Natural roofing
No roof ................................................. 11
Thatch/palm leaf ................................... 12
Rudimentary roofing
Bamboo ............................................... 21
Wood planks ........................................ 22
Cardboard ............................................ 23
Finished roofing
Tin / Metal ........................................... 31
Wood ................................................... 32
Ceramic Tiles ...................................... 33
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Cement / Concrete ............................... 34
Other____________________ ............ 96
(Specify)
907

Main
material of the
exterior walls of
principal
residence

908

What type of fuel
does your
household mainly
use for cooking?

Natural Walls
No walls ................................................ 11
Cane/Palm/Trunks ................................ 12
Dirt ....................................................... 13
Rudimentary walls
Bamboo with mud / matting ................. 21
Stone with mud ..................................... 22
Mud ...................................................... 23
Fibro ..................................................... 24
Plywood ................................................. 25
Cardboard ............................................. 26
Finished walls
Tin / Metal sheets ................................. 31
Cement / Concrete ................................ 32
Brick ..................................................... 31
Stone with lime/cement ........................ 33
Bricks ................................................... 34
Wood planks/shingles ........................... 35
Other____________________ ............... 96
(Specify)
ELECTRICITY . . . . . . . . . . . . . . . . . . . . . . 01

If 95

LPG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 02

►

NATURAL GAS . . . . . . . . . . . . . . . . . . . . . . 03

911

BIOGAS . . . . . . . . . . . . . . . . . . . . . . . . . . . . 04
KEROSENE . . . . . . . . . . . . . . . . . . . . . . . . . 05
COAL, LIGNITE . . . . .. . . . . . . . . . . . . . . . . . 06
CHARCOAL . . . . . . . . . . . . . . . . . . . . . . . . . 07
WOOD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 08
STRAW/SHRUBS/GRASS . . . . . . . . . . . . . . 09
AGRICULTURAL CROP . . . . . . . . . . . . . . . . 10
ANIMAL DUNG . . . . . . . . . . . . . . . . . . . . . . 11
NO FOOD COOKED
IN HOUSEHOLD . . . . . . . . . . . . . . . . . . . . . 95
OTHER 96
(SPECIFY)
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IN THE HOUSE . . . . . . . . . . . . . . . . . . . . . . . . 1
IN A SEPARATE BUILDING . . . . . . . . . . . . 2
OUTDOORS . . . . . . . . . . . . . . . . . . . . . . . . . . 3
OTHER 6
(SPECIFY)

909

Is the cooking
usually done in
the house, in a
separate building,
or outdoors?

910

Do you have a
separate room
which is used as a
kitchen?

Yes…………………….…….1

Does your
household own
any homestead?

Yes…………………….…….1

911

912

No……...…………...……..2

No……...…………...……..2

Does your household or any member of the household own the items?

Yes

No

Electricity connection?
Solar Electricity?
A radio?
A television?
A mobile phone?
A non-mobile phone?
A refrigerator?
A DVD/VCD player?
An electric fan?
An Almirah/wardrobe?
A water pump
An IPS?Generator
An air conditioner
A computer/laptop?
In your opinion, is your
household a high income
household, a middle income
household or a poor household?

A. Electricity .....................................
1
2
B. Solar electricity…………….
1
2
C. Radio .............................................
1
2
D. Television .....................................
1
2
E. Mobile phone ................................
1
2
F. Non-mobile phone .........................
1
2
G. Refrigerator ..................................
1
2
H. DVD/VCD player .........................
1
2
I. Fan .................................................
1
2
J. Almirah ........................................
1
2
K. Water Pump .................................
1
2
L. Generator/IPS ...............................
1
2
M. AC ...............................................
1
2
N. Computer/Laptop ..........................
1
2
High income……………………………………1

914

How many people live in your
household?

Total household size

915

How many adult members (15
years or older)

Number of adults in the household

916

How many children (less than
15 years)

Number of children in the household

913

Middle income………………………………….2
Low
income……………………………………..3
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Respon
ses

917

918

How many separate sleeping
rooms are there for the use of
your household members in
your residence?
What is your current place of
residence?

Number of rooms

Urban……………………………………1
Urban slum…………………….……….2
Rural……………………………………..3
Other……………………………………..4
Specify__________________________

919

If the government could provide
you with some service to ease
the burden of TB on you and
your household, what would you
prefer to have?
DO NOT READ. INDICATE
THE ITEMS MENTIONED. IF
NOT IN THE LIST, ADD ANY
NEW GOVT. SERVICE
MENTIONED.

920

Transport vouchers..………………………1
Food vouchers…………………….……….2
More efficient service……………………..3
Other……………………………………..4
Specify____________________________

How much would you be willing
to pay for not becoming ill with
TB in the first place? In TAKA
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Section 10.0 Performance of the Facility
The next part of the survey is about the quality of TB care that you received during your visits to
this facility. Please answer the questions in this part of the survey about this facility only. Do not
include any other facilities in your answer.
No.

Questions and filters

Coding categories

Section 10.1 Availability of TB Services
1001

Are the waiting time(s)
before being served by
health providers of this
facility acceptable to you?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4

1002

How often are you attended
to by the same health
providers in this facility?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4

1003

How often are the service
hours of this facility
inconvenient for you to get
your TB treatment?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4

1004

How often are drugs not
available when you require
them?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4

1005

How often do you
experience difficulties in
obtaining TB services in
this facility because of
language barriers?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4
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Response

Skip

1006

How often do you have to
go to another health unit for
TB services or treatment?

Never…………………….…….1
Sometimes……………...……..2
Usually……...…………………3
Always….……………………..4

1007

Is this health facility easy to
reach (distance)?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4

1008

How often are TB services
available during the
working hours of this
facility?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4

1009

How often are the relevant
health providers you come
to see in this facility
available?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4

Section 10.2 Communication and Information
1010

1011

1012

1013

Do the health providers in
this facility tell you when
you stop spreading TB to
others?

Yes………………….1

Do the health providers in
this facility tell you that TB
can be cured?

Yes………………….1

Do the health providers in
this facility tell you about
the importance of observed
treatment?

Yes………………….1

Do the health providers in
this facility tell you about
the side effects of TB
drugs?

Yes………………….1

No……...…………...2

No……...…………...2

No……...…………...2

No……...…………...2
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1014

1015

1016

1017

Do the health providers in
this facility tell you about
the need for sputum tests at
given points during your
treatment schedule?

Yes………………….1

Do the health providers in
this facility tell you about
the duration of the TB
treatment?

Yes………………….1

During your visits to this
facility, do health providers
tell you about how to store
your drugs obtained for
your treatment?

Yes………………….1

Does the health provider in
this facility tell you when
next to come back for TB
services?

Yes………………….1

No……...…………...2

No……...…………...2

No……...…………...2

No……...…………...2

Section 10.3 Patient – Provider interaction and counselling
1018

During your visits to this
facility, how often does the
health provider treat you
with respect?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4

1019

During your visits to this
facility, how often does the
health provider listen
carefully to you?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4

1020

During your visits to this
facility, how often do health
providers explain things in a
way you can understand?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4
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1021

During your visits to this
facility, how often do you
have sufficient time to
discuss your problems?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4

1022

During your visits to this
facility, how often do health
providers discuss with you
how to deal with your
problems?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4

1023

During your visits to this
facility, how often do you
experience discrimination
because you have TB?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4

1024

During your visits to this
facility, how often is your
privacy respected during
examination?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4

1025

Do health providers at this
facility tell you how TB can
affect your every day life?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4

Section 10.4 Infrastructure
1026

How often is this facility
clean?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4

245

1027

Is there safe drinking water
in this facility?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4

1028

How often are the toilets in
this facility usable?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4

1029

How often do you find
enough comfortable places
to sit on in this facility?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4

Section 10.5 Professional Competence
1030

1031

1032

1033

1034

Does this facility offer
services to examine your
sputum?

Yes………………….1

Does this facility offer
home based TB treatment?

Yes………………….1

Were you physically
examined during your first
visit to this health facility?

Yes………………….1

Was your sputum examined
when you were diagnosed
with TB?

Yes………………….1

How many working days
were there between your
first sputum submission and
the time you got your
results?

0-2 Working days……….…….1

No……...…………...2

No……...…………...2

No……...…………...2

No……...…………...2

3-4 Working days ……...……..2
More than 5 Working days...…3
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1035

1036

In case of germs in your
sputum that cause TB, were
your close contacts
examined by the TB
facility?

Yes………………….1

How often is there a
treatment observer checking
on your daily intake of TB
drugs?

Never……………………1

No……...…………...2

Sometimes……………...2
Usually……...………….3
Always….……………….4

Section 10.6 Affordability
1037

How often do you have to
pay for your regular TB
services (e.g. sputum tests,
TB-drugs, X-rays, etc.)?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4

1038

How often do you have to
pay a tip in order to receive
TB services?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4

1039

How often do costs (e.g.
transport) prevent you from
getting to the health
facility?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4

Section 10.7 Support
1040

How often do you receive
transport support from the
health facility?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4
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1041

How often do you receive
food support from the health
facility?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4

1042

How often do you receive
financial assistance from the
health facility?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4

Section 10.8 Stigma
1043

Does the health provider
talk to you the same way
you are spoken to when you
receive services other than
TB?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4

1044

Does the health provider
welcome you into the health
facility when you visit for
TB services?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4

1045

Does the health provider
turn his/her face away when
speaking with you?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4

1046

Do you feel that you are
treated with dignity when
you visit the health facility?

Never……………………1
Sometimes……………...2
Usually……...………….3
Always….……………….4
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Section 11.0 Quality of Life
Section 11.1 Health Related Quality of Life (FACIT-TB Questionnaire)
How would you describe your level of
feeling for the following statements:
(record the number in the right column)

Not
At All

Slight
ly

Moderat
ely

Quite
A Bit

Extrem
ely

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

A. Physical well-being
110
1

I feel ill

110
2

I get tired easily

110
3

I have a lack of energy

110
4

I have pain

110
5

I feel weak all over

110
6

I feel fatigued

110
7

I have been short of breath

110
8

I have nausea-“a sense of vomiting
outbreak”

110
9

Because of my physical condition, I
have trouble meeting the needs of
my family
I am bothered by fever (episode of
high body temperature)

111
0
111
1

I am forced to spend time in bed

111
2

I have discomfort or pain in my
stomach area

111
3

I have had itching
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Respo
nse

111
4

I have a loss of appetite

111
5

I have been coughing

111
6

I am bothered by side effects of
treatment

111
7

Dusts Worsen my symptoms

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

B. Social and economic well-being
111
8

I feel close to my friends

111
9

I get emotional support from my
family

1

2

3

4

5

112
0

I am satisfied with my family
communication about my illness

1

2

3

4

5

112
1

My family has accepted my illness

1

2

3

4

5

112
2

I feel close to my partner (or the
person who is my main support)

1

2

3

4

5

112
3

I get support from my friends

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

My physical condition and/or
medical treatment cause me
financial difficulties
C. Emotional well-being/Stigma of
having TB
112 I worry that my condition will get
worse
5
112
4

112
6

I worry about dying

112
7

I am concerned about what the
future holds for me

112
8

I am embarrassed by my illness
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112
9

It is hard to tell other people about
my infection

1

2

3

4

5

113
0

I am losing hope in the fight against
my illness

1

2

3

4

5

113
1

I am bothered by the change in
weight

1

2

3

4

5

113
2

I worry about spreading my
infection

1

2

3

4

5

113
3

I feel nervous

1

2

3

4

5

113
4

I feel sad

1

2

3

4

5

113
5

I am satisfied with how I am coping
with my illness

1

2

3

4

5

D. Functional well-being
113
6

I am content with the quality of my
life right now

1

2

3

4

5

113
7

My work (include work at home) is
fulfilling

1

2

3

4

5

113
8

I am able to work (include work at
home)

1

2

3

4

5

113
9

I am able to enjoy life

1

2

3

4

5

114
0

I am enjoying the things I usually
do for fun

1

2

3

4

5

114
1

I have accepted my illness

1

2

3

4

5

114
2

I am sleeping well

1

2

3

4

5

E. Spiritual well-being
114
3

I find strength in my faith or
spiritual belief

1

2

3

4

5

114
4

My illness has strengthened my
faith or spiritual belief

1

2

3

4

5
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114
5

My life is still productive

1

2

3

4

5

Section 11.2 EQ-5D-5L Questionnaire

Under each heading, please tick the ONE box that best describes your health TODAY.
Sl

Category

Options

Response

114
6

Mobility

I have no problems in walking
about.................................1
I have slight problems in walking
about.............................2
I have moderate problems in walking
about......................3
I have severe problems in walking
about...........................4
I am unable to walk
about..................................................5

114
7

Self-Care

I have no problems washing or dressing
myself...............1
I have slight problems washing or dressing
myself...........2
I have moderate problems washing or dressing
myself....3
I have severe problems washing or dressing
myself........4
I am unable to wash or dress
myself.................................5

114
8

Usual
Activities

I have no problems doing my usual
activities....................1

(e.g., work,
study,
housework,
family or
leisure
activities)

I have slight problems doing my usual
activities................2
I have moderate problems doing my usual
activities.........3
I have severe problems doing my usual
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activities.............4
I am unable to do my usual
activities.................................5
114
9

Pain/Discomfo
rt

I have no pain or
discomfort...............................................1
I have slight pain or
discomfort...........................................2
I have moderate pain or
discomfort....................................3
I have severe pain or
discomfort........................................4
I have extreme pain or
discomfort......................................5

115
0

Anxiety/Depre
ssion

I am not
anxious/depressed...............................................1
I am slightly
anxious/depressed.........................................2
I am moderately
anxious/depressed..................................3
I am severely
anxious/depressed......................................4
I am extremely
anxious/depressed....................................5

Section 11.3 SF-6D Questionnaire

Under each heading, please tick the ONE box that best describes your health TODAY.
Sl

Category

Options

Response

115
1

Physical
Functioning

My health does not limit me in vigorous
activities..................................1
My health limits me a little in vigorous
activities.....................................2
My health limits me a little in moderate
activities...................................3
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My health limits me a lot in moderate
activities......................................4
My health limits me a little in bathing and
dressing...............................5
My health limits me a lot in bathing and
dressing..................................6
115
2

Role
Limitation

I have no problems with your work or other
regular daily activities as a result of your
physical health or any emotional
problems......................1
I am limited in the kind of work or other
activities as a result of your physical
health........................................................................2
I accomplish less than you would like as a result
of emotional
problems...................................................................3
You are limited in the kind of work or other
activities as a result of your physical health and
accomplish less than you would like as a result
of emotional
problems..................................................................4

115
3

Social
Functioning

My health limits my social activities none of the
time..................................1
My health limits my social activities a little of the
time.................................2
My health limits my social activities some of the
time..................................3
My health limits my social activities most of the
time...................................4
My health limits my social activities all of the
time.......................................5

115
4

Pain

I have no
pain...............................................................................
.................1
I have pain, but it does not interfere with my normal
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work (both outside the home and
housework)..................................................................
..2
I have pain that interferes with your normal work
(both outside the home and housework) a little
bit............................................................................3
I have pain that interferes with your normal work
(both outside the home and housework)
moderately...................................................................
..4
I have pain that interferes with your normal work
(both outside the home and housework) quite a
bit...........................................................................5
I have pain that interferes with your normal work
(both outside the home and housework)
extremely.....................................................................
.6
115
5

Mental Health

I feel tense or downhearted and low none of the
time.................................1
I feel tense or downhearted and low a little of the
time................................2
I feel tense or downhearted and low some of the
time................................3
I feel tense or downhearted and low most of the
time.................................4
I feel tense or downhearted and all of the
time............................................5

115
6

Vitality

I have a lot of energy all of the time........................1
I have a lot of energy most of the time....................2
I have a lot of energy some of the time....................3
I have a lot of energy a little of the time……...........4
I have a lot of energy none of the time………........5
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Section 11.4 Visual Analog Scale
1157 Visual Analog Scale Score
1158

Comments by interviewer on the interview

1159

INTERVIEWERS: CHECK YOUR FILLED IN QUESTIONNAIRE CAREFULLY
BEFORE LEAVING THE RESPONDENTS AND END YOUR INTERVIEW BY
GIVING THANKS TO THE RESPONDENT.
RECORD THE END TIME OF THE
INTERVIEW:
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Hour
Minutes

APPENDIX D – PROVIDER QUESTIONNAIRE (DS-TB)

IDENTIFICATION
DIVISION_____________________________________________________
DISTRICT________________________________________________________________
UPAZILA _________________________________________________
NAME OF THE FACILITY_________________________________________
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TYPE OF THE FACILITY___________________________________________
(Union Health Center =01, Upazila Health Complex =02, District Hospital =03)
TYPE OF THE PROVIDER___________________________________________
(BRAC =01, Damien Foundation =02, Other =03, Please specify)
NAME OF THE MANAGER____________________________________
LOCATION OF FACILITY: RURAL=1, URBAN=2

INTERVIEWER VISITS
1

2

3

DATE
INTERVIEWER’S NAME &
CODE
RESULT CODE*
NEXT VISIT:
DATE
TIME
*RESULT CODES:
01 COMPLETED
02 NOT AVAILABLE
03 POSTPONED
04 REFUSED
SUPERVISOR

FINAL VISIT
CODE
RESULT CODE
TOTAL NO. OF VISITS

05 PARTLY COMPLETED
96 OTHER_________________
(SPECIFY)
FIELD EDITOR

OFFICE EDITOR

KEYED BY
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NAME____________________

NAME___________________

NAME____________

NAME_________

DATE _________________

DATE _________________

DATE ______________

DATE __________

Section 1: Number of Personnel, their salary, and contribution to the TB Control Program
Collect data based on each staff working on the day of data collection during day-shift (9:00am- 5:00pm). This table is for collecting information on TB clinics
open on day of the interview.
USE DECIMAL POINTS TO INDICATE PART-TIME WORK. FOR EXAMPLE, IF AN INDIVIDUAL WORKS IN TWO CLINICS, RECORD 0.5 FOR
THIS PERSON IN BOTH
A
B
C
D
E
F
G
H
Number
Incentive
%
Employed
Monthly
Monthly
Payment
involvement
SL#
TA/DA
Overtime
Total
Salary
Benefits
with TB
DESIGNATION
program
101

Civil Surgeon

102

Junior
Consultant
(Chest Clinic)

103

104

105

106

107
108
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109
110
111
112
113
114

115

Upazila Health
and Family
Planning Officer
(UHFPO)
Medical Officer
(TB/Leprosy)
Designated
Medical Officer
Chest Disease
Clinic
Medical Officer
Disease Control
(MODC)
Medical Officer,
NGOs
Program
Organizer
Medical
Technologist
(Laboratory)
Health Inspector
Assistant Health
Inspector
Family Planning
Inspector
Health Assistant
(HA)
Medical
Assistant (MA)
NGO
Community
Health Workers

116

117
118

119

120

121

122
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123

124

125

126

127

128
129

Leprosy and TB
Control
Assistant
Statistical
Assistant
Gene Xpert
Technician
Community
Health Worker
(CHW)

130

Section 2.0 Caseload (Number of New Patients Diagnosed, Number of Patients treated)
Please collect these information from Quarterly TB case finding reporting form (TB-10)
SL.

Indicator
Quarter1
(Oct 2015-Dec 2015)

201

202
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203

204

205
206

207

208

209
210

TB Case Detection
Rate
Total new pulmonary
smear-positive cases
notified
Total new (relapses)
smear positive cases
notified
Total new (failures)
smear positive cases
notified
Total new (loss to follow
up/after default) smear
positive cases notified
Xpert MTB/RIF positive
RIF sensitive new cases
Xpert MTB/RIF positive
RIF sensitive previously
treated cases
Total new pulmonary
smear-negative cases
notified
Total new
extrapulmonary cases
notified
Total others previously
treated* cases notified
Total cases registered

Male
A

Female
B

Total
C

Number
Quarter 2
Quarter 3
(Jan 2016-March 2016)
(April 2016-June 2016)
Male
D

Female
E

Total
F

Male
G

Female
H

Total
I

Quarter 4
(July 2016-September
2016)
Male
Female Total
J
K
L

211

212

213

214

262
214

215

Laboratory Activity
(Sputum Smear
Microscopy)
Number of presumptive
TB cases/suspects
examined for diagnosis
by sputum smear
microscopy
Number of presumptive
TB cases/suspects with
positive sputum smear
microscopy
Laboratory Activity
(GeneXpert Test)
Number of presumptive
TB cases/suspects
examined for diagnosis
by Xpert MTB/RIF
Number of presumptive
TB cases/suspects with
positive Xpert MTB/RIF
result
HIV Activities
Number of People living
with HIV/AIDS
(PLHWA) tested for
Acid Fast Bacilli (AFB)
Number of AFB positive
result among tested
PLWHA

Section 3.0 TB Patient Referral
Please enumerate the number of TB patients referred by different providers using TB Form-10
Sl.

TB Patient Referral

Number
Quarter 1
A

263

301
302
303
304
305
306
307
308
309
310
311
312

Private Practitioner (Graduate)
Private Practitioner (Non-Graduate)
Govt. field staff
Shasthya Sebika (SS)/ Non-govt. field staff (NGFS)
Village Doctor (VD)
Community Volunteer (CV)
Govt. Hospital
Private Hospital
Community Health Care Provider (CHCP)
TB Patient
Others (Please specify)
Total

Quarter 2
B

Quarter 3
C

Quarter 4
D

Section 4.0 Treatment outcomes (TB Patients Registered 3-6 Months Earlier)
Quarter |__|__| Year |__|__|
PLEASE COMPLETE THIS TABLE FOR PULMONARY TB PATIENTS REGISTERED 3-6 MONTHS EARLIER (USING TB-12
FORM)
Sl.

401
402
403

Type of Patients
M= Male
F=Female
New Cases
Smear Positive
Xpert MTB/RIF
Positive
Smear Negative

Smear
Negative
M
F
A

B

Smear
Positive
M
F
C

D

Died

Failure

M

F

M

F

E

F

G

H

Lost to
Follow-up
M
F
I

Transferred
Out
M
F

J

K

L

Not
Evaluated
M
F
M

N

Grand Total
M

F

Total

O

P

Q

264

PLEASE COMPLETE THIS TABLE FOR PULMONARY TB PATIENTS REGISTERED 3-6 MONTHS EARLIER (USING TB-12
FORM)
Sl.

404
405
406

407
408

Type of Patients
M= Male
F=Female
Retreatment
Relapses
Treatment after
failure
Treatment after
loss to follow
up/Default
Others
Total

Smear
Negative
M
F

Smear
Positive
M
F

M

F

M

F

A

C

E

F

G

H

B

D

Died

Failure

Lost to
Follow-up
M
F
I

J

Transferred
Out
M
F
K

L

Not
Evaluated
M
F

M

F

Total

M

O

P

Q

N

Grand Total

Quarter |__|__| Year |__|__|
PLEASE COMPLETE THIS TABLE FOR PULMONARY TB PATIENTS REGISTERED 3-6 MONTHS EARLIER (USING TB-12
FORM)
Sl.

409
410
411

Type of Patients
M= Male
F=Female
New Cases
Smear Positive
Xpert MTB/RIF
Positive
Smear Negative

Smear
Negative
M
F
A

B

Smear
Positive
M
F
C

D

Died

Failure

M

F

M

F

E

F

G

H

Lost to
Follow-up
M
F
I

Transferred
Out
M
F

J

K

L

Not
Evaluated
M
F
M

N

Grand Total
M

F

Total

O

P

Q

PLEASE COMPLETE THIS TABLE FOR PULMONARY TB PATIENTS REGISTERED 3-6 MONTHS EARLIER (USING TB-12
FORM)
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Sl.

412
413
414

415
416

Type of Patients
M= Male
F=Female
Retreatment
Relapses
Treatment after
failure
Treatment after
loss to follow
up/Default
Others
Total

Smear
Negative
M
F

Smear
Positive
M
F

M

F

M

F

A

C

E

F

G

H

B

D

Died

Failure

Lost to
Follow-up
M
F
I

J

Transferred
Out
M
F
K

L

Not
Evaluated
M
F

M

F

Total

M

O

P

Q

N

Grand Total

Quarter |__|__| Year |__|__|
PLEASE COMPLETE THIS TABLE FOR PULMONARY TB PATIENTS REGISTERED 3-6 MONTHS EARLIER (USING TB-12
FORM)
Sl.

417
418
419

Type of Patients
M= Male
F=Female
New Cases
Smear Positive
Xpert MTB/RIF
Positive
Smear Negative

Smear
Negative
M
F
A

B

Smear
Positive
M
F
C

D

Died

Failure

M

F

M

F

E

F

G

H

Lost to
Follow-up
M
F
I

Transferred
Out
M
F

J

K

L

Not
Evaluated
M
F
M

N

Grand Total
M

F

Total

O

P

Q

PLEASE COMPLETE THIS TABLE FOR PULMONARY TB PATIENTS REGISTERED 3-6 MONTHS EARLIER (USING TB-12
FORM)
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Sl.

420
421
422

423
424

Type of Patients
M= Male
F=Female
Retreatment
Relapses
Treatment after
failure
Treatment after
loss to follow
up/Default
Others
Total

Smear
Negative
M
F

Smear
Positive
M
F

M

F

M

F

A

C

E

F

G

H

B

D

Died

Failure

Lost to
Follow-up
M
F
I

J

Transferred
Out
M
F
K

L

Not
Evaluated
M
F

M

F

Total

M

O

P

Q

N

Grand Total

Quarter |__|__| Year |__|__|
PLEASE COMPLETE THIS TABLE FOR PULMONARY TB PATIENTS REGISTERED 3-6 MONTHS EARLIER (USING TB-12
FORM)
Sl.

425
426
427

Type of Patients
M= Male
F=Female
New Cases
Smear Positive
Xpert MTB/RIF
Positive
Smear Negative

Smear
Negative
M
F
A

B

Smear
Positive
M
F
C

D

Died

Failure

M

F

M

F

E

F

G

H

Lost to
Follow-up
M
F
I

Transferred
Out
M
F

J

K

L

Not
Evaluated
M
F
M

N

Grand Total
M

F

Total

O

P

Q

PLEASE COMPLETE THIS TABLE FOR PULMONARY TB PATIENTS REGISTERED 3-6 MONTHS EARLIER (USING TB-12
FORM)
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Sl.

428
429
430

431
432

Type of Patients
M= Male
F=Female
Retreatment
Relapses
Treatment after
failure
Treatment after
loss to follow
up/Default
Others
Total

Smear
Negative
M
F

Smear
Positive
M
F

M

F

M

F

A

C

E

F

G

H

B

D

Died

Failure

Lost to
Follow-up
M
F
I

J

Transferred
Out
M
F
K

L

Not
Evaluated
M
F

M

F

Total

M

O

P

Q

N

Grand Total

Section 5.0 Treatment outcomes (TB Patients Registered 12-15 Months Earlier)
Quarter |__|__| Year |__|__|
PLEASE COMPLETE THIS TABLE FOR PULMONRY TB PATIENTS REGISTERED 12-15 MONTHS EARLIER (USING TB-11
FORM)
Sl.

501
502

268

503
504
506

Type of Patients

M= Male
F=Female
New Cases
Smear Positive
Xpert MTB/RIF
Positive
Smear Negative
EP
Total

Cured

Treatment
Completed

Died

Failure

M

F

M

F

M

F

M

F

A

B

C

D

E

F

G

H

Lost to
Followup/Defaulted
M
F
I

J

Transferred
Out

Not
Evaluated

Grand Total

M

F

M

F

M

F

Total

K

L

M

N

O

P

Q

PLEASE COMPLETE THIS TABLE FOR PULMONARY TB PATIENTS REGISTERED 12-15 MONTHS EARLIER (USING TB-11
FORM)
Sl.

507
508
509

510
511

Type of Patients
M= Male
F=Female
Retreatment
Relapses
Failures
Treatment after
loss to follow
up/default
Others
Total

Smear
Negative
M
F

Smear
Positive
M
F

M

F

M

F

A

C

E

F

G

H

B

D

Died

Failure

Lost to
Follow-up
M
F
I

J

Transferred
Out
M
F
K

L

Not
Evaluated
M
F

M

F

Total

M

O

P

Q

N

Grand Total

Quarter |__|__| Year |__|__|
PLEASE COMPLETE THIS TABLE FOR PULMONRY TB PATIENTS REGISTERED 12-15 MONTHS EARLIER (USING TB-11
FORM)
Sl.

501
502
503
504
506

Type of Patients

M= Male
F=Female
New Cases
Smear Positive
Xpert MTB/RIF
Positive
Smear Negative
EP
Total

Cured

Treatment
Completed

Died

Failure

M

F

M

F

M

F

M

F

A

B

C

D

E

F

G

H

Lost to
Followup/Defaulted
M
F
I

J

Transferred
Out

Not
Evaluated

Grand Total

M

F

M

F

M

F

Total

K

L

M

N

O

P

Q
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PLEASE COMPLETE THIS TABLE FOR PULMONARY TB PATIENTS REGISTERED 12-15 MONTHS EARLIER (USING TB-11
FORM)
Sl.

507
508
509

510
511

Type of Patients
M= Male
F=Female
Retreatment
Relapses
Failures
Treatment after
loss to follow
up/default
Others
Total

Smear
Negative
M
F

Smear
Positive
M
F

M

F

M

F

A

C

E

F

G

H

B

D

Died

Failure

Lost to
Follow-up
M
F
I

J

Transferred
Out
M
F
K

L

Not
Evaluated
M
F

M

F

Total

M

O

P

Q

N

Grand Total

Quarter |__|__| Year |__|__|
PLEASE COMPLETE THIS TABLE FOR PULMONRY TB PATIENTS REGISTERED 12-15 MONTHS EARLIER (USING TB-11
FORM)
Sl.

501
502
503
504
506

Type of Patients

M= Male
F=Female
New Cases
Smear Positive
Xpert MTB/RIF
Positive
Smear Negative
EP
Total

Cured

Treatment
Completed

Died

Failure

M

F

M

F

M

F

M

F

A

B

C

D

E

F

G

H

Lost to
Followup/Defaulted
M
F
I

J

Transferred
Out

Not
Evaluated

Grand Total

M

F

M

F

M

F

Total

K

L

M

N

O

P

Q

270

PLEASE COMPLETE THIS TABLE FOR PULMONARY TB PATIENTS REGISTERED 12-15 MONTHS EARLIER (USING TB-11
FORM)
Sl.

507
508
509

510
511

Type of Patients
M= Male
F=Female
Retreatment
Relapses
Failures
Treatment after
loss to follow
up/default
Others
Total

Smear
Negative
M
F

Smear
Positive
M
F

M

F

M

F

A

C

E

F

G

H

B

D

Died

Failure

Lost to
Follow-up
M
F
I

J

Transferred
Out
M
F
K

L

Not
Evaluated
M
F

M

F

Total

M

O

P

Q

N

Grand Total

Quarter |__|__| Year |__|__|
PLEASE COMPLETE THIS TABLE FOR PULMONRY TB PATIENTS REGISTERED 12-15 MONTHS EARLIER (USING TB-11
FORM)
Sl.

501
502
503
504
506

Type of Patients

M= Male
F=Female
New Cases
Smear Positive
Xpert MTB/RIF
Positive
Smear Negative
EP
Total

Cured

Treatment
Completed

Died

Failure

M

F

M

F

M

F

M

F

A

B

C

D

E

F

G

H

Lost to
Followup/Defaulted
M
F
I

J

Transferred
Out

Not
Evaluated

Grand Total

M

F

M

F

M

F

Total

K

L

M

N

O

P

Q
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PLEASE COMPLETE THIS TABLE FOR PULMONARY TB PATIENTS REGISTERED 12-15 MONTHS EARLIER (USING TB-11
FORM)
Sl.

507
508
509

510
511

Type of Patients
M= Male
F=Female
Retreatment
Relapses
Failures
Treatment after
loss to follow
up/default
Others
Total

Smear
Negative
M
F

Smear
Positive
M
F

M

F

M

F

A

C

E

F

G

H

B

D

Died

Failure

Lost to
Follow-up
M
F
I

J

Transferred
Out
M
F
K

L

Not
Evaluated
M
F

M

F

Total

M

O

P

Q

N

Grand Total

Section 6.0 Quantity and Cost of Drugs
Number of TB Drugs received by the facility last year (January 2016- December 2016-PLEASE CONSULT LAST TWO REQUISITION
FORM TB-08)
Quarter |__|__| Year |__|__|

SL#

Drug name

Quantity
measures

A

Quantity received
from National TB
Control Program
(NTP) (units)
CAT I Patients

Quantity received
from National TB
Control Program
(NTP) (units)
CAT II Patients

B

C

Total received in
this quarter

Market price of drugs per
unit

D

E

4FDC

.
.

609

3FDC
(R150/H75/E275)
2 FDC
(R150/H75)
3 FDC (R60/H30/Z150)
(Dispersible)
2FDC (R60/H60)
(Dispersible)
2FDC (R60/H30)
(Dispersible)
Z 400 mg (Dispersible)
H 100 mg
(Dispersible)/For IPT
R 150 mg

610

H 300 mg

611

R 450 mg

612

Z 500 mg

613

E 400 mg

601
602

272

603
604
605
606
607
608

.
.
.
.
.
.
.
.
.
.
.

614

E 100 mg

615

S 1g

616

Inj. Water, 5 ml

617

D/ Syringe 5 cc

618

DST Liquid culture

619

DST Solid Culture

.
.
.
.
.
.
.
.
.
.
.
.

620
621
622
623
624

273

625

Quarter |__|__| Year |__|__|

SL#

601
602
603
604

Drug name

4FDC
3FDC (R150/H75/E275)
2 FDC
(R150/H75)
3 FDC (R60/H30/Z150)
(Dispersible)

Quantity received
from National TB
Control Program
(NTP) (units) for
CAT I Patients

Quantity received from
National TB Control
Program (NTP) (units)
for
CAT II Patients

E

F

Total received in
this quarter

G

609

2FDC (R60/H60)
(Dispersible)
2FDC (R60/H30)
(Dispersible)
Z 400 mg (Dispersible)
H 100 mg
(Dispersible)/For IPT
R 150 mg

610

H 300 mg

611

R 450 mg

612

Z 500 mg

613

E 400 mg

614

E 100 mg

615

S 1g

616

Inj. Water, 5 ml

617

D/ Syringe 5 cc

618

DST Liquid culture

619

DST Solid Culture

605
606
607
608

274

620
621
622
623
624
625

Quarter |__|__| Year |__|__|

SL#

601

Drug name

4FDC

609

3FDC (R150/H75/E275)
2 FDC
(R150/H75)
3 FDC (R60/H30/Z150)
(Dispersible)
2FDC (R60/H60)
(Dispersible)
2FDC (R60/H30)
(Dispersible)
Z 400 mg (Dispersible)
H 100 mg
(Dispersible)/For IPT
R 150 mg

610

H 300 mg

611

R 450 mg

612

Z 500 mg

613

E 400 mg

614

E 100 mg

615

S 1g

616

Inj. Water, 5 ml

602
603
604

275

605
606
607
608

Quantity received
from National TB
Control Program
(NTP) (units) for
CAT I Patients

Quantity received from
National TB Control
Program (NTP) (units)
for
CAT II Patients

H

I

Total received in
this quarter

J

617

D/ Syringe 5 cc

618

DST Liquid culture

619

DST Solid Culture

620
621
622
623
624
625

Quarter |__|__| Year |__|__|

276
SL#

601
602
603
604
605
606

Drug name

4FDC
3FDC (R150/H75/E275)
2 FDC
(R150/H75)
3 FDC (R60/H30/Z150)
(Dispersible)
2FDC (R60/H60)
(Dispersible)
2FDC (R60/H30)
(Dispersible)

Quantity received
from National TB
Control Program
(NTP) (units) for
CAT I Patients

Quantity received from
National TB Control
Program (NTP) (units)
for
CAT II Patients

K

L

Total received in
this quarter

M

609

Z 400 mg (Dispersible)
H 100 mg
(Dispersible)/For IPT
R 150 mg

610

H 300 mg

611

R 450 mg

612

Z 500 mg

613

E 400 mg

614

E 100 mg

615

S 1g

616

Inj. Water, 5 ml

617

D/ Syringe 5 cc

618

DST Liquid culture

619

DST Solid Culture

607
608

277

620
621
622
623
624
625

Section 7.0 Quantity and Cost of Laboratory Reagents/Supplies/Equipment
Number of Laboratory reagents/ supplies received by the facility last year (October 2015-September 2016- Laboratory Request Form)
Quarter 4 (July 2016- September 2016)
SL#

Reagent/Lab supplies’
name

Quantity
measures
per
patient
A

278

701

Carbol fuchsin (1%)
Solution

702

Methylene Blue (0.1%)

703

Sulphuric Acid (25%)

704

Burning Spirit

705

Slides

3.0 ml
/sm+
3.0
ml/sm+
6.0
ml/sm+
1.5
ml/sm+
1 pc/sm+

706

Sputum Containers

1 pc/sm+

707

Immersion Oil

711

Filter Paper Pieces

712

Request Form (TB 05)

713

Lab Register (TB 04)

714

Diamond Pencil

715

Slide Box

716
717
718
719

0.05
ml/sm+
100 pc/
clinic
1
pc/person

Quantity received
from National TB
Control Program
(NTP) (units)
B

Quantity purchased
from market (units)

Total received in
this quarter

Market price of reagents
per unit

C

D

E

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.

720
721
722

Quarter 3 (April 2016- June 2016)

SL#

Reagent/Lab supplies’
name

703

Carbol fuchsin (1%)
Solution
Methylene Blue
(0.1%)
Sulphuric Acid (25%)

704

Burning Spirit

705

Slides

706

Sputum Containers

707

Immersion Oil

708

Filter Paper Pieces

709

Request Form (TB 05)

710

Lab Register (TB 04)

711

Diamond Pencil

712

Slide Box

713

Filter Paper Pieces

701
702

279

714
715

Quantity received
from National TB
Control Program
(NTP) (units)
F

Quantity purchased
from market (units)

Total received in
this quarter

G

H

716
717
718
719
720
721
722

Quarter 2 (January 2016- March 2016)

SL#

280

Reagent/Lab supplies’
name

703

Carbol fuchsin (1%)
Solution
Methylene Blue
(0.1%)
Sulphuric Acid (25%)

704

Burning Spirit

705

Slides

706

Sputum Containers

707

Immersion Oil

708

Filter Paper Pieces

709

Request Form (TB 05)

710

Lab Register (TB 04)

701
702

Quantity received
from National TB
Control Program
(NTP) (units)
I

Quantity purchased
from market (units)

Total received in
this quarter

J

K

711

Diamond Pencil

712

Slide Box

713

Filter Paper Pieces

714
715
716
717
718
719
720
721

281

722

Quarter 1 (October 2016- December 2016)

SL#

Reagent/Lab supplies’
name

702

Carbol fuchsin (1%)
Solution
Methylene Blue (0.1%)

703

Sulphuric Acid (25%)

704

Burning Spirit

705

Slides

701

Quantity received
from National TB
Control Program
(NTP) (units)
L

Quantity purchased
from market (units)
M

Total
received in
this
quarter
N

706

Sputum Containers

707

Immersion Oil

708

Filter Paper Pieces

709

Request Form (TB 05)

710

Lab Register (TB 04)

711

Diamond Pencil

712

Slide Box

713

Filter Paper Pieces

714
715
716

282

717
718
719
720
721
722

Section 8.0 Cost of Other Supplies
Number of Supplies received by the facility last year (October 2015-September 2016)
Quarter 4 (July 2016- September 2016)
SL#

Supplies’ name

Quantity
measures
A

283

801

TB Register

802

Treatment Card

803

Pen

804

Paper

805

Box

806

Soap

807

Towel

808

Boxes

809

Tape

810

Raincoat

811

Torch light

812

Umbrella

813

Drug Baskets

814

Kit Bag

815

Poster

816

Sticker

817

Leaflet

818

Flip chart

Quantity received
from National TB
Control Program
(NTP) (units)
B

Quantity purchased
from market (units)

Total received in
this quarter

Market price of supplies
per unit

C

D

E

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

819

Flash Chart

820

Brochure

.
.
.
.
.
.
.
.
.
.
.
.

821
822
823
824
825
826
827
828
829

284

830

Quarter 3 (April 2016- June 2016)
SL#

Supplies’ name

801

TB Register

802

Treatment Card

803

Pen

804

Paper

805

Box

806

Soap

807

Towel

Quantity received
from National TB
Control Program
(NTP) (units)
F

Quantity purchased
from market (units)

Total received in
this quarter

G

H

285

808

Boxes

809

Tape

810

Raincoat

811

Torch light

812

Umbrella

813

Drug Baskets

814

Kit Bag

815

Poster

816

Sticker

817

Leaflet

818

Flip chart

819

Flash Chart

820

Brochure

821
822
823
824
825
826
827
828
829
830

Quarter 2 (January 2016- March 2016)
SL#

Supplies’ name

286

801

TB Register

802

Treatment Card

803

Pen

804

Paper

805

Box

806

Soap

807

Towel

808

Boxes

809

Tape

810

Raincoat

811

Torch light

812

Umbrella

813

Drug Baskets

814

Kit Bag

815

Poster

816

Sticker

817

Leaflet

818

Flip chart

819

Flash Chart

820

Brochure

Quantity received
from National TB
Control Program
(NTP) (units)
I

Quantity purchased
from market (units)

Total received in
this quarter

J

K

821
822
823
824
825
826
827
828
829
830

287

Quarter 4 (October 2015- December 2015)
SL#

Supplies’ name

801

TB Register

802

Treatment Card

803

Pen

804

Paper

805

Box

806

Soap

807

Towel

808

Boxes

809

Tape

Quantity received
from National TB
Control Program
(NTP) (units)
L

Quantity purchased
from market (units)

Total received in
this quarter

M

N

810

Raincoat

811

Torch light

812

Umbrella

813

Drug Baskets

814

Kit Bag

815

Poster

816

Sticker

817

Leaflet

818

Flip chart

819

Flash Chart

820

Brochure

288

821
822
823
824
825
826
827
828
829
830

Section 9.0 Other Capital Items
Number of Items used by the facility
SL#

Capital Items

Quantity
(Unit)
A
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901

Microscope

902

GeneXpert

903

Weight Scale

904

Signboard

905

Computer

906

Printer

907

Smart Phone

908

App development

909

Motor Cycle

910

Bicycle

911

Car

912

Ambulance

913
914
915
916
917
918
919

Quantity
received from
National TB
Control Program
(NTP) (units)
B

Quantity
purchased from
market (units)

Total is being
used

C

D

Life time
(In Years)

Market price of item per unit

E

F

Section 10. Other Costs
Section 10.1 Cost of Supervision (facility supervisory visits conducted in last year (October 2015-September 2016)

SL #

Title of person
conducting
supervisory visit
A

Number of
visits in
last year
(Oct 2015Sep 2016)
B

Duration of visit
(total for all visits
in days)

Per Diem (total)

Travel expenses (total)

Other expenses

What % of
costs paid by
facility?

C

D

E

F

H

1001
1002
1003
1004
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Section 10.2 Travel cost for Drug /Attending Meeting/Training

SL #

Title of person
conducting
travel
A

Number
of travel
in last
year (Oct
2015-Sep
2016)
B

Purpose of the
travel
(Use Code
from below)^

C

Duration of
visit (total for
all visits in
days)

Per Diem (total)

Travel expenses
(total)

Other
expenses

What % of
costs paid by
facility?

D

E

F

H

I

1005
1006
1007
1008
^Code: 1. Receiving drug 2. Attending Meetings 3. Training 4. Others (Please specify)

Section 10.3 Cost of Other Activities
No
1009

1010

1011

1012

1013
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1014

1015

1016

1017

1018

1019

Questions and Filters
Was Health education on TB
organized by the DOTS center?
If Health education on TB was
organized, How much money was paid
for this activity in last year (October
2015-September 2016)?
Was DOTS committee meeting
organized by the DOTS center?
If DOTS committee meeting was
organized, How much money was paid
for this activity in last year (October
2015-September 2016)?
Were Contact Tracing activities
organized by the DOTS center?
If Contact Tracing activities were
organized, How much money was paid
for this activity in last year (October
2015-September 2016)?
Were Refresher training activities
organized by the DOTS center?
If Refresher training activities were
organized, How much money was paid
for this activity in last year (October
2015-September 2016)?
Were Other meetings organized by the
DOTS center?
If Other meetings were organized,
How much money was paid for this
activity in last year (October 2015September 2016)?
Were Incentive payments were
provided to the providers by the
DOTS center?

Coding categories
Yes………………………………….1
No………………..…………………2
IF THIS ACTIVITY WAS NOT
ORGANIZED AND/OR NO MONEY
WAS PAID, RECORD “00000”

Record Response

Taka

Yes………………………………….1
No………………..…………………2
IF THIS ACTIVITY WAS NOT
ORGANIZED AND/OR NO MONEY
WAS PAID, RECORD “00000”

If 2
1013

Taka

Yes………………………………….1
No………………..…………………2
IF THIS ACTIVITY WAS NOT
ORGANIZED AND/OR NO MONEY
WAS PAID, RECORD “00000”

If 2
1015

Taka

Yes………………………………….1
No………………..…………………2
IF THIS ACTIVITY WAS NOT
ORGANIZED AND/OR NO MONEY
WAS PAID, RECORD “00000”

If 2
1017

Taka

Yes………………………………….1
No………………..…………………2
IF THIS ACTIVITY WAS NOT
ORGANIZED AND/OR NO MONEY
WAS PAID, RECORD “00000”
Yes………………………………….1
No………………..…………………2

Skip
If 2
1011

If 2
1019

Taka
If 2
1021

1020

1021

1022

1023

1024

292

If incentive payments were given to
the providers, How much money was
paid for this activity in last year
(October 2015-September 2016)?
Were Incentive payments were
provided to the patients by the DOTS
center?
If incentive payments were given to
the patients, How much money was
paid for this activity in last year
(October 2015-September 2016)?
Were Incentive payments were
provided to the community members
by the DOTS center?
If incentive payments were given to
the community members, How much
money was paid for this activity in last
year (October 2015-September 2016)?

IF THIS PAYMENT WAS NOT MADE
AND/OR NO MONEY WAS PAID,
RECORD “00000”
Yes………………………………….1
No………………..…………………2
IF THIS PAYMENT WAS NOT MADE
AND/OR NO MONEY WAS PAID,
RECORD “00000”

Date, Signature by Interviewer:

If 2
1023

Taka

Yes………………………………….1
No………………..…………………2
IF THIS PAYMENT WAS NOT MADE
AND/OR NO MONEY WAS PAID,
RECORD “00000”

Thank you for your cooperation! Is there anything you would like to ask or say?

Comments by Interviewer:

Taka

If 2
END

Taka

APPENDIX E – PROVIDER QUESTIONNAIRE (MDR-TB)
IDENTIFICATION
DIVISION _____________________________________________________
DISTRICT________________________________________________________________
UPAZILA _________________________________________________
NAME OF THE FACILITY_________________________________________
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TYPE OF THE FACILITY___________________________________________
(NIDCH =01, District Chest Hospital =02, Damien Foundation Hospital =03, Other=04, Please Specify)
DRUG REGIMEN FOLLOWED__________________________
(21 Month Regimen=1, 9 Month Regimen=02)
NAME OF THE MANAGER____________________________________
LOCATION OF FACILITY: RURAL=1, URBAN=2

INTERVIEWER VISITS
1

2

3

FINAL VISIT

DATE
INTERVIEWER’S NAME &
CODE

CODE
RESULT CODE

RESULT CODE*
NEXT VISIT:

DATE

TOTAL NO. OF VISITS

TIME
*RESULT CODES:
01 COMPLETED
02 NOT AVAILABLE
03 POSTPONED
SUPERVISOR

04 REFUSED
05 PARTLY COMPLETED
96 OTHER_________________
(SPECIFY)
FIELD EDITOR

OFFICE EDITOR

KEYED BY
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NAME____________________

NAME___________________

NAME____________

NAME_________

DATE _________________

DATE _________________

DATE ______________

DATE __________

Section 1: Number of Personnel, their salary, and contribution to the MDR-TB Control Program
Collect data based on each staff working on the day of data collection during day-shift (9:00am- 5:00pm). This table is for collecting information on TB clinics
open on day of the interview.
USE DECIMAL POINTS TO INDICATE PART-TIME WORK. FOR EXAMPLE, IF AN INDIVIDUAL WORKS IN TWO CLINICS, RECORD 0.5 FOR
THIS PERSON IN BOTH
A
B
C
D
E
F
G
H
Number
Incentive
%
Employed
Monthly
Monthly
Payment
involvement
SL#
TA/DA
Overtime
Total
Salary
Benefits
with TB
DESIGNATION
program
101

Professor

102

Associate
Professor

103
104
105
106
107
108
109
110

111
112
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113
114
115
116

117
118
119
120

Assistant
Professor
Consultant
Registrar
Assistant
Registrar
Medical Officer
HMO
Staff Nurse
Program
Organizer
Medical
Technologist
(Laboratory)
Health Inspector
Assistant Health
Inspector
Family Planning
Inspector
Health Assistant
(HA)
Medical
Assistant (MA)
NGO
Community
Health Workers
Leprosy and TB
Conrol Assistant
Statistical
Assistant
Gene Xpert
Technician

121

122

123

124

125

126
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127

128
129
130

Community
Health Worker
(CHW)

Section 2.0 Caseload (Number of New Patients Diagnosed, Number of Patients treated) last year (October 2015-September
2016)
PLEASE COMPLETE THIS TABLE FROM QUARTERLY REPORT ON DR TB CASE REGISTRATION (FORM DR TB 08)
Sl.
M=Male
F=Female
201
202
203
204
205
206

297

207

M

Quarter I
F

Total

M

A

B

C

D

Quarter II
F
Total
E

F

M
G

Quarter III
F
Total
H

I

M

Quarter IV
F
Total

J

K

L

MDR
XDR
RR
Other DR
Total (Confirmed
DR TB)
Presumptive DR
TB
Grand Total

PLEASE COMPLETE THIS TABLE FROM QUARTERLY REPORT ON DR TB CASE REGISTRATION (FORM DR TB 08)
Sl.

Patient registered in DR TB Register
Confirmed DR TB

208
209
210
211
212
213
214
215
216
217

New
Failure after CAT I
Failure after CAT II
Relapse after CAT II
Relapse after CAT I
Treatment after lost to follow up CAT II
Treatment after lost to follow up CAT I
Delayed Converters CAT II
Delayed Converters CAT I
Close Contact of DR TB with S/S

Quarter I
A

Quarter II
B

Quarter III
C

Quarter IV
D

218
219
220
221
222
223
224
225

Total
Pulmonary Diagnosed
New
Previously treated
Unknown TB treatment history
Extrapulmonary
New
Previously treated
Unknown TB treatment history
Total
Grand Total

Section 3.0 Xpert MTB/RIF Result
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Please enumerate the number of MDR-TB patients detected last year (October 2015-September 2016) USINF DR TB FORM 10A
Sl.

MDR-TB Patient Referral

Month
1
A

301
302
303
304
305
306

Number of total presumptive DR VTB cases tested
Number of MTB detected Rif resistance not detected (T)
Number of MTB detected Rif resistance detected (RR)
Number of MTB detected Rif resistance indeterminate (TI)
Number of MTB not detected (N)
Number of invalid/no result/ error (I)

2
B

3
C

4
D

5
E

6
F

7
G

8
H

9
I

10
J

11
K

12
L

Section 4.0 Treatment outcomes (MDR-TB Patients got treatment 24 to 36 months earlier)
PLEASE COMPLETE THIS TABLE FOR MDR TB PATIENTS GOT TREATMENT 24 TO 36 MONTHS EARLIER USING DR TB
FORM 09
Quarter |__|__| Year |__|__|
Sl.

Patient Group

401
402
403
404
405

MDR
XDR
RR
Other
Presumptive
DR TB
Total

Total
number
of DR TB
patients
registered
during
the
quarter
A

299

406

Number
of
confirmed
DR TB
patients
registered
during
the
quarter
B

Cured

Treatment
Completed

Failure

C

D

E

Died

Lost to
follow
up

Transferred
Out

Still on
Treatment

Not
Evaluated

G

H

I

J

K

F

Total

TREATMENT OUTCOME ACCORDING TO THE REGISTRATION GROUP
Sl.

Patient Group

Total
number
of DR TB
patients
registered
during
the
quarter
A

Number
of
confirmed
DR TB
patients
registered
during
the
quarter
B

Cured

Treatment
Completed

Failure

Died

Lost to
follow
up

Transferred
Out

Still on
Treatment

Not
Evaluated

Total

C

D

E

F

G

H

I

J

K

407
408
409
410
411
412

413

414

300

415

416

417
418
419

420
421
422

New
Failure after CAT
I
Failure after CAT
II
Relapse after
CAT II
Relapse after
CAT I
Treatment after
lost to follow up
CAT II
Treatment after
lost to follow up
CAT I
Delayed
Converters CAT
II
Delayed
Converters CAT
I
Close Contact of
DR TB with S/S
Pulmonary
Diagnosed
New
Previously
treated
Unknown TB
treatment history
Extrapulmonary
New
Previously
treated
Unknown TB
treatment history

PLEASE COMPLETE THIS TABLE FOR MDR TB PATIENTS GOT TREATMENT 24 TO 36 MONTHS EARLIER USING DR TB
FORM 09
Quarter |__|__| Year |__|__|
Sl.

Patient Group

401
402
403
404
405

MDR
XDR
RR
Other
Presumptive
DR TB
Total

Total
number
of DR TB
patients
registered
during
the
quarter
A

301

406

Number
of
confirmed
DR TB
patients
registered
during
the
quarter
B

Cured

Treatment
Completed

Failure

C

D

E

Died

Lost to
follow
up

Transferred
Out

Still on
Treatment

Not
Evaluated

G

H

I

J

K

F

Total

TREATMENT OUTCOME ACCORDING TO THE REGISTRATION GROUP
Sl.

Patient Group

407

New

Total
number
of DR TB
patients
registered
during
the
quarter
A

Number
of
confirmed
DR TB
patients
registered
during
the
quarter
B

Cured

Treatment
Completed

Failure

Died

Lost to
follow
up

Transferred
Out

Still on
Treatment

Not
Evaluated

Total

C

D

E

F

G

H

I

J

K

408
409
410
411
412

413

414

302

415

416

417
418
419

420
421
422

Failure after CAT
I
Failure after CAT
II
Relapse after
CAT II
Relapse after
CAT I
Treatment after
lost to follow up
CAT II
Treatment after
lost to follow up
CAT I
Delayed
Converters CAT
II
Delayed
Converters CAT
I
Close Contact of
DR TB with S/S
Pulmonary
Diagnosed
New
Previously
treated
Unknown TB
treatment history
Extrapulmonary
New
Previously
treated
Unknown TB
treatment history

PLEASE COMPLETE THIS TABLE FOR MDR TB PATIENTS GOT TREATMENT 24 TO 36 MONTHS EARLIER USING DR TB
FORM 09
Quarter |__|__| Year |__|__|
Sl.

Patient Group

401
402
403
404
405

MDR
XDR
RR
Other
Presumptive
DR TB
Total

Total
number
of DR TB
patients
registered
during
the
quarter
A

303

406

Number
of
confirmed
DR TB
patients
registered
during
the
quarter
B

Cured

Treatment
Completed

Failure

C

D

E

Died

Lost to
follow
up

Transferred
Out

Still on
Treatment

Not
Evaluated

G

H

I

J

K

F

Total

TREATMENT OUTCOME ACCORDING TO THE REGISTRATION GROUP
Sl.

Patient Group

407

New

Total
number
of DR TB
patients
registered
during
the
quarter
A

Number
of
confirmed
DR TB
patients
registered
during
the
quarter
B

Cured

Treatment
Completed

Failure

Died

Lost to
follow
up

Transferred
Out

Still on
Treatment

Not
Evaluated

Total

C

D

E

F

G

H

I

J

K

408
409
410
411
412

413

414

304

415

416

417
418
419

420
421
422

Failure after CAT
I
Failure after CAT
II
Relapse after
CAT II
Relapse after
CAT I
Treatment after
lost to follow up
CAT II
Treatment after
lost to follow up
CAT I
Delayed
Converters CAT
II
Delayed
Converters CAT
I
Close Contact of
DR TB with S/S
Pulmonary
Diagnosed
New
Previously
treated
Unknown TB
treatment history
Extrapulmonary
New
Previously
treated
Unknown TB
treatment history

PLEASE COMPLETE THIS TABLE FOR MDR TB PATIENTS GOT TREATMENT 24 TO 36 MONTHS EARLIER USING DR TB
FORM 09
Quarter |__|__| Year |__|__|
Sl.

Patient Group

401
402
403
404
405

MDR
XDR
RR
Other
Presumptive
DR TB
Total

Total
number
of DR TB
patients
registered
during
the
quarter
A

305

406

Number
of
confirmed
DR TB
patients
registered
during
the
quarter
B

Cured

Treatment
Completed

Failure

C

D

E

Died

Lost to
follow
up

Transferred
Out

Still on
Treatment

Not
Evaluated

G

H

I

J

K

F

Total

TREATMENT OUTCOME ACCORDING TO THE REGISTRATION GROUP
Sl.

Patient Group

407

New

Total
number
of DR TB
patients
registered
during
the
quarter
A

Number
of
confirmed
DR TB
patients
registered
during
the
quarter
B

Cured

Treatment
Completed

Failure

Died

Lost to
follow
up

Transferred
Out

Still on
Treatment

Not
Evaluated

Total

C

D

E

F

G

H

I

J

K

408
409
410
411
412

413

414

306

415

416

417
418
419

420
421
422

Failure after CAT
I
Failure after CAT
II
Relapse after
CAT II
Relapse after
CAT I
Treatment after
lost to follow up
CAT II
Treatment after
lost to follow up
CAT I
Delayed
Converters CAT
II
Delayed
Converters CAT
I
Close Contact of
DR TB with S/S
Pulmonary
Diagnosed
New
Previously
treated
Unknown TB
treatment history
Extrapulmonary
New
Previously
treated
Unknown TB
treatment history

Section 5.0 Quantity and Cost of Drugs
Number of TB Drugs received by the facility last year (January 2016- December 2016-PLEASE CONSULT LAST TWO REQUISITION
FORM DR TB-09)
Quarter |__|__| Year |__|__|

SL#

Drug name

Quantity
measures

A
501
502

307

503
504
505

Pyrazinamide 500 mg
Tab
Kanamycin 1 gm Vial
(Only for IP)
Ethionamide 250 mg
Tab
Cycloserine 250 mg Tab

512

Ofloxacin 400 mg Tab
Levofloxacin 250 mg
Tab
Moxifloxacin 400 mg
Tab
Clofazimine (Cfz 50 mg
Tab)
Amox/Clav 500/125 mg
Tab
Linezolid (Lzd)
Capreomycin 1 gm Vial
(Only for IP)
PAS 4 gm sachet

513

Omeprazole 20 mg Tab

506
507
508
509
510
511

Quantity received
from National TB
Control Program
(NTP) (units)
CAT I Patients

Quantity received
from National TB
Control Program
(NTP) (units)
CAT II Patients

B

C

Total received in
this quarter

Market price of drugs per
unit

D

E

.
.
.
.
.
.
.
.
.
.
.
.
.

514

Domperidone 10 mg
Tab

.

515

Pyridoxine 25 mg Tab

516

Multivitamin

517

Alprazolam 0.5 mg

.
.
.
.
.
.

518
519
520
521
522
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523

Others

524

Syringe, 5 cc

525

Distilled Water, 3 cc

526
527
528
529
530
531
532
533
534
535

Quarter |__|__| Year |__|__|

.
.
.
.
.
.
.
.
.
.
.
.
.
.

SL#

501
502
503
504
505
506

309

507
508
509
510
511
512
513
514

Drug name

Pyrazinamide 500 mg
Tab
Kanamycin 1 gm Vial
(Only for IP)
Ethionamide 250 mg
Tab
Cycloserine 250 mg Tab
Ofloxacin 400 mg Tab
Levofloxacin 250 mg
Tab
Moxifloxacin 400 mg
Tab
Clofazimine (Cfz 50 mg
Tab)
Amox/Clav 500/125 mg
Tab
Linezolid (Lzd)
Capreomycin 1 gm Vial
(Only for IP)
PAS 4 gm sachet

Omeprazole 20 mg Tab
Domperidone 10 mg
Tab

515

Pyridoxine 25 mg Tab

516

Multivitamin

Quantity received
from National TB
Control Program
(NTP) (units) for
CAT I Patients

Quantity received from
National TB Control
Program (NTP) (units)
for
CAT II Patients

E

F

Total received in
this quarter

G

517

Alprazolam 0.5 mg

518
519
520
521
522
523

Others

524

Syringe, 5 cc

525

Distilled Water, 3 cc

526
527

310

528
529
530
531
532
533
534
535

Quarter |__|__| Year |__|__|

SL#

501
502
503
504

311

505
506
507
508
509
510
511
512
513
514
515

Drug name

Pyrazinamide 500 mg
Tab
Kanamycin 1 gm Vial
(Only for IP)
Ethionamide 250 mg
Tab
Cycloserine 250 mg Tab
Ofloxacin 400 mg Tab
Levofloxacin 250 mg
Tab
Moxifloxacin 400 mg
Tab
Clofazimine (Cfz 50 mg
Tab)
Amox/Clav 500/125 mg
Tab
Linezolid (Lzd)
Capreomycin 1 gm Vial
(Only for IP)
PAS 4 gm sachet

Omeprazole 20 mg Tab
Domperidone 10 mg
Tab
Pyridoxine 25 mg Tab

Quantity received
from National TB
Control Program
(NTP) (units) for
CAT I Patients

Quantity received from
National TB Control
Program (NTP) (units)
for
CAT II Patients

H

I

Total received in
this quarter

J

516

Multivitamin

517

Alprazolam 0.5 mg

518
519
520
521
522
523

Others

524

Syringe, 5 cc

525

Distilled Water, 3 cc

526

312

527
528
529
530
531
532
533
534
535

Quarter |__|__| Year |__|__|

SL#

501
502
503
504

313

505
506
507
508
509
510
511
512
513
514
515

Drug name

Pyrazinamide 500 mg
Tab
Kanamycin 1 gm Vial
(Only for IP)
Ethionamide 250 mg
Tab
Cycloserine 250 mg Tab
Ofloxacin 400 mg Tab
Levofloxacin 250 mg
Tab
Moxifloxacin 400 mg
Tab
Clofazimine (Cfz 50 mg
Tab)
Amox/Clav 500/125 mg
Tab
Linezolid (Lzd)
Capreomycin 1 gm Vial
(Only for IP)
PAS 4 gm sachet

Omeprazole 20 mg Tab
Domperidone 10 mg
Tab
Pyridoxine 25 mg Tab

Quantity received
from National TB
Control Program
(NTP) (units) for
CAT I Patients

Quantity received from
National TB Control
Program (NTP) (units)
for
CAT II Patients

K

L

Total received in
this quarter

M

516

Multivitamin

517

Alprazolam 0.5 mg

518
519
520
521
522
523

Others

524

Syringe, 5 cc

525

Distilled Water, 3 cc

526

314

527
528
529
530
531
532
533
534
535

Section 7.0 Quantity and Cost of Laboratory Reagents/Supplies/Equipment
Number of Laboratory reagents/ supplies received by the facility last year (October 2015-September 2016- Laboratory Request Form)
Quarter 4 (July 2016- September 2016)
SL#

601
602
603

Reagent/Lab supplies’
name

Quantity
measures
per
patient
A

Basic fuchsin

1 gm/sm+

Phenol crystals
Methanol (or
denatured ethanol)

5 gm/sm+
10 ml/sm+

315

604

Methylene Blue

605

Sulphuric Acid conc.

0.1
gm/sm+
33 ml/sm+

606

Burning Spirit

50 ml/sm+

607

Slides

608

Sputum Containers

609

Bamboo Sticks

610

Immersion Oil

36
pcs/sm+
36
pcs/sm+
36
pcs/sm+
2 ml/sm+

611

Xylene

25 ml/sm+

612

Toilet Paper Rolls

613

Filter Paper Pieces

614

Culture Media (Solid)
Culture Media
(Liquid)

615

3
rolls/clinic
20 pcs/
clinic

Quantity received
from National TB
Control Program
(NTP) (units)
B

Quantity purchased
from market (units)

Total received in
this quarter

Market price of reagents
per unit

C

D

E

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.

616
617
618
619
620
621
622

Quarter 3 (April 2016- June 2016)

SL#

Reagent/Lab supplies’
name

316

601

Basic fuchsin

602

604

Phenol crystals
Methanol (or
denatured ethanol)
Methylene Blue

605

Sulphuric Acid conc.

606

Burning Spirit

607

Slides

608

Sputum Containers

609

Bamboo Sticks

610

Immersion Oil

611

Xylene

612

Toilet Paper Rolls

603

Quantity received
from National TB
Control Program
(NTP) (units)
F

Quantity purchased
from market (units)

Total received in
this quarter

G

H

613

Filter Paper Pieces

614
615
616
617
618
619
620
621
622

317

Quarter 2 (January 2016- March 2016)

SL#

Reagent/Lab supplies’
name

601

Basic fuchsin

602

604

Phenol crystals
Methanol (or
denatured ethanol)
Methylene Blue

605

Sulphuric Acid conc.

606

Burning Spirit

607

Slides

603

Quantity received
from National TB
Control Program
(NTP) (units)
I

Quantity purchased
from market (units)

Total received in
this quarter

J

K

608

Sputum Containers

609

Bamboo Sticks

610

Immersion Oil

611

Xylene

612

Toilet Paper Rolls

613

Filter Paper Pieces

614
615
616
617
618

318

619
620
621
622

Quarter 1 (October 2016- December 2016)

SL#

Reagent/Lab supplies’
name

601

Basic fuchsin

602

Phenol crystals

Quantity received
from National TB
Control Program
(NTP) (units)
L

Quantity purchased
from market (units)
M

Total
received in
this
quarter
N

604

Methanol (or denatured
ethanol)
Methylene Blue

605

Sulphuric Acid conc.

606

Burning Spirit

607

Slides

608

Sputum Containers

609

Bamboo Sticks

610

Immersion Oil

611

Xylene

612

Toilet Paper Rolls

613

Filter Paper Pieces

603

319

614
615
616
617
618
619
620
621
622

Section 8.0 Cost of Other Supplies
Number of Supplies received by the facility last year (October 2015-September 2016)
Quarter 4 (July 2016- September 2016)
SL#

Supplies’ name

Quantity
measures
A

320

701

TB Register

702

Treatment Card

703

Pen

704

Paper

705

Box

706

Soap

707

Towel

708

Boxes

709

Tape

710

Raincoat

711

Torch light

712

Umbrella

713

Drug Baskets

714

Kit Bag

715

Poster

716

Sticker

717

Leaflet

718

Flip chart

Quantity received
from National TB
Control Program
(NTP) (units)
B

Quantity purchased
from market (units)

Total received in
this quarter

Market price of supplies
per unit

C

D

E

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

719

Flash Chart

720

Brochure

.
.
.
.
.
.
.
.
.
.
.
.

721
722
723
724
725
726
727
728
729

321

730

Quarter 3 (April 2016- June 2016)
SL#

Supplies’ name

701

TB Register

702

Treatment Card

703

Pen

704

Paper

705

Box

706

Soap

707

Towel

Quantity received
from National TB
Control Program
(NTP) (units)
F

Quantity purchased
from market (units)

Total received in
this quarter

G

H
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708

Boxes

709

Tape

710

Raincoat

711

Torch light

712

Umbrella

713

Drug Baskets

714

Kit Bag

715

Poster

716

Sticker

717

Leaflet

718

Flip chart

719

Flash Chart

720

Brochure

721
722
723
724
725
726
727
728
729
730

Quarter 2 (January 2016- March 2016)
SL#

Supplies’ name

323

701

TB Register

702

Treatment Card

703

Pen

704

Paper

705

Box

706

Soap

707

Towel

708

Boxes

709

Tape

710

Raincoat

711

Torch light

712

Umbrella

713

Drug Baskets

714

Kit Bag

715

Poster

716

Sticker

717

Leaflet

718

Flip chart

719

Flash Chart

720

Brochure

Quantity received
from National TB
Control Program
(NTP) (units)
I

Quantity purchased
from market (units)

Total received in
this quarter

J

K

721
722
723
724
725
726
727
728
729
730

324

Quarter 4 (October 2015- December 2015)
SL#

Supplies’ name

701

TB Register

702

Treatment Card

703

Pen

704

Paper

705

Box

706

Soap

707

Towel

708

Boxes

709

Tape

Quantity received
from National TB
Control Program
(NTP) (units)
L

Quantity purchased
from market (units)

Total received in
this quarter

M

N

710

Raincoat

711

Torch light

712

Umbrella

713

Drug Baskets

714

Kit Bag

715

Poster

716

Sticker

717

Leaflet

718

Flip chart

719

Flash Chart

720

Brochure

325

721
722
723
724
725
726
727
728
729
730

Section 8.0 Other Capital Items
Number of Items used by the facility
SL#

Capital Items

Quantity
(Unit)
A

326

801

Microscope

802

GeneXpert

803

Weight Scale

804

Signboard

805

Computer

806

Printer

807

Smart Phone

808

App development

809

Motor Cycle

810

Bicycle

811

Car

812

Ambulance

813

LPA

814

LJ

815

MGIT

816
817
818
819

Quantity
received from
National TB
Control Program
(NTP) (units)
B

Quantity
purchased from
market (units)

Total is being
used

C

D

Life time
(In Years)

Market price of item per unit

E

F

Section 9. Other Costs
Section 9.1 Cost of Supervision (facility supervisory visits conducted in last year (October 2015-September 2016)

SL #

Title of person
conducting
supervisory visit
A

Number of
visits in
last year
(Oct 2015Sep 2016)
B

Duration of visit
(total for all visits
in days)

Per Diem (total)

Travel expenses (total)

Other expenses

What % of
costs paid by
facility?

C

D

E

F

H

901
902
903
904

327

Section 9.2 Travel cost for Drug /Attending Meeting/Training

SL #

Title of person
conducting
travel
A

Number
of travel
in last
year (Oct
2015-Sep
2016)
B

Purpose of the
travel
(Use Code
from below)^

C

Duration of
visit (total for
all visits in
days)

Per Diem (total)

Travel expenses
(total)

Other
expenses

What % of
costs paid by
facility?

D

E

F

H

I

905
906
907
908
^Code: 1. Receiving drug 2. Attending Meetings 3. Training 4. Others (Please specify)

Section 9.3 Cost of Other Activities
No
909

910

911

912

913
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914

915

916

917

918

919

Questions and Filters
Was Health education on TB
organized by the DOTS center?
If Health education on TB was
organized, How much money was paid
for this activity in last year (October
2015-September 2016)?
Was DOTS committee meeting
organized by the DOTS center?
If DOTS committee meeting was
organized, How much money was paid
for this activity in last year (October
2015-September 2016)?
Were Contact Tracing activities
organized by the DOTS center?
If Contact Tracing activities were
organized, How much money was paid
for this activity in last year (October
2015-September 2016)?
Were Refresher training activities
organized by the DOTS center?
If Refresher training activities were
organized, How much money was paid
for this activity in last year (October
2015-September 2016)?
Were Other meetings organized by the
DOTS center?
If Other meetings were organized,
How much money was paid for this
activity in last year (October 2015September 2016)?
Were Incentive payments were
provided to the providers by the
DOTS center?

Coding categories
Yes………………………………….1
No………………..…………………2
IF THIS ACTIVITY WAS NOT
ORGANIZED AND/OR NO MONEY
WAS PAID, RECORD “00000”

Record Response

Taka

Yes………………………………….1
No………………..…………………2
IF THIS ACTIVITY WAS NOT
ORGANIZED AND/OR NO MONEY
WAS PAID, RECORD “00000”

If 2
913

Taka

Yes………………………………….1
No………………..…………………2
IF THIS ACTIVITY WAS NOT
ORGANIZED AND/OR NO MONEY
WAS PAID, RECORD “00000”

If 2
915

Taka

Yes………………………………….1
No………………..…………………2
IF THIS ACTIVITY WAS NOT
ORGANIZED AND/OR NO MONEY
WAS PAID, RECORD “00000”

If 2
917

Taka

Yes………………………………….1
No………………..…………………2
IF THIS ACTIVITY WAS NOT
ORGANIZED AND/OR NO MONEY
WAS PAID, RECORD “00000”
Yes………………………………….1
No………………..…………………2

Skip
If 2
911

If 2
919

Taka
If 2
921

920

921

922

923

924
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If incentive payments were given to
the providers, How much money was
paid for this activity in last year
(October 2015-September 2016)?
Were Incentive payments were
provided to the patients by the DOTS
center?
If incentive payments were given to
the patients, How much money was
paid for this activity in last year
(October 2015-September 2016)?
Were Incentive payments were
provided to the community members
by the DOTS center?
If incentive payments were given to
the community members, How much
money was paid for this activity in last
year (October 2015-September 2016)?

IF THIS PAYMENT WAS NOT MADE
AND/OR NO MONEY WAS PAID,
RECORD “00000”
Yes………………………………….1
No………………..…………………2
IF THIS PAYMENT WAS NOT MADE
AND/OR NO MONEY WAS PAID,
RECORD “00000”

Date, Signature by Interviewer:

If 2
923

Taka

Yes………………………………….1
No………………..…………………2
IF THIS PAYMENT WAS NOT MADE
AND/OR NO MONEY WAS PAID,
RECORD “00000”

Thank you for your cooperation! Is there anything you would like to ask or say?

Comments by Interviewer:

Taka

If 2
END

Taka

